{
    "1": {
        "question": "<div class=\"qtext\"><p>A 42-year-old man with a history of lymphoma, hypertension, and type 2 diabetes presents to the emergency department with fever, nausea, and vomiting. His symptoms began 1 day after starting treatment for relapsed Hodgkin lymphoma with ifosfamide, carboplatin, and etoposide, and mercaptoethane sulfonate sodium (mesna) for hemorrhagic cystitis prophylaxis. His hypertension and diabetes are well controlled with lisinopril and metformin, respectively. </p>\n<p>BP is 138/88 mm Hg, heart rate is 95/min, respiratory rate is 23/min, temperature is 38°C, and oxygen saturation is 98% while breathing room air. The physical examination is unremarkable.</p>\n<p>Laboratory data:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Serum</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136‒145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.4 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5‒5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Chloride</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">106 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">98‒106</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">19 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23‒28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> BUN</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">24 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8‒20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.2 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7‒1.3</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Glucose</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">89 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">70‒99, fasting</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Albumin</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.0 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5‒5.5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Urine</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Ketones</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3+</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Glucose</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Protein</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> pH</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">5.5</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.5‒8.0</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which of the following is the MOST LIKELY cause of ketonuria?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Mesna"
            },
            {
                "label": "B.",
                "text": "Diabetes"
            },
            {
                "label": "C.",
                "text": "Starvation"
            },
            {
                "label": "D.",
                "text": "Ifosfamide"
            },
            {
                "label": "E.",
                "text": "Lisinopril"
            }
        ],
        "correct_answer": "Mesna",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p>Mesna is the most likely cause of ketonuria in this patient initiating treatment for lymphoma.</p>\n<p>Production of ketone bodies is increased when there is a decreased availability of glucose for cellular metabolism,  such as with starvation or insulin deficiency or insensitivity (starvation or diabetic ketoacidosis [DKA], respectively). This patient’s normal serum glucose, albumin, and anion gap make both starvation ketoacidosis and DKA unlikely. The low serum bicarbonate may reflect a non-anion gap metabolic acidosis or respiratory alkalosis, especially in the setting of fever and tachypnea, although an arterial blood gas is not given. Routine urinalysis tests for the ketone bodies acetoacetic acid and acetone, but not β-hydroxybutyrate, via reaction with nitroprusside that is imbedded in the test strip, resulting in the generation of a purple color. </p>\n<p>Drugs containing free sulfhydryl groups can react with nitroprusside, causing a false positive urine ketone result. Common drugs with free sulfhydryl groups include mesna, captopril, d-penicillamine, dimercaprol, and <em>N</em>-acetylcysteine. In fact, some authorities have suggested using false positive urine ketone results to confirm adherence to mesna therapy.</p>\n<p>Neither ifosfamide nor lisinopril would cause false positive urine ketones.</p>\n</div>",
        "references": [
            "Gordon-Smith EC, Hows JM, Ward L, et al: Mesna and false-positive results in ward testing for urinary ketones.Lancet1(8271): 563, 1982",
            "Cantwell BM, Pooley J, Harris AL: False-positive ketonuria during ifosfamide and mesna therapy.Eur J Cancer Clin Oncol22(2): 229‒230, 1986",
            "Goren MP, Pratt CB: False-positive ketone tests: a bedside measure of urinary mesna.Cancer Chemother Pharmacol25(5): 371‒372, 1990",
            "Csako G, Elin RJ: Unrecognized false-positive ketones from drugs containing free-sulfhydryl group(s).JAMA269(13): 1634, 1993"
        ]
    },
    "2": {
        "question": "<div class=\"qtext\"><p>A 60-year-old man presents to the nephrology clinic for evaluation of kidney disease. He has a history of hypertension and gout. He does not take NSAIDs or illicit drugs, although he drank home-distilled whiskey for 10 years before quitting last year. He has no family history of kidney disease. His only medication is amlodipine. Review of systems is positive for paresthesias in his upper and lower limbs.</p>\n<p>BP is 150/90 mm Hg, pulse is 80/min, and he is afebrile. He has no lower extremity edema, rashes, or other skin lesions.</p>\n<p>Laboratory data:</p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 29.087%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;width: 38.6412%;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;width: 29.087%;\">22 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;width: 32.2718%;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;width: 38.6412%;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;width: 29.087%;\">45 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;width: 32.2718%;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;width: 38.6412%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;width: 29.087%;\">4.0 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;width: 32.2718%;\">0.7–1.3</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;width: 38.6412%;\">Uric acid<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;width: 29.087%;\">9.0 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;width: 32.2718%;\">3.0-7.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;width: 38.6412%;\">Urine protein-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;width: 29.087%;\">0.5 mg/mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;width: 32.2718%;\">&lt;0.2</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis shows trace protein, no blood, no glucose, and no pyuria. Abdominal ultrasound shows both kidneys with increased echogenicity without hydronephrosis.</p>\n<p>A kidney biopsy is performed and demonstrates diffuse interstitial fibrosis and tubular atrophy. No active glomerular lesions are noted. IF and EM are unremarkable.</p>\n<p><strong>Which of the following is the MOST LIKELY etiology of kidney disease?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Autosomal dominant tubulointerstitial kidney disease"
            },
            {
                "label": "B.",
                "text": "Lead toxicity"
            },
            {
                "label": "C.",
                "text": "Acute interstitial nephritis"
            },
            {
                "label": "D.",
                "text": "Cadmium toxicity"
            },
            {
                "label": "E.",
                "text": "Hypertension"
            }
        ],
        "correct_answer": "Lead toxicity",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely etiology of this patient’s kidney disease is chronic lead nephropathy. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, the patient has a history of “moonshine” whiskey consumption, which is a potential source of lead exposure when the homemade distillation apparatus uses components that contain lead. Occupational sources of exposure include those industries involved in smelting, paint removal, and fuel, paint, battery, and ammunition production. Recently, municipal water supplies have emerged as an important source of lead exposure. With acute lead poisoning, findings of proximal tubule injury (Fanconi syndrome) can be seen, including glucosuria, phosphaturia, and aminoaciduria. Chronic lead exposure, often termed lead nephropathy, can present with hypertension, hyperuricemia with gout, and CKD. Other clinical manifestations include cognitive impairment, peripheral neuropathy, and microcytic anemia. Physical findings are nonspecific except for the appearance of Burton’s line, a blue-gray discoloration at the gum line. The urinalysis is bland, with non-nephrotic range proteinuria. Kidney biopsy findings are also nonspecific, with chronic tubulointerstitial disease manifested by fibrosis and tubular atrophy. For patients with acute lead poisoning, chelation therapy may be indicated. For patients with chronic lead nephropathy, management is supportive in addition to removing the source of exposure. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Despite the findings of tubulointerstitial disease, there was no family history of kidney disease to suggest autosomal dominant tubulointerstitial kidney disease. There was no evidence of acute interstitial nephritis on the biopsy. Hypertensive kidney disease is commonly diagnosed but poorly defined, and histologic manifestations may differ in different ethnic groups. In this case, the presence of gout and hyperuricemia, as well as the history of lead exposure, makes lead nephropathy more likely. Cadmium nephrotoxicity presents with proximal tubule dysfunction, but also bone pain, fractures, and osteoporosis, and does not fit the exposure history in this case.</p>\n</div>",
        "references": [
            "Soderland P, Lovekar S, Weiner DE, et al: Chronic kidney disease associated with environmental toxins and exposures.Adv Chronic Kidney Dis17(3): 254–264, 2010",
            "Batuman V, Wedeen RP: The persistence of chronic lead nephropathy.Am J Kidney Dis64: 1–3, 2014",
            "Marquez JI, Schindlbeck MA: Lead toxicity from a retained bullet.N Engl J Med379(25): 2451, 2018",
            "Babu MS, Murthy K, Sasidharan S: Burton’s line.Am J Med125(10): 963–964, 2012"
        ]
    },
    "3": {
        "question": "<div class=\"qtext\"><p>A 20-year-old man with no significant medical history presents to urgent care with low-grade fever, urinary frequency, and mild dysuria. He appears well; his BP is 110/63 mm Hg, heart rate is 78/min, temperature is 37.9°C, and body mass index is 23 kg/m<sup>2</sup>. Abdominal examination demonstrates no distension, tenderness, or masses, and there is no costovertebral tenderness. Urinalysis is positive for leukocyte esterase, 2+ protein, and 2+ blood. </p>\n<p>He is treated with antibiotics and returns for follow-up in 10 days. Urinalysis shows persistent protein and blood but no leukocyte esterase. Urinary symptoms have resolved, and he is no longer febrile. He is referred to nephrology for evaluation of proteinuria and hematuria. Urine sediment review shows 15–20 RBCs/hpf with 50% acanthocytes. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">9 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">0.9 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.7–1.3</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Albumin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.6 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">ANCA<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">Negative</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">HIV</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">Negative</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">ANA</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">Negative</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">C3</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">102 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">100–233</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">C4</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">26 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">14–48</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Urine protein-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">2.5 mg/mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">&lt;0.2</td>\n</tr>\n</tbody>\n</table>\n<p>Urine culture is negative.</p>\n<p>An image from a kidney ultrasound is shown below (RK, right kidney; LK, left kidney). No hydronephrosis or nephrolithiasis is seen.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv7m2b1q3.png\" width=\"60%\"/><br/>\n<figcaption>(<em>Ultrasound image courtesy of Lauren Burke, MD, University of North Carolina)</em></figcaption>\n</figure>\n<p><strong>Which ONE of the following is the most appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "24-hour urine protein, creatinine, and calcium"
            },
            {
                "label": "B.",
                "text": "Ultrasound-guided lower pole kidney biopsy"
            },
            {
                "label": "C.",
                "text": "Lisinopril and prednisone"
            },
            {
                "label": "D.",
                "text": "CT-guided upper pole kidney biopsy"
            },
            {
                "label": "E.",
                "text": "CT urogram and cystoscopy"
            }
        ],
        "correct_answer": "CT-guided upper pole kidney biopsy",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has a horseshoe kidney and should undergo CT-guided percutaneous biopsy of the upper pole of the kidney to evaluate the etiology of proteinuria and dysmorphic hematuria, which is most likely glomerular disease. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Horseshoe kidney is the most common anatomic kidney fusion abnormality, with a 0.25% prevalence. Horseshoe kidney results from a disturbance around the fourth to sixth week of gestation, at which time embryonic migration of the kidneys occurs and the kidneys become fused across the midline. The fusion consists of kidney parenchymal tissue or a fibrous tissue isthmus and 90% of the time exists at the lower poles. Although 30% of patients with horseshoe kidneys are asymptomatic, they are predisposed to urinary tract infections, nephrolithiasis, ureteropelvic junction obstruction, and a variety of benign and malignant tumors. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Because horseshoe kidney is a rare finding and glomerular disease is also infrequent, concurrence of these conditions is uncommon. However, case reports have described several glomerular diseases in horseshoe kidneys, including membranous nephropathy, FSGS, MPGN, IgA nephropathy, and amyloidosis. In all cases but one (in which open biopsy was performed), diagnosis was made via percutaneous kidney biopsy with no complications reported.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The prevalence of stone disease ranges from 21% to 60% in horseshoe kidneys. Both urinary stasis and infection are felt to contribute to stone formation. A retrospective review of stone disease identified a high rate of metabolic abnormalities linked to nephrolithiasis, including reduced urine volume, hypercalciuria, hypocitraturia, and hyperuricosuria. Although the patient is at increased risk of both urinary tract infections and nephrolithiasis because of the horseshoe kidney, the infection has been treated and imaging demonstrates no evidence of nephrolithiasis, so a 24-hour urine analysis for stone risk factors would not be useful in this case.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The frequency of benign and malignant tumors is increased in horseshoe kidney, and if neoplasm were suspected, then CT urogram and cystoscopy would be appropriate; however, the urine sediment revealed numerous acanthocytes and heavy proteinuria, so kidney biopsy would be the most appropriate next step.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although no large case series have been published because of the rarity of the concurrence of glomerular disease and horseshoe kidney, case reports demonstrate that several diagnoses are possible, suggesting that kidney biopsy is important for accurate diagnosis and treatment. Empirical use of lisinopril and prednisone would only be considered if kidney biopsy were not possible or proved nondiagnostic or pending a diagnosis in the setting of severe kidney injury. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Routine kidney biopsies target the lower pole. In horseshoe kidneys, the upper pole is preferred to avoid the abdominal aorta. CT-guided biopsy may be preferred over ultrasound-guided biopsy given the atypical anatomy. </p>\n</div>",
        "references": [
            "Chaabouni Y, Guesmi R, Hentati Y, et al: Minimal change disease in horseshoe kidney.Pan Afr Med J26: 243, 2017",
            "Schiappacasse G, Aguirre J, Soffia P, et al: CT findings of the main pathological conditions associated with horseshoe kidneys.Br J Radiol88(1045): 2014045, 2015",
            "Raj GV, Auge BK, Assimos D, Preminger GM: Metabolic abnormalities associated with renal calculi in patients with horseshoe kidneys.J Endourol18(2): 157–161, 2004",
            "Hogan JJ, Mocanu M, Berns JS: The native kidney biopsy: updated and evidence for best practice.Clin J Am Soc Nephrol11(2): 354–362, 2016",
            "Davis R, Jones JS, Barocas DA, et al: Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline.J Urol188(6 Suppl): 2473–2481, 2012"
        ]
    },
    "4": {
        "question": "<div class=\"qtext\"><p>A 75-year-old woman with a history of hypertension and diabetes is brought to the emergency department after being found confused at home. She was in her usual state of health the previous day. She is unable to provide any history, but her children report that since her husband passed away 2 weeks ago, she has hardly eaten while consuming an increased amount of alcohol. Medications include chlorthalidone and metformin.</p>\n<p>On arrival, BP is 92/60 mm Hg and heart rate is 104/min. Skin turgor is poor. She is lethargic but answers simple questions, and there are no focal neurologic deficits. She receives 0.9% saline 2 L and potassium chloride 60 mEq over the next few hours, and urine output increases from 20 to 300 mL/h. Mental status remains unchanged.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 29.971%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\"><strong>On Arrival</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\"><strong>6 Hours Later</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">110 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">121</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">2.9 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">3.4</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">78 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">93</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">98–106<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Glucose<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">154 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">102</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">70–99, fasting</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">38 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">18</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">1.3 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">0.9</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Serum osmolality<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">240 mOsm/kg H<sub>2</sub>O<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">263</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">275–295</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Urine sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">11 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Varies</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Urine osmolality<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">190 mOsm/kg H<sub>2</sub>O<span style=\"white-space:pre;\"> </span><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Varies</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which of the following is the next BEST STEP in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "5% dextrose IV"
            },
            {
                "label": "B.",
                "text": "0.9% saline IV and desmopressin"
            },
            {
                "label": "C.",
                "text": "No additional management"
            },
            {
                "label": "D.",
                "text": "0.45% saline IV"
            },
            {
                "label": "E.",
                "text": "5% dextrose IV and desmopressin"
            }
        ],
        "correct_answer": "5% dextrose IV and desmopressin",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with severe hyponatremia and overcorrection should receive 5% dextrose IV and desmopressin to decrease the serum sodium back into the safe range.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient presented with severe hyponatremia and rapidly overcorrected after receiving isotonic fluid. The etiology of her hyponatremia is uncertain, and there are several factors that may contribute to her presentation, including excessive fluid consumption in the setting of alcohol use and low solute intake. Additionally, hypotension, tachycardia, and low urine sodium concentration with an inappropriately high urine osmolality all suggest volume depletion. She takes chlorthalidone, which can also predispose to hyponatremia, although the low urine sodium indicates an absence of diuretic effect at the time of presentation. Uncontrolled diabetes is yet another consideration, although the modestly elevated serum glucose is reassuring in this regard. The duration of hyponatremia is also uncertain, despite information that she was in her usual state of health one day before presentation. Without definitive laboratory data to confirm the acute onset of hyponatremia, she should be managed as having chronic hyponatremia. In this setting, the rate of correction should not exceed 6–8 mEq/L in 24 hours to avoid osmotic demyelination (OD). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has several risk factors for both overcorrection and OD, including female sex, low initial plasma sodium concentration, low initial urine sodium concentration, alcohol use disorder, and hypokalemia. Volume expansion suppresses antidiuretic hormone, leading to a large, dilute urine output. The contribution of potassium supplementation to correction is equivalent to the provision of sodium, a fact that may be underappreciated by practitioners. This patient’s sodium has corrected by 11 mEq/L within 6 hours, and prompt re-lowering of her serum sodium is indicated. The next best step would be to administer 5% dextrose in addition to desmopressin. If retained, 5% dextrose at a dose of 6 mL/kg would be expected to lower her serum sodium approximately by 2 mEq/L. To induce water retention, desmopressin 1–2 mg IV every 6–8 hours should be provided. Without desmopressin, it is challenging to deliver the volume of 5% dextrose required to relower the plasma sodium concentration to target.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Re-lowering the serum sodium should be done promptly even if there are no new or worsened neurologic symptoms in the setting of overcorrection. The signs and symptoms of osmotic demyelination often do not appear for several days and cannot be used to guide therapy. Changing her fluids to 0.45% or 0.9% saline, with or without desmopressin, would not provide the water required to effectively re-lower her serum sodium concentration.</p>\n</div>",
        "references": [
            "Oh MS, Uribarri J, Barrido D, et al: Danger of central pontine myelinolysis in hypotonic dehydration and recommendation for treatment.Am J Med Sci298: 41–43, 1989",
            "Lien YH, Shapiro JI, Chan L: Study of brain electrolytes and organic osmolytes during correction of chronic hyponatremia. Implications for the pathogenesis of central pontine myelinolysis.J Clin Invest88: 303–309, 1991",
            "Sterns RH: Treatment of severe hyponatremia.Clin J Am Soc Nephrol13(4): 641–649, 2018",
            "George JC, Zafar W, Bucaloiu ID, et al: Risk factors and outcomes of rapid correction of severe hyponatremia. Clin J Am Soc Nephrol 13(7): 984–992, 2018"
        ]
    },
    "5": {
        "question": "<div class=\"qtext\"><p>A 29-year-old man with ESRD caused by ureteropelvic junction obstruction has received maintenance HD for the last year via a tunneled, cuffed dialysis catheter (TCC). He has a history of mitral valve endocarditis after mechanical mitral valve replacement 6 months ago. He has received warfarin for the last 6 months to maintain an international normalized ratio (INR) in the 2.5–3.0 range. He now has a mature arteriovenous fistula that has been successfully cannulated for the last 6 HD sessions.</p>\n<p>He is referred for removal of the TCC.</p>\n<p><strong>Which of the following is the next BEST STEP in management before TCC removal?</strong> </p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Bridge warfarin to heparin and hold heparin for 4 hours"
            },
            {
                "label": "B.",
                "text": "No additional management"
            },
            {
                "label": "C.",
                "text": "Hold warfarin until INR <1.5"
            },
            {
                "label": "D.",
                "text": "Hold warfarin for 3 days"
            },
            {
                "label": "E.",
                "text": "Initiate aspirin and hold warfarin for 3 days"
            }
        ],
        "correct_answer": "Bridge warfarin to heparin and hold heparin for 4 hours",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with a mechanical mitral valve requires continuous anticoagulation to prevent valve thrombosis and should be admitted to the hospital for heparin bridging peri- and post-procedurally.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The peri-procedural management of anticoagulation is based on the perceived risk for bleeding, but there is no consensus as to what constitutes a high or serious risk. Some centers routinely remove TCCs without modifying anticoagulation. Interventional radiology guidelines identify placement or removal of central venous catheters as low risk and do not suggest that anticoagulation be interrupted. However, they do not specifically address the large-diameter devices designed for hemodialysis, which may confer greater risk of bleeding. Platelet dysfunction and anemia may also increase the risk of bleeding. The nephrology literature favors a conservative approach as described below. Various case series have documented bleeding rates between 1.4% and 8% depending on the method of removal. The need for transfusion appears to be very uncommon, but there is a tendency for wound infection to occur in those patients who have bleeding with hematoma formation, even if no transfusion is required. In nonemergent circumstances, anticoagulation should generally be held before the procedure to minimize risk. Typically, warfarin may be held for 3 days before the procedure. In most cases, this approach will result in a subtherapeutic INR for a few days during which the procedure may be done safely. Direct oral anticoagulants can typically be held for 1–2 days or less depending on the particular agent and circumstances.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">However, the presence of the mechanical mitral valve poses a high thrombotic risk. Therefore, this patient’s anticoagulation should be bridged with heparin. Once the procedure is accomplished and hemostasis is achieved, heparin can be resumed, and warfarin can be restarted. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although aspirin may be continued for TCC procedures, it does not provide significant anticoagulation in the setting of a mechanical valve and therefore would not be sufficient on its own as a warfarin bridge. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Published INR thresholds for TCC procedures vary, and operators may have different comfort levels for the degree of INR prolongation. An INR &lt;1.8 is generally acceptable. Other typical hemostatic parameters include platelet count &gt;50,000/μL and hemoglobin &gt;7 g/dL, although the evidence for these specific thresholds is low.</p>\n</div>",
        "references": [
            "Agarwal AK, Haddad N, Boubes K: Avoiding problems in tunneled dialysis catheter placement.Semin Dial32(6): 535–540, 2019",
            "Crockett MT, Moynagh MR, Kavanagh EC: The novel oral anticoagulants: an update for the interventional radiologist.Am J Roentgenol199(3): W376–W379, 2012",
            "Porazko T, Hobot J, Ziembik Z, et al: Tunneled haemodialysis catheter removal: an underappreciated problem, not always simple and safe.Int J Environ Res PublicHealth17(9): 3027, 2020",
            "Patel IJ, Shiraz R, Davidson JC, et al: Society of interventional radiology concensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions—part II: recommendations.J Vasc Interv Radiol30(8): 1168–1184, 2019",
            "Sunkara T, Ofori E, Zarubin V, et al: Perioperative management of direct oral anticoagulants (DOACs): a systemic review.Health Serv Insights9(Suppl 1): 25–30, 2016"
        ]
    },
    "6": {
        "question": "<div class=\"qtext\"><p>A 28-year-old woman with a history of polycystic ovary syndrome (PCOS) presents to the clinic for evaluation of hypertension. PCOS was diagnosed approximately 1 year ago, prompting therapy with an oral contraceptive pill (OCP). Her office BP has averaged &gt;140/90 mm Hg at multiple clinic visits over the last several months. Home BP readings, taken in mornings and evenings, confirm elevated BP, ranging from 142–158/84–96 mm Hg and averaging 146/88 mm Hg. Medications include a combined estrogen-progestin OCP, a multivitamin, and occasional acetaminophen. She does not use NSAIDs, over-the-counter medications, or illicit drugs. A sleep study done 2 months ago was negative for sleep apnea. She feels well, and a review of systems is negative.</p>\n<p>BP is 150/92 mm Hg in both arms, with a pulse of 80/min. Body mass index is 28 kg/m<sup>2</sup>. Physical examination is unremarkable, and there is no edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">137 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">4.2 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">25 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">12 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">0.75 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Thyroid-stimulating hormone<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">1.1 μU/mL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">0.5–4.0</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis is bland without proteinuria. EKG is unremarkable.</p>\n<p><strong>In addition to counseling about sodium intake and weight loss, which of the following is the BEST NEXT STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe lisinopril"
            },
            {
                "label": "B.",
                "text": "Obtain EKG"
            },
            {
                "label": "C.",
                "text": "Obtain renal artery ultrasound"
            },
            {
                "label": "D.",
                "text": "Change combined to progestin-only OCP"
            },
            {
                "label": "E.",
                "text": "Measure serum aldosterone and plasma renin"
            }
        ],
        "correct_answer": "Change combined to progestin-only OCP",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This young woman with new-onset hypertension, associated with initiating combined estrogen-progestin OCPs, should change OCP formulation to avoid estrogen.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, the patient’s combined OCP raises concern for medication-induced hypertension. The mechanism of BP elevation as a result of estrogen administration is not completely understood but may relate to estrogen-mediated increased angiotensinogen production by the liver. The frequency of hypertension in patients taking pharmacologic estrogen is thought to be &lt;5%, with only mild increases in BP observed in most (mean systolic BP increase, 3–6 mm Hg). Hypertensive emergency with OCP use is rare. In patients with a history of hypertension during pregnancy, family history of hypertension, or family history of early coronary artery disease, close BP monitoring is advised with OCP use.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Prescribing an antihypertensive medication such as lisinopril may be appropriate if hypertension persists weeks to months after estrogen discontinuation but would not be the next best step at this time. Echocardiography may be useful to diagnose left ventricular hypertrophy as a consequence of prolonged hypertensive damage to the myocardium and may also help diagnose aortic coarctation in young women with hypertension, but this patient’s BP is equal in both arms, and she is unlikely to have had significant heart damage after only a few months of stage 1 hypertension. Renal artery duplex ultrasonography is a useful first step to evaluate renovascular disease, including fibromuscular dysplasia, which is an underdiagnosed cause of hypertension in young women. Measuring aldosterone and renin levels is a first step in evaluating for primary aldosteronism, but serum potassium and bicarbonate are normal and would not obviate the need to discontinue estrogen from the OCP formulation. Investigations such as these would be reasonable if hypertension were to persist after withdrawal of estrogen-containing medications.</p>\n</div>",
        "references": [
            "Shufelt C, LeVee A: Hormonal contraception in women with hypertension.JAMA324(14): 1451–1452, 2020",
            "Mir D, Ardabilygazir A, Afshariyamchlou S, Sachmechi I: Malignant hypertension in association with low estrogen dose oral contraceptives: case report and review of literature.Cureus10(7): e2978, 2018"
        ]
    },
    "7": {
        "question": "<div class=\"qtext\"><p>A 66-year-old man with a history of heart failure with reduced ejection fraction and ESRD secondary to diabetic nephropathy presents to the emergency department with shortness of breath and edema. He initiated HD one month ago and has not missed any treatments but has been unable to achieve his estimated dry weight of 78 kg. He reports that fluid removal during dialysis has been limited because of low BP and that he has gained an additional 4 kg during the last week. Current medications include aspirin, atorvastatin, lisinopril, carvedilol, and insulin.</p>\n<p>BP is 125/78 mm Hg, heart rate is 68/min, respiratory rate is 22/min, and oxygen saturation is 93% while breathing room air. Weight is 84 kg. Physical examination reveals jugular venous distention, an S3 gallop, crackles at the lung bases, and 3+ lower extremity edema. The remainder of the examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">131 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">4.7 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">95 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">98–106</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">22 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">64 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">5.2 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">0.7–1.3</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Glucose<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">88 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">70–99, fasting</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Estimated GFR<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">8 mL/min/1.73 m<sup>2</sup><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">≥60</td>\n</tr>\n</tbody>\n</table>\n<p>Twenty-four-hour urine output is 500 mL. Chest x-ray demonstrates bilateral pulmonary edema.</p>\n<p>HD with an ultrafiltration (UF) goal of 3 L over 4 hours is prescribed, but because of hypotension, only 1.5 L of UF is achieved.</p>\n<p><strong>Which of the following is the next BEST STEP in therapy?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe furosemide 120 mg twice daily"
            },
            {
                "label": "B.",
                "text": "Increase the duration of dialysis to 4.5 hours"
            },
            {
                "label": "C.",
                "text": "Prescribe spironolactone 50 mg daily"
            },
            {
                "label": "D.",
                "text": "Change modality to peritoneal dialysis"
            },
            {
                "label": "E.",
                "text": "Decrease the duration of dialysis to 3 hours"
            }
        ],
        "correct_answer": "Prescribe furosemide 120 mg twice daily",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient, who has residual kidney function, volume overload, and inadequate UF during HD, may benefit from high-dose loop diuretics.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">High-dose loop diuretic therapy has been associated with lower rates of hospitalization, less intradialytic hypotension, and improved volume management. Additional benefits include lower interdialytic weight gain and more dietary freedom because of enhanced potassium excretion. Studies have shown that these benefits accrue in patients with ESRD who have urine output as low as 200 mL/day.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Increasing the duration of dialysis can improve net UF during treatment, but adding 30 minutes to the duration of HD would be unlikely to result in adequate UF for this patient who is several kilograms above his dry weight. Longer dialysis times &gt;4.5 hours are impractical for most outpatient dialysis centers. Greater frequency of dialysis, such as daily, is often used during hospitalization but is not usually sustainable for outpatients receiving in-center treatment. Longer or more frequent treatments can often be incorporated into a home HD regimen.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Diuretic therapy with other classes of diuretics, such as thiazide diuretics or mineralocorticoid receptor antagonists, are less likely to augment urine output as effectively as high-dose loop diuretics. Additionally, spironolactone may increase the risk of hypotension and hyperkalemia. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient may ultimately benefit from transition to PD if intradialytic hypotension prevents adequate volume removal during HD. However, other measures such as loop diuretics are easier to implement immediately and should be attempted first. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Shortening the HD treatment would result in a higher UF rate, which would increase the risk of intradialytic hypotension and result in less fluid removal. Staying below a UF rate threshold of 13 mL/kg per hour has been associated with improved outcomes in some observational studies.</p>\n</div>",
        "references": [
            "Sibbel S, Walker AG, Colson C, et al: Association of continuation of loop diuretics at hemodialysis initiation with clinical outcomes.Clin J Am Soc Nephrol14: 95–102, 2019",
            "Bragg-Gresham JL, Fissell RB, Mason NA, et al: Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS).Am J Kidney Dis49(3): 426–431, 2007",
            "Kumra R, Bargman JM: A review of diuretic use in dialysis patients.Adv Perit Dial30: 115–119, 2014"
        ]
    },
    "8": {
        "question": "<div class=\"qtext\"><p>A 58-year-old woman with CKD stage 3, type 2 diabetes mellitus, hypertension, and hyperlipidemia presents to the outpatient clinic for routine follow-up. She feels well and has no complaints. Current medications include atorvastatin, hydrochlorothiazide, maximum dose lisinopril, and metformin.</p>\n<p>On exam, BP is 130/78 mm Hg and heart rate is 72/min. Weight is 75 kg, and body mass index is 34 kg/m<sup>2</sup>. She has trace lower extremity edema. The remainder of her examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 39.9614%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30.1158%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 39.9614%;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30.1158%;\">137 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 39.9614%;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30.1158%;\">5.2 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 39.9614%;\">Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30.1158%;\">102 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">98–106</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 39.9614%;\">CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30.1158%;\">24 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 39.9614%;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30.1158%;\">35 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 39.9614%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30.1158%;\">1.4 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 39.9614%;\">Glucose<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30.1158%;\">153 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">70–99, fasting</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 39.9614%;\">eGFR<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30.1158%;\">46 mL/min/1.73 m<sup>2</sup><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">≥60</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 39.9614%;\">Hemoglobin A<sub>1c</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30.1158%;\">7.9%<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">4.0–5.6</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 39.9614%;\">Urine protein-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 30.1158%;\">1.9 mg/mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">&lt;0.2</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which of the following is the MOST APPROPRIATE medication to preserve kidney function?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Insulin glargine"
            },
            {
                "label": "B.",
                "text": "Dapagliflozin"
            },
            {
                "label": "C.",
                "text": "Liraglutide"
            },
            {
                "label": "D.",
                "text": "Spironolactone"
            },
            {
                "label": "E.",
                "text": "No change in therapy"
            }
        ],
        "correct_answer": "Dapagliflozin",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next most appropriate medication to prescribe for this patient is dapagliflozin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient would benefit from starting dapagliflozin, a sodium-glucose cotransporter type 2 inhibitor (SGLT2i). SGLT2is have been shown to reduce albuminuria, slow the rate of eGFR decline, and delay progression to ESRD. This patient is prescribed a maximal dose of ACEI and continues to have substantial proteinuria (urine protein-to-creatinine ratio of 1.9 mg/mg). Her glycemic control is also suboptimal, so she would benefit from adding an SGLT2i. These medications also confer significant cardiovascular benefits in patients with proteinuric CKD, with and without diabetes, and congestive heart failure.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that would also provide glycemic control. Studies of GLP-1 receptor agonists have also demonstrated substantial improvements in albuminuria. Semaglutide was recently shown to improve kidney and cardiovascular outcomes in a large-scale clinical trial, but such data are not available for liraglutide, and the body of evidence for the benefit of SGLT2i is much more robust than for GLP-1 receptor agonists at this time. Most clinicians would initiate SGLT2i before GLP-1 receptor agonists to manage diabetic kidney disease. Other hypoglycemic agents that have been shown to reduce albuminuria include dipeptidyl-peptidase-4 (DPP-4) inhibitors and thiazolidinediones, but neither of these classes of medications have demonstrated reduction in the rate of eGFR decline or progression to ESRD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Adding insulin therapy would improve glycemic control. Tight glycemic control can reduce albuminuria, but insulin therapy has not been shown to slow the progression of diabetic kidney disease.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Spironolactone has been shown to reduce proteinuria when added to treatment with ACEI or ARB. However, this patient would be at risk for hyperkalemia, as her serum potassium is already mildly elevated. Furthermore, spironolactone would not improve glycemic control. Studies with finerenone, a nonsteroidal mineralocorticoid receptor blocker (MRB), show evidence of clinical benefit for kidney outcomes, but whether this benefit is a class effect that extends to other MRBs remains to be determined.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">As discussed above, this patient would benefit from addition of a hypoglycemic agent that can improve glycemic control, reduce albuminuria, and slow her progression of nephropathy, so continuing current management would not be the best choice. </p>\n</div>",
        "references": [
            "Scheen AJ: Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.Diabetes Metab45(2): 110–121, 2019",
            "Sloan LA: Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.JDiabetes11(12): 938–948, 2019",
            "Greco EV, Russo G, Giandalia A, et al: GLP-1 receptor agonists and kidney protection.Medicina55(6): 233–247, 2019",
            "Nicotera R, Casarella A, Longhitano E, et al: Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases.Pharmacol Res159: 105019, 2020",
            "Heerspink HJL, Stefansson BV, Correa-Rotter R, et al: Dapagliflozin in patients with chronic kidney disease.N Engl J Med383(15): 1436–1446, 2020",
            "Perkovic V, Jardine MJ, Neal B, et al: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.N Engl J Med380(24): 2295–2306, 2019",
            "Bakris GL, Agarwal R, Anker SD, et al: Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.N Engl J Med383(23): 2219–2229, 2020",
            "Perkovic V, Tuttle KR, Rossingg P et al: Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes.N Engl J Med391(2): 109–121, 2024"
        ]
    },
    "9": {
        "question": "<div class=\"qtext\"><p>A 75-year-old woman with a history of hypertension and gastroesophageal reflux presents to the emergency department with progressive weakness for the last 2 weeks. Her medications are omeprazole and hydrochlorothiazide, which was recently substituted for amlodipine because of ankle edema. Because of weakness and fatigue, the patient has not taken any medications for the last 3 days, and she has been eating poorly because of feeling too exhausted to cook. </p>\n<p>Vital signs include BP of 99/56 mm Hg, heart rate of 92/min, temperature of 36.9°C, oxygen saturation of 98% while breathing room air, and weight of 52 kg. Physical examination reveals a fatigued woman with dry mucous membranes and no edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\"><strong>Serum</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">137 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">2.4 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">98 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">98–106</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">30 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">41 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">1.5 (baseline, 0.9) mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Glucose<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">87 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">70–99, fasting</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Calcium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">8.5 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">8.6–10.2</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Albumin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">3.5 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">3.5–5.5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\"><strong>Urine</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">45 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">Varies</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">36 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">Varies<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">45 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">Varies<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Magnesium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">13 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">Varies<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">98 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">Varies<br/></td>\n</tr>\n</tbody>\n</table>\n<p>Isotonic saline 2 L IV and potassium chloride 160 mEq are administered. Repeat serum potassium 12 hours later is 3.0 mEq/L.</p>\n<p><strong>Which of the following is the MOST LIKELY cause of continued hypokalemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Inadequate potassium administration"
            },
            {
                "label": "B.",
                "text": "Saline administration"
            },
            {
                "label": "C.",
                "text": "Hypomagnesemia"
            },
            {
                "label": "D.",
                "text": "Persistent kaliuresis from hydrochlorothiazide"
            },
            {
                "label": "E.",
                "text": "Metabolic alkalosis"
            }
        ],
        "correct_answer": "Hypomagnesemia",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has profound hypokalemia in the setting of thiazide diuretic and proton-pump inhibitor (PPI) use, and magnesium depletion should be suspected. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The first step in the evaluation of hypokalemia is differentiating renal from non-renal potassium loss. Renal potassium wasting is confirmed by assessing renal potassium handling. Transtubular potassium gradient (TTKG) &gt;7 (as opposed to &lt;3, indicating GI losses) was historically used but should only be used in the setting of non-dilute urine with similar urine and serum osmolality. Because of this limitation, TTKG is no longer recommended to assess renal potassium handling. A spot urine potassium of &gt;40 mEq/L in the setting of hypokalemia may help to identify renal potassium wasting but may be falsely negative with dilute urine. A spot urine K/Cr accounts for fluctuations of urinary concentration, with a urine K/Cr ratio &gt;13 mEq/g signifying inappropriate renal potassium wasting in the setting of hypokalemia. In this case, the urine K/Cr ratio is (36 mEq/L) ¸ (0.98 g/L) = 36.7 mEq/g.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypokalemia caused by renal potassium wasting occurs as a result of increased distal sodium delivery, increased flow, and high aldosterone, all of which stimulate potassium secretion into the lumen via the apical renal outer medullary potassium channel (ROMK). Thiazide diuretics cause inhibition of the sodium chloride co-transporter (NCC), resulting in increased distal sodium delivery and flow, both of which stimulate potassium secretion. Hydrochlorothiazide has a half-life of 5.6‒14.8 hours, so should no longer be active in this patient who has not taken any medications for 3 days.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Serum magnesium levels should be assessed as part of the initial evaluation of hypokalemia caused by renal potassium wasting. Hypokalemia associated with hypomagnesemia is refractory to potassium repletion. Long-term use of PPIs can cause chronic hypomagnesemia. PPIs, by causing increased luminal pH, decrease the affinity of the apical enterocyte transcellular Mg<sup>2+</sup> transport channels, transient receptor potential melastatin (TRPM)-6 and -7, to luminal Mg<sup>2+</sup>, resulting in decreased enteric magnesium absorption. Thiazide diuretics further exacerbate hypomagnesemia by increasing urinary magnesium excretion at the distal convoluted tubule. Animal models have shown that thiazide-induced NCC inhibition decreases the number of active TRPM6 channels. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Intracellular magnesium is a cofactor for ROMK and inhibits potassium efflux in a concentration-dependent manner. Prolonged hypomagnesemia can lead to disinhibition of ROMK in the distal tubule and refractory potassium wasting. Therefore, it is essential to assess for and replete magnesium in patients with hypokalemia. Fractional excretion of magnesium can be used to distinguish between renal (hydrochlorothiazide) and non-renal (PPI) causes of hypmagnesemia. In this case, data on serum magnesium are lacking, but hypomagnesemia can be inferred. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">It has been estimated that 200 mEq potassium is required for each 70 kg of body weight to raise the serum potassium by 1 mEq/L, although these amounts may vary greatly depending on other sources of potassium input and output, and total body potassium is difficult to estimate as it is predominantly intracellular. In this case, however, 160 mEq of potassium should have raised the potassium by 1.1 mEq/L in this 52-kg patient, so potassium supplementation would appear to be sufficient in the absence of ongoing losses.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">As mentioned above, administration of sodium with kaliuresis can cause ongoing potassium loss, but 2 L isotonic fluid volume resuscitation in a volume-depleted patient such as this one would not be expected to impair correction of serum potassium. Correction of volume depletion would be expected to reduce aldosterone stimulation, reducing potassium excretion and balancing the effect of saliuresis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Metabolic alkalosis can cause or worsen hypokalemia through cellular shift, but the effect is trivial. The carbonic anhydrase inhibitor acetazolamide should be avoided, as it would worsen hypokalemia. </p>\n</div>",
        "references": [
            "Palmer BF, Clegg DJ: Physiology and pathophysiology of potassium homeostasis: core curriculum 2019.Am J Kidney Dis74(5): 682‒695, 2019",
            "Unwin RJ, Luft FC, Shirley DG: Pathophysiology and management of hypokalemia: a clinical perspective.Nat Rev Nephrol7(2): 75‒84, 2011",
            "Palmer BF: A physiologic-based approach to the evaluation of a patient with hypokalemia.Am J Kidney Dis56(6): 1184‒1190, 2010",
            "Perazella MA: Proton pump inhibitors and hypomagnesemia: a rare but serious complication.Kidney Int83(4): 553‒556, 2013",
            "Huang CL, Kuo E: Mechanism of hypokalemia in magnesium deficiency.J Am Soc Nephrol18(10): 2649‒2652, 2007",
            "Franken GAC, Adella A, Bindels RJM, de Baaij JHF: Mechanisms coupling sodium and magnesium reabsorption in the distal convoluted tubule of the kidney.Acta Physiol (Oxf)231(2): e13528, 2021"
        ]
    },
    "10": {
        "question": "<div class=\"qtext\"><p>A 19-year-old man with no significant past medical history presents to the emergency room complaining of right testicular pain. He was feeling well until about 2 hours before presentation, when he suddenly developed sharp pain in his right testicle. He did not experience any preceding trauma, fever, or chills. His pain has been associated with nausea but no emesis. Mild dysuria is present, but the color and amount of urine have been normal.</p>\n<p>On examination, he is in moderate distress. His BP is 135/88 mm Hg and heart rate is 90/min. There is no rash. His lungs are clear, and cardiovascular examination reveals regular rate and rhythm. His abdomen is soft and without tenderness or masses. The scrotal skin is normal in appearance bilaterally without lesions, erythema, or induration. The testes are firm, similar in size, and non-tender to palpation. No masses are appreciated, and palpation of the right epididymis elicits no pain. The cremasteric reflex is positive in both testes. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">WBC count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">6,100/µL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">4000–11,000</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Hemoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">13.1 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">14–18</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Platelet count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">260,000/mL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">150,000–450,000</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">4.8 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">18 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px;\">Creatinine <br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 33.6717%;\">1.0 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 26.1739%;\">0.7–1.3</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis demonstrates a pH of 6.1, specific gravity of 1.015, 3+ blood, and negative protein, leukocyte esterase, and nitrite.</p>\n<p><strong>In addition to obtaining a urine culture, which of the following is the MOST appropriate next step in evaluation of the patient’s right scrotal pain?</strong> </p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Non-contrast CT of the abdomen and pelvis"
            },
            {
                "label": "B.",
                "text": "Ultrasound with duplex Doppler evaluation of the scrotum"
            },
            {
                "label": "C.",
                "text": "Urine nucleic acid amplification test forChlamydia trachomatis"
            },
            {
                "label": "D.",
                "text": "Abdominal arteriogram"
            },
            {
                "label": "E.",
                "text": "ANCA serology"
            }
        ],
        "correct_answer": "Non-contrast CT of the abdomen and pelvis",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient should undergo a non-contrast CT scan of the abdomen and pelvis to evaluate for nephrolithiasis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although an uncommon presentation, ureteral colic may present as unilateral scrotal pain. Inflammation of the ureter may cause irritation of the genitofemoral nerve, which originates from the first and second lumbar nerves and courses behind the ureter, referring pain to the scrotum. Dysuria and urgency are common symptoms of nephrolithiasis that occur when the stone is located in the distal ureter. The presence of microscopic hematuria in addition to scrotal pain and dysuria, in the absence of physical examination findings, should prompt consideration of nephrolithiasis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Testicular torsion causes sudden onset of pain caused by ischemia of the spermatic cord. Prompt diagnosis of torsion is critical, because prolonged ischemia may lead to testicular loss. Physical examination may demonstrate an elevated scrotum with diffuse tenderness and swelling of the testicle. The absence of a cremasteric reflex is a characteristic finding of acute testicular torsion. Although physical examination is often pathognomonic, Doppler ultrasound may be performed to confirm the diagnosis. Given the absence of physical findings on examination, testicular torsion is unlikely. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Epididymitis is the most common etiology for acute scrotal pain in adults. Most cases are infectious, but trauma and autoimmune disease may also be associated with epididymitis, particularly when the presentation is subacute or chronic. <em>Chlamydia trachomatis</em> and <em>Neisseria gonorrhoeae </em>are responsible for most infections in men &lt;35 years of age, whereas <em>Escherichia coli</em> infection is more common in older men and is associated with benign prostatic hypertrophy. The onset of pain is typically more gradual than that seen with testicular torsion, and swelling and tenderness are typically localized to the epididymis, although advanced cases can progress to the testicle. The cremasteric reflex is positive. Although lower urinary tract symptoms may be present with epididymitis, the urinalysis does not demonstrate pyuria, and thus it is unlikely the etiology for the patient’s dysuria, particularly with a negative examination. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Both immunoglobulin A vasculitis (IgAV) and polyarteritis nodosa (PAN) are systemic vasculitides that may present with scrotal pain. Palpable purpura, arthritis, kidney disease, abdominal pain, and gastrointestinal bleeding are common manifestations of IgAV. Scrotal involvement by IgAV is very similar to testicular torsion with pain, tenderness, and swelling of the involved scrotum. Imaging with ultrasound and radionuclide scanning demonstrates normal testicular blood flow in IgAV, whereas decreased blood flow would be present with testicular torsion. Arteriogram is not typically needed for diagnosis. PAN is a necrotizing vasculitis that primarily affects medium-sized vessels and involves the skin, kidneys, nerves, and gastrointestinal tract. Although most cases are idiopathic, hepatitis B and C infection may be associated with PAN. Whereas PAN is a medium-vessel vasculitis, ANCA causes a small-vessel vasculitis manifesting frequently as glomerulonephritis. Testicular involvement from PAN presents with pain and tenderness in the scrotum and may occur in up to 28% of affected patients. Although arteriogram may demonstrate characteristic aneurysms and irregular constriction of the larger vessels, biopsy of the affected organ is the preferred method of diagnosis. Despite hematuria found on urinalysis, in the absence of other symptoms of a systemic vasculitis and a normal examination, vasculitis is unlikely the etiology for the patient’s scrotal pain. </p>\n</div>",
        "references": [
            "McGee SR: Referred scrotal pain: case reports and review.J Gen Intern Med8(12): 694–701, 1993",
            "Wampler SM, Llanes M: Common scrotal and testicular problems.Prim Care37(3): 613–626, 2010",
            "Meeuwissen J, Maertens J, Verbeken E, Blockmans D: Case reports: testicular pain as a manifestation of polyarteritis nodosa.Clin Rheumatol27(11): 1463–1466, 2008"
        ]
    },
    "11": {
        "question": "<div class=\"qtext\"><p>A 68-year-old woman with long-standing type 2 diabetes complicated by neuropathy and hypertension is evaluated for proteinuria and increased serum creatinine. Her medications include glipizide, valsartan, amlodipine, atorvastatin, and aspirin. She reports no changes to her medication regimen and does not use over-the-counter medications, herbal supplements, or NSAIDs. She feels well and reports no problems with urination, changes in weight, fever, rash, arthralgias, or cardiopulmonary symptoms.</p>\n<p>BP is 142/60 mm Hg, heart rate is 75/min, and body mass index is 29 kg/m<sup>2</sup>. On examination, she has retinal cotton wool spots and 1+ edema of her lower extremities bilaterally.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 29.971%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\"><strong>6 Months Ago</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\"><strong>Current Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">WBC count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">8000/µL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">7300<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">4000–11,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Hemoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">12.6 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">12.4<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">12–16<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Platelet count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">230,000/µL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">263,000<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">150,000–450,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">4.5 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">4.7<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">1.1 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">1.9<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">0.5–1.1<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Calcium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">9.0 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">9.2<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">8.6–10.2<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Albumin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">3.9 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">3.8<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">3.5–5.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Total protein<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">7.1 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">6.8<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">5.5–9.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Hemoglobin A<sub>1C</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">7.2%<span style=\"white-space:pre;\"> </span><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">7.3<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">4.0–5.6<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Urine protein-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\">0.8 mg/mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">2.5<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">&lt;0.2<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Free kappa light chain<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">30 mg/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">3.3–19.4<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Free lambda light chain<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">7 mg/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">5.7–26.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">Free kappa-to-free lambda light chain ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.5869%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px; width: 22.4421%;\">4.28<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 15px; width: 29.971%;\">0.26–1.65<br/></td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis demonstrates 3+ protein but is otherwise normal. Urine microscopy demonstrates occasional granular casts. </p>\n<p>Serum protein electrophoresis (SPEP) and immunofixation are normal. Urine protein electrophoresis (UPEP) and immunofixation reveal 2.5 g protein/24 h consisting of 90% albumin with no Bence-Jones proteins.</p>\n<p>Kidney ultrasound demonstrates bilateral 11-cm kidneys with mildly increased echogenicity. The postvoid bladder volume is 25 mL.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe canagliflozin"
            },
            {
                "label": "B.",
                "text": "Perform kidney biopsy"
            },
            {
                "label": "C.",
                "text": "Perform bone marrow biopsy"
            },
            {
                "label": "D.",
                "text": "Measure antinuclear antibodies"
            },
            {
                "label": "E.",
                "text": "Prescribe spironolactone"
            }
        ],
        "correct_answer": "Perform kidney biopsy",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate next step for this patient with worsening proteinuria and kidney function is to perform a kidney biopsy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient has evidence of diabetes-related microvascular disease and may well have diabetic kidney disease, this diagnosis would be unlikely to explain the relatively rapid worsening of proteinuria and eGFR. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient, the SPEP and UPEP with immunofixation (SIFE and UIFE, respectively) were negative for a monoclonal protein, but the serum free light chain ratio was abnormal, which is suspicious for a monoclonal gammopathy of renal significance (MGRS). The serum free light chain assay, which individually measures kappa and lambda light chains, is the most sensitive test to diagnose MGRS. In one study, only 85% of patients with monoclonal immunoglobulin deposition disease (MIDD) had a positive SPEP, SIFE, UPEP, or UIFE. All patients, however, had an abnormal serum free light chain assay.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A wide spectrum of kidney diseases can be induced by monoclonal immunoglobulins, including some glomerular lesions that may mimic diabetic nephropathy. In these cases, IF and EM are essential to establishing the diagnosis. Amyloidosis and C3 glomerulopathy, for example, can be induced by light chains and present with heavy albuminuria rather than Bence-Jones proteinuria.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although bone marrow biopsy could reveal a plasma cell or lymphocyte dyscrasia, demonstration of myeloma or a lymphocytic lymphoma would be unexpected in the absence of more overt laboratory abnormalities or cytopenias.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Measurement of antinuclear antibodies, and/or other studies such as anti-phospholipase A2 receptor antibodies, complement levels, and hepatitis serologies, among others, would be reasonable to obtain in the investigation of proteinuria and decreased kidney function. However, even if results were abnormal, kidney biopsy would still be necessary to determine whether an MGRS is present.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Optimizing the medical management of this patient’s diabetes by adding a sodium-glucose transporter type 2 inhibitor, such as canagliflozin, or a mineralocorticoid receptor blocker, such as spironolactone or finerenone, are adjunctive treatments that can reduce proteinuria and preserve kidney function in patients with diabetic kidney disease. However, these measures would not obviate the need for a kidney biopsy in this case.</p>\n</div>",
        "references": [
            "Hsieh JT, Chang FP, Yang AH, et al: Timing of kidney biopsy in type 2 diabetic patients: a stepwise approach.BMC Nephrol21: 131, 2020",
            "Leung N, Bridoux F, Batuman V, et al: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.Nat Rev Nephrol15: 45–59, 2019",
            "Nasr SH, Valeri AM, Cornell LD, et al: Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution.Clin J Am Soc Nephrol7(2): 231–239, 2012"
        ]
    },
    "12": {
        "question": "<div class=\"qtext\"><p>A 55-year-old man with CKD stage 5 caused by type 2 diabetes presents for preemptive kidney transplant evaluation. CKD was diagnosed 15 years ago and gradually progressed. Three years ago, a kidney biopsy showed diabetic nephropathy with 70% tubular atrophy and interstitial fibrosis. One year ago, the patient was diagnosed with monoclonal gammopathy of undetermined significance (MGUS) during evaluation for worsening proteinuria. At that time, serum protein electrophoresis (SPEP) showed serum M protein of 2 g/dL, and immunofixation identified IgG kappa monoclonal protein with kappa-to-lambda free light chain ratio of 2.2. A bone marrow biopsy showed 6% plasma cells. A low-dose whole-body CT scan was negative for lytic lesions. His hemoglobin was 12.5 g/dL. The patient feels well, and no other potential barriers to transplantation were revealed during pretransplant evaluation. </p>\n<p>His current medications include insulin, lisinopril, furosemide, calcitriol, sevelamer, and pregabalin.</p>\n<p>Office BP is 155/90 mm Hg and body mass index is 29 kg/m<sup>2</sup>. The physical examination is normal.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">WBC count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">7000/μL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4000–11,000</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">Hemoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">12.2 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">14–18</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">Platelet count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">190,000/μL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">150,000–450,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">Calcium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">9 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8.6–10.2<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">5.9 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">eGFR<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">10 mL/min/1.73 m<sup>2</sup><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">≥60<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">SPEP M-spike<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.3 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">Free kappa-to-free lambda light chain ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.4<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.26–1.65<br/></td>\n</tr>\n</tbody>\n</table>\n<p>Serum immunoglobulin levels are normal.<br/></p>\n<p>The patient’s daughter and brother are potential living kidney donors.</p>\n<p><strong>Which of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Proceed with transplantation"
            },
            {
                "label": "B.",
                "text": "Repeat bone marrow biopsy"
            },
            {
                "label": "C.",
                "text": "Repeat low-dose whole-body CT"
            },
            {
                "label": "D.",
                "text": "Defer transplantation"
            },
            {
                "label": "E.",
                "text": "Repeat kidney biopsy"
            }
        ],
        "correct_answer": "Proceed with transplantation",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Following discussion of the risks of developing multiple myeloma (MM), this patient should be offered the opportunity to proceed with living donor kidney transplantation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">MGUS is a premalignant, monoclonal plasma cell proliferative disorder that is diagnosed when the serum M protein is &lt;3 g/dL, the bone marrow plasma cell fraction is &lt;10%, and in the absence of systemic manifestations of MM including hypercalcemia, AKI, anemia, and lytic bone lesions (CRAB). This patient has mild anemia, but it is more likely attributable to the anemia of advanced CKD. MGUS affects 3% of adults &gt;50 years old. Annually, 1% of cases progress to MM, and the cumulative probability of progression is 12% at 10 years, 25% at 20 years, and 30% at 25 years. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">MGUS may also develop after transplantation, with a 5-year incidence rate of 2.7%. Twenty-one percent of these cases are transient. Both pre- and post-transplant patients with MGUS have similar patient and graft survival compared with those without MGUS. In a study of 3518 patients, retrospective analysis elicited 23 pre-transplant and 19 post-transplant MGUS cases. Over a median follow-up of 8.5 years, none of these cases progressed to symptomatic MM, but 2 patients developed smoldering MM, which is diagnosed when the serum M-spike is ≥3 g/dL and/or bone marrow clonal plasma cell prevalence is 10–60% in the absence of CRAB. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">MGUS should not preclude otherwise appropriate candidates from kidney transplantation. However, these patients should be evaluated with laboratory testing including SPEP, calcium, immunoglobulin, and serum free light chain levels to ensure stability of disease. Repeat bone marrow or kidney biopsy or low-dose whole-body CT are not indicated. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Of note, the free light chain ratio is affected by declining GFR, and many authors suggest an alternative normal range of 0.37–3.1 in patients with advanced CKD.</p>\n</div>",
        "references": [
            "Jimenez-Zepeda VH, Heilman RL, Engel RA, et al: Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants.Transplantation92(5): 570–574, 2011",
            "Gagnon MF, Cardinal H, Emond JP, et al: The evolution of monoclonal gammopathy of undetermined significance in kidney transplant recipients.Transplant Direct5(10): e489, 2019",
            "Cowan AJ, Johnson CK, Libby EN: Plasma cell diseases and organ transplant: A comprehensive review.Am J Transplant18(5): 1046–1058, 2018",
            "Kyle RA, Therneau TM, Rajkumar SV, et al: Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later.Mayo Clin Proc79(7): 859–866, 2004",
            "Naina HVK, Harris S, Dispenzieri A, et al: Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.Am J Nephrol35(4): 365–371, 2012",
            "Hutchinson CA, Harding S, Hewins P, et al: Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease.Clin J Am Soc Nephrol3(6): 1684–1690, 2008"
        ]
    },
    "13": {
        "question": "<div class=\"qtext\"><p>A 50-year-old woman with a history of living unrelated kidney transplant 3 years ago presents with reduced urine output for the last 2 days. She has otherwise been well and asymptomatic except for chronic aching pain in her knees. ESRD was caused by IgA nephropathy, and medical history includes osteoarthritis, gastroesophageal reflux disease, and hypertension. One month ago, she was evaluated by her primary care provider who prescribed a vitamin D supplement, alendronate, and omeprazole. The patient also received her annual standard-dose, tetravalent influenza vaccine injection at the office visit. Her other medications are mycophenolate mofetil, tacrolimus, prednisone, carvedilol, and amlodipine. The patient has not had any side effects from medications and says she does not miss any medication doses.</p>\n<p>Laboratory testing shows serum creatinine 3.4 mg/dL (baseline, 1.3; reference range, 0.5–1.1) and tacrolimus trough 7 ng/mL (reference range, 5–10 &gt;3 months after transplantation). A kidney biopsy shows Banff grade 1B acute cellular rejection (severe tubulitis and moderate interstitial inflammation).</p>\n<p><strong>Which medication is MOST LIKELY responsible for AKI?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Ergocalciferol"
            },
            {
                "label": "B.",
                "text": "Influenza vaccine"
            },
            {
                "label": "C.",
                "text": "Omeprazole"
            },
            {
                "label": "D.",
                "text": "Alendronate"
            },
            {
                "label": "E.",
                "text": "Tacrolimus"
            }
        ],
        "correct_answer": "Omeprazole",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Omeprazole is the medication most likely to have caused AKI because of acute rejection by interfering with mycophenolate metabolism.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Immunosuppressive medications prescribed to patients with kidney transplants interact with many other commonly prescribed medications, and these interactions may affect drug levels. Mycophenolate mofetil (MMF) pharmacokinetics may be affected by several classes of medications, which could cause allograft rejection in the case of increased MMF metabolism with subtherapeutic levels or toxicity from side effects (nausea, diarrhea, leukopenia, or infection) in the case of decreased metabolism with supratherapeutic levels. Omeprazole is the most likely culprit for this patient’s acute rejection because proton pump inhibitors increase gastric pH and impair MMF absorption. In some cases, this effect may be circumvented by using enteric-coated MMF.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">MMF is an inhibitor of inosine monophosphate dehydrogenase, which is a rate-limiting enzyme in de novo purine synthesis, and MMF inhibits both B- and T-cell proliferation. MMF is a prodrug with oral bioavailability of 80–90%. After administration, MMF is converted into its active metabolite, mycophenolic acid (MPA), in intestinal and liver cells. Most of the MPA is metabolized to its inactive form by glucuronyltransferases in the liver and excreted into the bile. Next, glucuronidated MPA (G-MPA) undergoes de-glucuronidation by the intestinal flora, resulting in MPA reformation in the gut. The reabsorption of MPA leads to a secondary peak in blood MPA concentrations (enterohepatic recycling). Ultimately, 90% of the G-MPA is excreted in the urine through active tubular secretion. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although cyclosporine decreases MPA trough levels through the inhibition of G-MPA excretion into the bile, leading to diminished enterohepatic recirculation, this effect does not occur with tacrolimus or mammalian target of rapamycin inhibitors. Again, this effect can be overcome by using enteric-coated MMF. Certain antibiotics, such as ciprofloxacin, amoxicillin/clavulanic acid, and metronidazole also reduce the enterohepatic recirculation of MPA, potentially by killing intestinal flora or inhibiting glucuronidation. Cholestyramine also decreases biliary excretion of MMF metabolites and enterohepatic recirculation. Calcium supplements, if taken at the same time as MMF, may significantly reduce its absorption by forming a cation-anion complex with MMF. If the administration of calcium is separated from MMF by at least 2 hours, no significant drug-drug interaction is seen.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ergocalciferol does not affect MMF pharmacokinetics. Some IV bisphosphonates can cause AKI, but PO alendronate does not, nor does it affect anti-rejection medication pharmacokinetics. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although there has been concern that immunization may provoke rejection, influenza vaccination is recommended for all kidney transplant recipients. Studies show that graft and patient survival is superior in vaccinated patients, and increased risk of rejection has not been observed. Some studies suggest a better response to a double dose or booster dose of the vaccine. The nasal, live-virus vaccine formulation, like other live virus vaccines, should not be given to kidney transplant recipients.</p>\n</div>",
        "references": [
            "Benjanuwattra J, Pruksakorn D, Koonrungsesomboon N: Mycophenolic acid and its pharmacokinetic drug-drug interactions in humans: review of the evidence and clinical implications.J Clin Pharmacol60(3): 295–311, 2020",
            "Gregoor PJ, de Sévaux RG, Hené RJ, et al: Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients.Transplantation68(10): 1603–1606, 1999",
            "Kofler S, Shvets N, Bigdeli AK, et al: Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients—a prospective case-controlled study.Am J Transplant9(7): 1650–1656, 2009",
            "Ratna P, Mathew BS, Annapandian VM, et al: Pharmacokinetic drug interaction of mycophenolate with co-amoxiclav in renal transplant patients.Transplantation91(6): e36–38, 2011",
            "Kalantar-Zadeh K, Molnar MZ, Kovesdy CP, et al: Management of mineral and bone disorder after kidney transplantation.Curr Opin Nephrol Hypertens21(4): 389–403, 2012",
            "Arora S, Kipp G, Bhanot N, et al: Vaccinations in kidney transplant recipients: clearing the muddy waters.World J Transplant9: 1–13, 2019"
        ]
    },
    "14": {
        "question": "<div class=\"qtext\"><p>A 21-year-old woman who underwent kidney transplantation is seen in the outpatient clinic. At age 16, she received a deceased donor kidney transplant for a diagnosis of FSGS. Her post-transplant course has been stable, with no episodes of rejection or hospital admissions. Current medications include tacrolimus, mycophenolate, and lisinopril. Family history reveals no kidney disease in the patient’s parents, but 1 sister of 7 siblings also developed ESRD attributed to FSGS. The patient has a 2-year-old son who is healthy.</p>\n<p>Physical examination, including vital signs, is unremarkable, other than small cataracts bilaterally. Laboratory data reveal creatinine 1.1 mg/dL (reference range, 0.5–1.1) and urinalysis without albumin or blood.</p>\n<p>The patient is referred to ophthalmology, and she is diagnosed with anterior lenticonus and dot-and-fleck retinopathy. Subsequent audiometry reveals subclinical sensorineural hearing loss.</p>\n<p><strong>Which of the following is the MOST LIKELY outcome for this patient’s son?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "End-stage renal disease"
            },
            {
                "label": "B.",
                "text": "Sensorineural deafness"
            },
            {
                "label": "C.",
                "text": "Nephrotic syndrome"
            },
            {
                "label": "D.",
                "text": "Anterior lenticonus"
            },
            {
                "label": "E.",
                "text": "Microscopic hematuria"
            }
        ],
        "correct_answer": "Microscopic hematuria",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient, with a probable diagnosis of autosomal recessive Alport syndrome, is most likely to have a son who is hemizygous for a type IV collagen mutation, which frequently manifests as asymptomatic microscopic hematuria.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Because Alport syndrome is one of the myriad causes of secondary FSGS, and it is often not possible to distinguish primary from secondary FSGS on histopathologic grounds, an underlying diagnosis of Alport syndrome can be missed, such as occurred in this case. Alport syndrome is caused by mutations in genes encoding components of type IV collagen, which is present in the GBM. The classic lesion is a mutation in the <em>COL4A5</em> gene, which is present on the X chromosome and encodes the α5 chain of type IV collagen; this mutation is responsible for kidney disease in 80% of patients with Alport syndrome. Other inheritance patterns, including autosomal dominant and autosomal recessive, also exist but are less common (15% and 5% of patients, respectively). Certain ophthalmologic features may distinguish X-linked from autosomal recessive Alport syndrome. Lenticonus, central retinopathy, and macular hole are rare in women with X-linked disease and suggest autosomal recessive inheritance. Alport syndrome may also be accompanied by anterior lenticonus, dot-and-fleck retinopathy, and sensorineural deafness, all of which are present in this patient and ultimately revealed the correct diagnosis. The inheritance pattern, affecting 2 female siblings of 8 children, suggests autosomal recessive inheritance. Thus, this patient’s son would carry 1 of 2 alleles for Alport syndrome, which may present as asymptomatic microscopic hematuria, frequently diagnosed as thin basement membrane disease. ESRD can occur in patients with Alport syndrome, such as this one, but the patient’s son would not be expected to develop progressive kidney disease. Sensorineural deafness, anterior lenticonus, and proteinuria (usually non-nephrotic) would also develop in those affected by disease but not in carriers.</p>\n</div>",
        "references": [
            "Savige J, Sheth S, Leys A, et al: Ocular features in Alport syndrome: pathogenesis and clinical significance.Clin J Am Soc Nephrol10(4): 703–709, 2015",
            "Tryggvason K, Patrakka J: Thin basement membrane nephropathy.J Am Soc Nephrol17(3): 813–822, 2006",
            "Savige J, Storey H, Cheong HI, et al: X-linked and autosomal recessive Alport syndrome: pathogenic variant features and further genotype-phenotype correlations.PLoS One11(9): e0161802, 2016",
            "Kamiyoshi N, Nozu K, Xue JF, et al: Genetic, clinical, and pathologic backgrounds of patients with autosomal dominant Alport syndrome.Clin J Am Soc Nephrol11(8): 1141–1149, 2016"
        ]
    },
    "15": {
        "question": "<div class=\"qtext\"><p>A 23-year-old man is referred for evaluation of CKD. During a life insurance evaluation 4 months ago, a serum creatinine of 1.7 mg/dL was found. The patient has no significant medical history, and he was born at term. He takes no prescribed or over-the-counter medications, including NSAIDs, herbal products, or illicit drugs. The patient’s mother is well. His father died in a motor vehicle accident at age 26. Both the patient and his 20-year-old sister have had nocturia since childhood. Review of systems is otherwise negative.</p>\n<p>On examination, BP is 110/70 mm Hg, heart rate is 64/min, and body mass index is 24 kg/m<sup>2</sup>. Pupils, fundi, and visual acuity are grossly normal. Hearing is grossly intact to whispered speech. Heart, lung, and abdominal examinations are normal, and there is no edema or rash. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 39.6727%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">142 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.0 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.8 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Calcium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">9.5 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">8.6–10.2<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Phosphorus<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.4 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">3.0–4.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Albumin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.2 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">3.5–5.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Urine albumin-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">42 mg/g<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">&lt;30<br/></td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis reveals specific gravity 1.010, trace albumin, and no blood. Microscopy is unremarkable.</p>\n<p>Kidney ultrasound shows normal-sized kidneys with mildly increased echogenicity.</p>\n<p><strong>Which of the following tests would be MOST LIKELY to yield a diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Kidney disease genetic panel"
            },
            {
                "label": "B.",
                "text": "24-hour urine protein electrophoresis"
            },
            {
                "label": "C.",
                "text": "Kidney biopsy"
            },
            {
                "label": "D.",
                "text": "Vision and hearing testing"
            },
            {
                "label": "E.",
                "text": "24-hour urine oxalate measurement"
            }
        ],
        "correct_answer": "Kidney disease genetic panel",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with CKD of unknown etiology, low-grade albuminuria, and a family history of nocturia, a kidney disease genetic panel may be revealing.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">CKD that occurs before the age of 25 years has a high likelihood of genetic origin. Nocturia, as experienced by this patient and his sibling, suggests a concentrating defect that can be an early symptom of CKD. Testing for monogenic forms of kidney disease has traditionally been cumbersome and expensive, but several commercially available genetic testing panels are now available in the United States. Autosomal dominant tubulointerstitial kidney disease (ADTKD) is most likely given the possibility of an affected sibling, along with the clinical features of low-grade albuminuria and possible concentrating defect. Although management options are limited, identification of a genetic cause of CKD may help with future family planning.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Twenty-four-hour urine protein measurement, especially for low molecular weight proteins, could be considered for patients with suspected Dent disease, an X-linked disorder caused by a mutation in a voltage-gated chloride transporter in renal tubular lysosomes. This disease is also accompanied by calciuria and phosphaturia, causing nephrocalcinosis, which is not present in this patient.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney biopsy would not be expected to be diagnostic in this patient with minimal albuminuria, no hematuria, and a bland urine sediment. Histologic findings in ADTKD are nonspecific.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Formal vision and hearing testing may assist with early diagnosis of Alport syndrome, another genetic disorder involving one of several genes encoding components of type IV collagen, a constituent of the GBM. The absence of hematuria and significant proteinuria make Alport syndrome less likely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Twenty-four-hour urine oxalate measurement could help identify primary hyperoxaluria, a genetic disorder of oxalate metabolism that affects the liver and kidneys. The lack of nephrolithiasis or nephrocalcinosis makes this diagnosis unlikely.</p>\n</div>",
        "references": [
            "Groopman EE, Marasa M, Cameron-Christie S, et al: Diagnostic utility of exome sequencing for kidney disease.N Engl J Med380(2): 142–151, 2019",
            "Vivante A, Skorecki K: Introducing routine genetic testing for patients with CKD.Nat Rev Nephrol15(6): 321–322, 2019",
            "Vivante A, Hildebrandt F: Exploring the genetic basis of early-onset chronic kidney disease.Nat Rev Nephrol12(3): 133–146, 2016"
        ]
    },
    "16": {
        "question": "<div class=\"qtext\"><p>A 46-year-old man is seen in the emergency department for elevated serum creatinine and hypertension. He moved from Brazil 2 months ago and has been unable to refill his antihypertensive medications, including labetalol and amlodipine. Review of systems is unremarkable except for intermittent left-sided back pain for the last month. As a child, he experienced multiple hospitalizations for kidney infections and had urologic surgery, but he is unable to provide more details. </p>\n<p>BP is 176/96 mm Hg and heart rate is 102/min. Serum creatinine is 3.1 mg/dL (reference range, 0.7–1.3; baseline unknown) and potassium is 4.9 mEq/L (reference range, 3.5–5.0). Urine dipstick shows no protein or blood.</p>\n<p>Kidney and bladder ultrasound show a post-void bladder volume of 44 mL. His right kidney is atrophic and measures 4.4 cm in length, and a representative image of his left kidney is shown below.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv7m2b1q16.png\" width=\"75%\"/><br/>\n<figcaption><em>Image courtesy of University of Massachusetts Memorial Medical Center.</em></figcaption>\n</figure>\n<p><strong>Which of the following is the next BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Urinary bladder catheter"
            },
            {
                "label": "B.",
                "text": "Tamsulosin"
            },
            {
                "label": "C.",
                "text": "Percutaneous nephrostomy tube"
            },
            {
                "label": "D.",
                "text": "CT of the abdomen and pelvis"
            },
            {
                "label": "E.",
                "text": "Tolvaptan"
            }
        ],
        "correct_answer": "CT of the abdomen and pelvis",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in management for this patient with hydronephrosis on ultrasound is CT of the abdomen and pelvis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has evidence of hydronephrosis of his left kidney on the ultrasound image shown, with expansion of the renal pelvis that extends to the calyces. The precise cause and chronicity of the hydronephrosis cannot be determined from the provided ultrasound image or report, but it can be concluded that the hydronephrosis is not caused by bladder outlet obstruction given the low bladder volume. This patient has an atrophic right kidney with a history of multiple episodes of pyelonephritis and surgeries as a child, which would raise suspicion for either recurrent nephrolithiasis or a congenital anomaly of the kidney and urinary tract (CAKUT). A CT scan of the abdomen and pelvis without IV contrast would be the most appropriate next step to evaluate for obstructing stones and would provide additional information on other potential causes of urinary tract obstruction to inform the most appropriate urologic intervention. CT urography with IV contrast could provide more detailed information, but concern for contrast-associated AKI in this patient with decreased kidney function makes a non-contrast CT the preferred initial study. MRI with gadolinium would also provide detailed images of the urinary tract but would not detect stones as well as CT.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Placing a urinary bladder catheter or prescribing tamsulosin would not be appropriate, because the cause of his hydronephrosis is not bladder outlet obstruction (i.e., from benign prostate hypertrophy), as his low bladder volume indicates that the obstruction is proximal to the bladder.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Placing a percutaneous nephrostomy (PCN) tube may be necessary to bypass the obstruction, but in the absence of an emergent indication for drainage, such as suspected infection or more severe CKD, the cause of the obstruction should be established so that alternative therapies (ureteral stent, removal of impacted ureteral stone) can be considered if appropriate. If relief of obstruction is deemed emergent, diagnostic studies, such as anterograde pyelography, can be accomplished after placement of a PCN tube.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Tolvaptan would not be appropriate for this patient, because the abnormalities on ultrasound are not caused by ADPKD. In contrast to hydronephrosis, kidney cysts appear as discrete, round, hypoechoic (black) lesions distributed throughout the renal parenchyma.</p>\n</div>",
        "references": [
            "Niyyar VD, O’Neill WC: Point-of-care ultrasound in the practice of nephrology.Kidney Int93(5): 1052–1059, 2018",
            "O’Neill WC: Renal relevant radiology: use of ultrasound in kidney disease and nephrology procedures.Clin J Am Soc Nephrol9(2): 373–381, 2014",
            "Silverman SG, Leyendecker JR, Arnis ES: What is the current role of CT urography and MR urography in the evaluation of the urinary tract?Radiology250(2): 309–323, 2009"
        ]
    },
    "17": {
        "question": "<div class=\"qtext\"><p>A 64-year-old man with CKD G3b/A2 attributed to hypertension is referred for outpatient evaluation. He has not had routine medical care and takes no medications, including over-the-counter medications or herbal supplements. He was hospitalized 1 year ago for hypertensive urgency and was told at that time that he had decreased kidney function. Investigations for reversible causes of secondary hypertension were negative. He was prescribed amlodipine but discontinued it because of edema and did not return for care until recently. He has a 40 pack-year history of cigarette smoking. BP measured during a nurse visit 1 month ago was 164/88 mm Hg.</p>\n<p>BP is 162/92 mm Hg in both arms and heart rate is 92/min. On examination, he is thin and in no distress. Lung examination reveals scattered wheezes on auscultation. There are no bruits, and there is no peripheral edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 39.6727%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\"><strong>Result</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">142 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.9 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">22 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.8 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Urine protein-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.6 mg/mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">&lt;0.2<br/></td>\n</tr>\n</tbody>\n</table>\n<p>He is instructed on measurement of home BP and counseled on smoking cessation.</p>\n<p><strong>Which of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Atenolol and furosemide"
            },
            {
                "label": "B.",
                "text": "Lisinopril and carvedilol"
            },
            {
                "label": "C.",
                "text": "Lisinopril and losartan"
            },
            {
                "label": "D.",
                "text": "Hydralazine and isosorbide mononitrate"
            },
            {
                "label": "E.",
                "text": "Hydralazine and nifedipine"
            }
        ],
        "correct_answer": "Lisinopril and carvedilol",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with stage 2 hypertension and CKD should receive 2 agents from different classes to treat to a BP target of &lt;130/80 mm Hg.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Drug treatment should be initiated once BP is confirmed &gt;130–140/80–90 mm Hg on 2 separate occasions in patients at high risk for atherosclerotic cardiovascular disease (ASCVD &gt;10% risk at 10 years), including patients with CKD with or without diabetes. This patient would be considered high risk because of CKD. First-line agents for hypertension include thiazide diuretics, dihydropyridine calcium channel blockers, and ACEIs/ARBs. Second-line agents include α1-adrenergic blockers, α2-adrenergic agonists, mineralocorticoid receptor antagonists, and other direct-acting vasodilators. Initiating 2 antihypertensive medications from different classes is recommended when the average systolic and diastolic BP are &gt;20 and &gt;10 mm Hg above target, respectively. Commonly prescribed combinations for initiation of BP management for stage 2 hypertension include any pair of a long-acting dihydropyridine calcium channel blocker, a thiazide diuretic, and an ACEI/ARB. Lisinopril is an appropriate choice for this patient with CKD and proteinuria. Reflex tachycardia is expected when a vasodilator such as lisinopril is initiated, and this patient’s heart rate is already relatively high, so the α/β-adrenergic antagonist carvedilol would be an appropriate second agent. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The goal BP to prevent ASCVD and slow GFR decline in patients with CKD is unknown. The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated positive effects of intensive systolic BP lowering to &lt;120 mm Hg on ASCVD and mortality but not on slowing GFR decline. Some experts have noted that BP &lt;120 mm Hg during carefully controlled SPRINT conditions may reflect a practical BP of &lt;130 mm Hg under usual office conditions. KDIGO 2021 guidelines recommend a systolic BP target of &lt;120 mm Hg.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Atenolol and other β-blockers are no longer recommended as first-line agents to control BP. A β-blocker and a diuretic may be used in combination to treat congestive heart failure (CHF) but would not be the preferred initial management for this patient. The combination of ACEI and ARB is not recommended, as several large clinical trials have shown increased risk of hyperkalemia, AKI, and other adverse outcomes with this strategy. Hydralazine as monotherapy would not be first-line treatment for the reasons outlined above, and the combination of 2 direct-acting vasodilators (hydralazine and nifedipine) would likely cause significant reflex tachycardia in this patient, whose heart rate is already 92/min. In addition, the patient was intolerant of amlodipine and would be unlikely to tolerate the related agent nifedipine. Hydralazine and isosorbide mononitrate is another combination that is used for patients with CHF intolerant of ACEI/ARB therapy but are not indicated for hypertension management. </p>\n</div>",
        "references": [
            "Cheung AK, Chang TI, Cushman WC, et al: Executive summary of the KDIGO 2021 Clinical Practice Guideline for the management of blood pressure in chronic kidney disease.Kidney Int99(3): 559-569,2021",
            "Carey RM, Whelton PK, 2017 ACC/AHA Hypertension Guideline Writing Committee: Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline.Ann Intern Med168(5): 351–358, 2018",
            "Cheung AK, Rahman M, Reboussin DM, et al: Effects of intensive BP control in CKD.J Am Soc Nephrol28(9): 2812–2823, 2017",
            "Ku E, Lee BJ, Wei J, Weir MR: Hypertension in CKD: core curriculum 2019.Am J Kidney Dis74(1): 120–131, 2019"
        ]
    },
    "18": {
        "question": "<div class=\"qtext\"><p>A 57-year-old man with a history of hypertension and coronary artery disease presents to the emergency department with headache and blurry vision for the last 24 hours. He denies chest pain. Medications include amlodipine, hydrochlorothiazide, and lisinopril. He notes that he was recently traveling and forgot several doses of his medications. Home BP is typically 150–160/90–100 mm Hg.</p>\n<p>BP is 224/122 mm Hg, heart rate is 62/min, and body mass index is 38 kg/m<sup>2</sup>. Heart examination is notable for an S4 gallop. Lung examination reveals fine crackles at both bases. Fundoscopic examination shows papilledema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 39.6727%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Hemoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">11 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">14–18<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Platelet count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">120,000/μL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">150,000–450,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Haptoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">60 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">83–267<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Lactate dehydrogenase<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">420 U/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">80–225<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Troponin I<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.04 ng/mL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">≤0.04<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.1 mg/dL (baseline, 1.3)<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">0.7–1.3<br/></td>\n</tr>\n</tbody>\n</table>\n<p>EKG shows left ventricular hypertrophy but no ST segment deviations or T-wave abnormalities. Chest x-ray shows increased opacities at both lung bases and a normal mediastinum.</p>\n<p><strong>Which of the following is the next BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Nicardipine"
            },
            {
                "label": "B.",
                "text": "Hydralazine"
            },
            {
                "label": "C.",
                "text": "Esmolol"
            },
            {
                "label": "D.",
                "text": "Nitroglycerin"
            },
            {
                "label": "E.",
                "text": "Nitroprusside"
            }
        ],
        "correct_answer": "Nicardipine",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in management of this patient presenting with a hypertensive emergency is nicardipine.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient presents with hypertensive emergency, characterized by uncontrolled hypertension (systolic BP ≥180 mm Hg and/or diastolic BP ≥120 mm Hg) with evidence of end-organ damage. This patient has AKI and evidence of microangiopathic hemolytic anemia. Nonadherence to treatment of chronic hypertension is a common precipitant of hypertensive emergency. IV therapy is indicated for the management of hypertensive emergencies. Generally, the choice of medication is directed at the specific clinical presentation. Nicardipine may be used in most hypertensive emergencies, with the notable exception of acute decompensated heart failure. Reflex tachycardia can occur so control of heart rate may be necessary, particularly if there is concomitant cardiac ischemia. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with chronic hypertension may tolerate high BP without cerebral edema, but because of impaired autoregulation, may be at risk for cerebral hypoperfusion and ischemia with overly rapid BP correction. Thus, a reasonable goal would be to titrate nicardipine IV continuous infusion to decrease BP by 20–25% in the first hour and then resume the oral antihypertensive regimen 6–12 hours later, with BP reaching target at approximately 48 hours. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hydralazine may cause unpredictable BP responses and by itself may be deleterious in patients with underlying coronary artery disease, as reflex tachycardia and sympathetic stimulation may provoke coronary ischemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Esmolol would be a reasonable choice for a patient with acute aortic dissection, usually in combination with a vasodilator. β-Adrenergic blockade should be avoided if pheochromocytoma is suspected as the cause of the emergency, and some authors apply this prohibition to cases of cocaine toxicity as well, although this contention is controversial, and treatment of patients with cocaine-induced chest pain with β-adrenergic blockade appears to be safe and effective. Esmolol would likely cause significant bradycardia in this patient, whose heart rate is already low. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Nitroglycerin (NTG) IV would be most appropriate in patients with an acute coronary syndrome, which is not present here. NTG commonly provokes or exacerbates headache and would not be preferred in this patient whose presenting complaint included headache. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Nitroprusside is a rapid-acting antihypertensive agent suitable for hypertensive emergencies but should be avoided in patients with AKI or advanced CKD because of risk of cyanide toxicity.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Note that hypertension-induced thrombotic microangiopathy may indicate an underlying complement disorder. </p>\n</div>",
        "references": [
            "Peixoto AJ: Acute severe hypertension.N Engl J Med381(19): 1843–1852, 2019",
            "Padilla Ramos A, Varon J: Current and newer agents for hypertensive emergencies.Curr Hypertens Rep16(7): 450, 2014",
            "Gosse P, Boulestreau R, Brockers C, et al: The pharmacological management of malignant hypertension.J Hypertens38(11): 2325–2330, 2020",
            "Rangel C, Shu RG, Lazar LD, et al: β-blockers for chest pain associated with recent cocaine use.Arch Intern Med170(10): 874–879, 2010",
            "Palma LMP, Sridharan M, Sethi S: Complement in secondary thrombotic microangiopathy.Kidney Int Rep6(1): 11–23, 2021"
        ]
    },
    "19": {
        "question": "<div class=\"qtext\"><p>A 45-year-old woman is evaluated in the emergency department for weakness and dizziness. She has irritable bowel syndrome and several prior evaluations for syncopal events over the last 3 years. On two of these occasions, she was found to have hypokalemia. Her medications include potassium chloride 10 mEq twice daily and hyoscyamine as needed.</p>\n<p>On physical examination, she appears well nourished and is in no apparent distress. BP is 100/56 mm Hg and pulse is 70/min. The remainder of the examination is unremarkable. </p>\n<p>Laboratory data are as follows: </p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n</table><table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; width: 20%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; width: 20%;\">8 Months ago</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; width:20%;\">3 Months ago</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; width: 20%;\">Current</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; width: 20%;\">Reference Range</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"><strong>Serum</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">  Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">135 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">  Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">2.8 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">  Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">88 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">98–106</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">  Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">35 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">  Creatinine <br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">0.6 mg/dl<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"><strong>Urine</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">  Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">56 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">12 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">44 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">Varies with intake</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">  Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">48 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">&lt;10 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">52 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px;\">Varies with intake</td>\n</tr>\n</tbody>\n</table>\n<p>The 24-h urine calcium excretion is 240 mg.</p>\n<p><strong>Which of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Laxative abuse"
            },
            {
                "label": "B.",
                "text": "Surreptitious diuretic abuse"
            },
            {
                "label": "C.",
                "text": "Gordon syndrome"
            },
            {
                "label": "D.",
                "text": "Surreptitious vomiting"
            },
            {
                "label": "E.",
                "text": "Gitelman syndrome"
            }
        ],
        "correct_answer": "Surreptitious diuretic abuse",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with unexplained hypokalemia and metabolic alkalosis most likely is taking loop diuretics surreptiously. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Abuse of loop diuretics should be considered in patients with unexplained hypokalemia and metabolic alkalosis. Loop diuretics promote alkalosis through several mechanisms. They promote urinary sodium, potassium, and chloride loss and lead to volume depletion, which then leads to renin-angiotensin-aldosterone system (RAAS) activation. This secondary hyperaldosteronism then further drives potassium loss and alkalosis. Potassium depletion can independently maintain an alkalosis. Loop diuretics also promote renal calcium loss. Depending on the timing in relation to diuretic intake, the urine chloride may be high (while diuretic is active) or low (after the diuretic effect wanes). Wide variability in urine chloride may raise suspicion for diuretic abuse. Urine assays for diuretics may be helpful if clinical suspicion is high. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s clinical profile would also be consistent with Bartter syndrome if the urine sodium and chloride levels were consistently &gt;15 mEq/L. Bartter syndrome is caused by defects in the thick ascending limb of the loop of Henle that interfere with the function of the sodium-potasium-2-chloride transporter. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Vomiting leads to metabolic alkalosis through gastric hydrogen chloride loss and the development of secondary hyperaldosteronism. Hypovolemia and chloride depletion lead to low urine chloride excretion. The urinary sodium concentration can be elevated above 15 mEq/L in concert with metabolic alkalosis, when excess filtered bicarbonate acts as a non-reabsorbable anion and is excreted with sodium to maintain electroneutrality. With greater depletion of the extracellular fluid volume, sodium, chloride, and bicarbonate are avidly reabsorbed, leading to urine sodium and chloride levels that are both &lt;15 mEq/L and increased serum bicarbonate levels.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Laxative abuse, resulting in diarrhea, most commonly leads to non-anion gap metabolic acidosis through gastrointestinal bicarbonate losses. However, longer-term abuse may lead to total body potassium depletion, resulting in metabolic alkalosis. Laxative abuse is also associated with a low urine chloride and does not fit with this clinical presentation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Gordon syndrome, also known as type 2 pseudohypoaldosteronism, arises because of abnormalities within the with-no K(Lys) (WNK) protein kinase family. These genes affect regulation of functional Na-Cl cotransporters in the distal tubule, resulting in enhanced sodium transport. Gordon syndrome is characterized by hypertension, hyperkalemia, and metabolic acidosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Gitelman syndrome, an autosomal recessive tubulopathy, is frequently not detected until late childhood or adulthood. The clinical picture is similar to chronic thiazide ingestion with hypokalemia, metabolic alkalosis, hypomagnesemia, and elevated urine chloride, but with normal to low urine calcium.</p>\n<p> </p>\n</div>",
        "references": [
            "Gennari JF, Weise WJ: Acid-base disturbances in gastrointestinal disease.Clin J Am Soc Nephrol3: 1861–1868, 2008",
            "Galla JH: Metabolic alkalosis.J Am Soc Nephrol11: 369–375, 2000"
        ]
    },
    "20": {
        "question": "<div class=\"qtext\"><p>A 52-year-old man presents to the clinic for follow-up of ANCA-associated glomerulonephritis (GN). Four years ago, he presented with AKI and anti-myeloperoxidase (MPO) antibodies. Kidney biopsy demonstrated a pauci-immune, necrotizing, and crescentic GN. He was treated with plasma exchange and high-dose corticosteroids for the first 2 weeks, followed by cyclophosphamide IV monthly for 6 months. He required dialysis for 3 months before kidney function improved. He remains on mycophenolate mofetil (MMF) for maintenance of remission, which was initiated after he completed cyclophosphamide. The most recent creatinine from 1 year ago was 1.7 mg/dL (eGFR, 35 mL/min/1.73 m<sup>2</sup>).</p>\n<p>His past medical history includes type 2 diabetes, hypertension, and gout. His medications include losartan, allopurinol, and insulin glargine, in addition to MMF. He feels generally well and does not report any fever, rash, eye pain or redness, joint pain, visible hematuria, cough, or dyspnea. </p>\n<p>On examination, he is in no distress. BP is 128/82 mm Hg. He has 1+ lower extremity edema, but is otherwise unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 39.6727%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">58 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.9 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Glucose<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">220 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">70–99, fasting<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Albumin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">3.5–5.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Erythrocyte sedimentation rate<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2 mm/h<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">0‒15<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Hemoglobin A<sub>1c</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">7.4%<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">4.0‒5.6<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top; width: 39.6727%;\">Urine protein-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.3 mg/mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\">&lt;0.2<br/></td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis shows 3+ albumin and 1+ blood. There are 5 RBC/HPF that are crenated in appearance, but otherwise microscopy is negative. </p>\n<p><strong>In addition to consideration of cystoscopy, which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Repeat kidney biopsy"
            },
            {
                "label": "B.",
                "text": "Prescribe high-dose prednisone"
            },
            {
                "label": "C.",
                "text": "Prescribe rituximab"
            },
            {
                "label": "D.",
                "text": "Discontinue mycophenolate"
            },
            {
                "label": "E.",
                "text": "Change mycophenolate to azathioprine"
            }
        ],
        "correct_answer": "Repeat kidney biopsy",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most important next step in management of this patient with a history of renal-limited ANCA vasculitis is to repeat kidney biopsy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient developed CKD stage 3b after recovery from severe AKI. The current diagnosis is unclear, and increased creatinine could indicate either AKI or progressive CKD. The laboratory data suggest that diabetic kidney disease is possible, but secondary glomerulosclerosis and tubular atrophy or other chronic processes are also possible. The urine sediment is nonspecific. Kidney biopsy would allow identification of active ANCA vasculitis and determine the benefit of further immunosuppression. If no features of active glomerulonephritis were present, it would be reasonable to stop immunosuppression given the duration of remission. Although rising ANCA titers appear to be helpful in predicting renal relapse in some circumstances, such testing is neither adequately sensitive nor specific to establish the cause of the decline in kidney function in this case. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The Cyclophosphamide versus Azathioprine during Remission of Systemic Vasculitis (CYCAZEREM) trial demonstrated that azathioprine may be used for maintenance therapy without increasing relapse rates in patients with pauci-immune glomerulonephritis. Based on the results of the Maintenance of Remission using Rituximab in Systemic ANCA-Associated Vasculitis (MAINRITSAN) trial, rituximab has emerged as an alternative therapy for maintenance of remission in these patients and has been shown to be superior to azathioprine. Rituximab would also be appropriate for managing relapse. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The presence of microscopic hematuria should prompt referral for cystoscopy in this patient who has had significant exposure to cyclophosphamide.</p>\n</div>",
        "references": [
            "Jayne D, Rasmussen N, Andrassy K, et al: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.N Engl J Med349(1): 36‒44, 2003",
            "Guillevin L, Pagnoux C, Karras A, et al: Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.N Engl J Med371(19): 1771‒1780, 2014",
            "Specks U: Accurate relapse prediction in ANCA-associated vasculitis-the search for the Holy Grail.J Am Soc Nephrol26(3): 505–507, 2015"
        ]
    },
    "21": {
        "question": "<div class=\"qtext\"><p>A 56-year-old woman with a history of multiple myeloma presents to the emergency room with nausea, vomiting, and diarrhea. She was diagnosed with myeloma 3 months ago and initiated chemotherapy 1 month ago with carfilzomib, lenalidomide, and dexamethasone, most recently administered 2 weeks ago. Symptoms began within the last week, and the patient has also noted decreased urine output and easy bruising on the skin.</p>\n<p>On physical examination, BP is 182/78 mm Hg and pulse is 108/min. Heart, lung, and abdominal examination is normal, and skin reveals scattered ecchymoses and petechiae. </p>\n<p>Laboratory data:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">WBC count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">7100/μL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4000–11,000</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Hemoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">6.3 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">12–16</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Platelet count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">34,000/μL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">150,000–450,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\"><strong>Serum</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.857%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8567%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">77 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">7.33 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.5–1.1<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">Lactate dehydrogenase<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">876 U/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">80–225<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">Haptoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;10 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">83–267<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">ADAMTS13 activity<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">48%<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&gt;60%<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Urine protein-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.1 mg/mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;0.2<br/></td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis reveals 3+ albumin, 5–10 RBC/HPF, and no casts or crystals.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Plasmapheresis"
            },
            {
                "label": "B.",
                "text": "Complement mutation analysis"
            },
            {
                "label": "C.",
                "text": "Kidney biopsy"
            },
            {
                "label": "D.",
                "text": "Eculizumab"
            },
            {
                "label": "E.",
                "text": "High cut-off HD"
            }
        ],
        "correct_answer": "Eculizumab",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with probable thrombotic microangiopathy (TMA) in the setting of recently initiated chemotherapy with carfilzomib should receive eculizumab.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The association of AKI, hemolytic anemia, thrombocytopenia, and hypertension suggests the syndrome of TMA, which can be confirmed by identification of schistocytes in a peripheral blood smear. The treatment of TMA depends on correctly establishing the underlying cause. In this case, drug-induced HUS should be considered because of the exposure to the proteasome inhibitor carfilzomib. This agent causes decreased expression of vascular endothelial growth factor (VEGF), which is necessary for proper functioning of podocytes and endothelial cells. VEGF inhibition is thought to mediate some causes of TMA. Some patients with drug-induced HUS have also been shown to have genetic mutations in proteins associated with the alternate complement cascade, including factors B, H, I, membrane cofactor, and thrombomodulin. Eculizumab, a monoclonal antibody that targets C5 and blocks the terminal complement cascade, has been effective in some cases of drug-induced HUS. Although it would be of interest to obtain complement mutation analysis, treatment of this patient who has severe manifestations of HUS should not be delayed. In addition to administering eculizumab, carfilzomib should be withdrawn.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Plasmapheresis with plasma exchange is useful in patients with TMA caused by TTP, which is caused by absolute or functional deficiency of the ADAMTS13, a protein responsible for cleaving large von Willebrand factor multimers. TTP is usually accompanied by severe thrombocytopenia, neurologic signs and symptoms, and fever. TTP is diagnosed by ADAMTS13 activity &lt;5% of normal. In this case, the measured ADAMTS13 activity of 48% excludes the diagnosis of TTP, so plasmapheresis is not indicated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney biopsy would be useful to establish TMA as the cause of AKI, but the histopathology does not distinguish among the various causes of TMA and would be unlikely to inform the choice of therapy. Moreover, kidney biopsy would be associated with increased risk of bleeding in this patient with thrombocytopenia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">High cut-off HD (HCO-HD) has been proposed to remove large quantities of pathogenic free light chains in patients with multiple myeloma and AKI because of cast nephropathy. Recent studies have not shown significant clinical benefit of HCO-HD compared with conventional HD. Furthermore, cast nephropathy would not explain hemolysis, and there is no evidence of a heavy burden of light chain proteinuria. This patient’s AKI is more likely caused by drug-induced TMA than light chain-associated cast nephropathy.</p>\n</div>",
        "references": [
            "Lodhi A, Kumar A, Saqlain MU, Suneja M: Thrombotic microangiopathy associated with proteasome inhibitors.Clin Kidney J8(5): 632–636, 2015",
            "Gosain R, Gill A, Fuqua J, et al: Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment.Clin Case Rep5(12): 1926–1930, 2017",
            "Kavanagh D, Goodship T: Genetics and complement in atypical HUS.Pediatr Nephrol25(12): 2431–2442, 2010",
            "Hutchison CA, Cockwell P, Moroz V, et al: High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.Lancet Haematol6(4): e217–e228, 2019"
        ]
    },
    "22": {
        "question": "<div class=\"qtext\"><p>A 76-year-old woman with ESRD is seen during dialysis rounds. She has been treated with in-center HD via a left upper extremity arteriovenous fistula for 3 years. A recent fall resulted in fracture of her hip, which was surgically repaired. Her home medications include cholecalciferol, cinacalcet, sevelamer, and calcitriol. </p>\n<p>Bone densitometry shows a T-score of -2.7.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">PTH<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">614 pg/mL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">130–585 (dialysis patients)<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">Alkaline phosphatase<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">113 U/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">30–120</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">25-Hydroxyvitamin D <br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">32 ng/mL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">30–60<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">Phosphorus <br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.2 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.0–4.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">Calcium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8.7 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8.6–10.2<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">Albumin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.4 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.5<br/></td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Parathyroidectomy"
            },
            {
                "label": "B.",
                "text": "Denosumab"
            },
            {
                "label": "C.",
                "text": "Etelcalcetide"
            },
            {
                "label": "D.",
                "text": "Teriparatide"
            },
            {
                "label": "E.",
                "text": "Alendronate"
            }
        ],
        "correct_answer": "Denosumab",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with osteoporosis and a history of fracture should be treated with the antiresorptive agent denosumab. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Bone densitometry, also referred to as dual energy x-ray absorptiometry (DEXA) scanning, is used to assess bone health and fracture risk. The result is reported as a T-score, which compares the bone density in the patient to that of a healthy 30-year-old of the same sex. A T-score of &lt;-2.5 establishes the diagnosis of osteoporosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Renal osteodystrophy affects bone quality and strength through multiple mechanisms and may be superimposed on low bone mineral density, contributing to fracture risk. Identification of the most appropriate therapy for patients with ESRD at high fracture risk requires categorization of the renal osteodystrophy component as low turnover, high turnover, or normal, based on the rate and quality of remodeling of bone that should normally occur. Although bone biopsy is the gold standard test to properly categorize patients, it is cumbersome, invasive, and expensive, and many centers lack the necessary expertise and experience to provide this diagnostic procedure. In the absence of bone biopsy, alkaline phosphatase and PTH levels well above normal suggest high bone turnover, whereas low or low-normal levels suggest low bone turnover, sometimes referred to as adynamic bone disease. Patients with osteoporosis and high turnover are candidates for antiresorptive therapy such as denosumab. Denosumab is a monoclonal antibody against the receptor activator of nuclear factor κB ligand (RANKL), which reduces bone turnover by inhibiting osteoclast development and proliferation. Denosumab is given as a subcutaneous injection every 6 months. Hypocalcemia is a frequent side effect in patients with CKD, especially those receiving dialysis, in whom hypocalcemia develops in more than one-third of cases. Treatment with calcium and vitamin D preparations and close monitoring are necessary. Bisphosphonates, such as alendronate, are also antiresorptive, but their use for osteoporosis in ESRD is currently contraindicated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Anabolic agents such as the PTH analog teriparatide are indicated for patients with low bone turnover. Etelcalcetide is an IV formulation of a calcimimetic agent similar to cinacalcet, which this patient is already prescribed. Although etelcalcetide may be more effective at lowering the PTH level than cinacalcet if oral absorption is limited, it would not address the underlying osteoporosis. Surgical parathyroidectomy could be performed to address severe hyperparathyroidism in cases refractory to calcimimetic therapy but also would not address the osteoporosis present in this patient, and this patient’s PTH is only modestly above target. Additionally, the alkaline phosphatase is normal, suggesting that bone turnover may be overestimated by PTH in this patient.</p>\n</div>",
        "references": [
            "Damasiewicz MJ, Nickolas TL: Rethinking bone disease in kidney disease.JBMR Plus2(6): 309–322, 2018",
            "Kunizawa K., Hiramatsu R, Hoshino J, et al: Denosumab for dialysis patients with osteoporosis: a cohort study.Sci Rep10(1):2496, 2020",
            "Block GA, Bushinsky DA, Cheng S, et al: Effect of Etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial.JAMA317(2): 156–164, 2017"
        ]
    },
    "23": {
        "question": "<div class=\"qtext\"><p>A 27-year-old man without significant past medical history presents to the emergency department with altered mental status and shortness of breath. His partner reports that the patient has had a “sinus headache” for several days and has been ingesting large quantities of aspirin-containing pain relievers.</p>\n<p>BP is 136/88 mm Hg. Initial oxygen saturation is 84% on ambient air but improves to 98% while breathing 4 L/min by nasal cannula. Heart examination is normal. Lung examination is significant for crackles bilaterally. Neurologic examination reveals slurred speech but no focal cranial nerve deficits. The remainder of the physical examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><strong> </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Serum</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">145 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">5.4 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Chloride</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">118 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">98–106</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">9 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> BUN</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.9 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7–1.3</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Glucose</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">118 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">70–99, fasting</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Osmolality</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">312 mOsm/kg H<sub>2</sub>O<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">275‒295</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Lactic acid</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1 mmol/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7‒2.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Arterial blood gas</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> pH</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">7.28</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">7.38‒7.44</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> pCO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">20 mm Hg</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">38‒42</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> pO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">65 mm Hg</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">75‒100</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Urinalysis</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> pH</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">5</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.5‒8.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Protein</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Glucose</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Ketones</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Negative</td>\n</tr>\n</tbody>\n</table>\n<p>Salicylate level is pending.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Activated charcoal"
            },
            {
                "label": "B.",
                "text": "0.9% saline"
            },
            {
                "label": "C.",
                "text": "5% dextrose with isotonic sodium bicarbonate"
            },
            {
                "label": "D.",
                "text": "Acetazolamide"
            },
            {
                "label": "E.",
                "text": "Hemodialysis"
            }
        ],
        "correct_answer": "Hemodialysis",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Altered mental status and non-cardiogenic pulmonary edema necessitating supplemental oxygen are indications for urgent HD in cases of salicylate poisoning. Other indications for HD include severe acidemia (pH &lt;7.2) and/or markedly elevated level of salicylates (&gt;7.2 mmol/L or &gt;100 mg/dL). The correlation between clinical toxicity and salicylate level is stronger for acute poisoning compared with chronic poisoning. In cases with severe symptoms and signs, such as this, definitive treatment should be initiated without delay.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Activated charcoal may be administered to all alert and cooperative patients to prevent further absorption of salicylate, although it is most effective within the first 2 hours of ingestion. Altered mental status, as in this patient, is a contraindication.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">IV volume expansion with alkaline fluid should be considered in patients with salicylate overdose. Alkalinization of the urine enhances excretion of salicylates, whereas alkalinization of the blood promotes movement of salicylate out of the central nervous system. Marked alkalemia, such as pH ≥7.5, should be avoided. Volume expansion and alkalinization therapy would be inappropriate management in this patient with signs and symptoms of severe intoxication and volume overload.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acetazolamide may alkalinize the urine, enhancing salicylate removal, but at the expense of acidifying the blood, leading to increased salicylate movement into the brain and worsened mental status. </p>\n</div>",
        "references": [
            "Juurlink DN, Gosselin S, Kielstein JT, et al: Extracorporeal treatment for salicylate poisoning: systematic review and recommendations from the EXTRIP Workgroup.Ann Emerg Med66(2): 165‒181, 2015",
            "Palmer BF, Clegg DJ: Salicylate toxicity.N Engl J Med382(26): 2544‒2555, 2020"
        ]
    },
    "24": {
        "question": "<div class=\"qtext\"><p>A 52-year-old woman presents to clinic for evaluation of proteinuria. She has a history of ANA-positive systemic lupus erythematosus manifesting as joint pain and episcleritis. She also has a history of hypertension and type 2 diabetes with no known neuropathy or retinopathy. Medications include hydroxychloroquine, metformin, maximum dose lisinopril, and ibuprofen as needed for pain.</p>\n<p>Physical examination is notable for elevated BP and mild pedal edema. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\"><strong> </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">5.2 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">58 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.4 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Glucose<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">220 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">70–99, fasting</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Hemoglobin A<sub>1c</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8%</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.0‒5.6</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Urine protein-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3 mg/mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;0.2</td>\n</tr>\n</tbody>\n</table>\n<p>Urine microscopy demonstrates only rare crenated RBCs and rare renal tubular epithelial cells.</p>\n<p>A kidney biopsy is performed. Representative light microscopy findings are shown below. IF demonstrates moderate IgG and albumin deposition in a linear pattern along glomerular and tubular basement membranes. EM demonstrates diffusely thickened basement membranes and mesangial expansion.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv7m2b1q24.png\" width=\"50%\"/><br/>\n<figcaption><em>Image courtesy of H. Davis Massey, DDS, MD, PhD, Virginia Commonwealth University</em></figcaption>\n</figure>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Canagliflozin"
            },
            {
                "label": "B.",
                "text": "Mycophenolate and prednisone"
            },
            {
                "label": "C.",
                "text": "Cyclophosphamide and prednisone"
            },
            {
                "label": "D.",
                "text": "Losartan"
            },
            {
                "label": "E.",
                "text": "Tacrolimus"
            }
        ],
        "correct_answer": "Canagliflozin",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Canagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), is the next best step in management for this patient with diabetic kidney disease who is already taking a maximum dose of ACEI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient, with a history of lupus, diabetes, and hypertension, presents with CKD and high-grade proteinuria. Although the differential diagnosis is broad, major considerations include diabetic kidney disease and membranous lupus nephritis. Kidney biopsy shows nodular sclerosis (classic Kimmelstiel-Wilson lesions) consistent with diabetic kidney disease. Nodular sclerosis is also seen rarely in the absence of diabetes and is associated with smoking, hypertension, and hyperlipidemia (idiopathic nodular sclerosis), and light microscopic findings may also be confused with monoclonal immunoglobulin deposition disease. Typical findings for diabetic nephropathy by IF and EM are as described by Tervaert et al.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Glucocorticoids, mycophenolate mofetil, cyclophosphamide, and tacrolimus are often used in the treatment of lupus nephritis. The light microscopic findings in lupus nephritis are widely variable, but the nodular sclerotic lesions seen here are diagnostic of diabetic nephrosclerosis. In addition, in patients with lupus nephritis, immune deposits positive for immunoglobulins, C3, and C1q are expected on IF, and electron dense deposits are expected on EM.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The combination of ACEI and ARB has not been found to be beneficial in decreasing risk of death from cardiovascular disease. Patients receiving this combination are at higher risk of adverse events, including AKI, hypotension, and hyperkalemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Diabetes is a major risk factor for vascular disease and CKD. SGLT2i therapy on a background of maximally tolerated ACEI or ARB decreases progression of diabetic kidney disease and improves cardiovascular outcomes.</p>\n</div>",
        "references": [
            "Tervaert TWC, Mooyaart AL, Amann K, et al: Pathologic classification of diabetic nephropathy.J Am Soc Nephrol21(4): 556‒563, 2010",
            "Yusuf S, TeoKK, ONTARGET Investigators, et al:  Telmisartan, ramipril, or both in patients at high risk for vascular events.N Eng J Med358(15): 1547‒1559, 2008",
            "Perkovic V, Jardine MJ, Neal B, et al: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.N Engl J Med380(24): 2295‒2306, 2019",
            "Alsaad KO, Herzenberg AM: Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update.J Clin Pathol60(1): 18–26, 2007"
        ]
    },
    "25": {
        "question": "<div class=\"qtext\"><p>A 54-year-old man presents for outpatient evaluation of new-onset lower extremity muscle weakness and constipation. He has a past medical history of well-controlled hypertension, for which he takes hydrochlorothiazide. He denies nausea, vomiting, diarrhea, polyuria, polydipsia, acute episodes of sweating, or weight loss. He admits that a recent divorce has left him with little motivation and poor eating habits, subsisting mostly on candy and pizza.</p>\n<p>On examination, BP is 180/100 mm Hg and heart rate is 62/min. He appears overweight and disheveled. Heart rate is regular without a displaced point of maximum impulse, and lungs are clear. There is no edema, muscle wasting, abnormal fat distribution, or striae. Strength is 3/5 in his lower extremities and 4/5 in his upper extremities.</p>\n<p>Fasting laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align;width: 25%;\"><strong>6 Months Ago</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Current</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.5 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.2 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">24 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">32</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">18 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">15</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.9 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.8</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7–1.3</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Glucose<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">95 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">97</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">70–99, fasting</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Aldosterone<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3 ng/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Supine or seated ≤10; standing ˂21; low-sodium diet (supine) ≤30<br/>\n</p></td>\n</tr>\n</tbody>\n</table>\n<p>EKG shows normal sinus rhythm and prominent U-waves.</p>\n<p><strong>Which ONE of the following is the MOST likely finding on diagnostic laboratory testing?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "A mutation in the gene encoding 11β-hydroxysteroid dehydrogenase"
            },
            {
                "label": "B.",
                "text": "Increased urinary cortisol-to-cortisone ratio"
            },
            {
                "label": "C.",
                "text": "Stenosis of the right renal artery"
            },
            {
                "label": "D.",
                "text": "Increased urinary and plasma metanephrines"
            },
            {
                "label": "E.",
                "text": "Increased plasma cortisol"
            }
        ],
        "correct_answer": "Increased urinary cortisol-to-cortisone ratio",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely laboratory finding in this patient is an increased urinary cortisol-to-cortisone ratio.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with new-onset hypertension, hypokalemia, and metabolic alkalosis, coupled with a suppressed plasma aldosterone concentration, the most likely diagnosis is the syndrome of apparent mineralocorticoid excess (SAME), in this case resulting from excessive licorice ingestion. This diagnosis is established by demonstrating an increased urinary cortisol-to-cortisone ratio. His muscle weakness and constipation derive from severe hypokalemia. Hydrochlorothiazide will further increase his urinary potassium losses by increasing distal urinary flow rates and increasing distal sodium delivery. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The mineralocorticoid receptor (MR) in the principal cell has equal affinity for cortisol and aldosterone. Normally, 11β-hydroxysteroid dehydrogenase type 2 converts cortisol to cortisone, which has low affinity for the MR. Licorice contains glycyrrhizic acid,<strong> </strong>which is converted after ingestion to the active metabolite glycyrrhetinic acid. In excess quantities, glycyrrhetinic acid can inhibit 11β-hydroxysteroid dehydrogenase type 2, leading to activation of the MR by physiologic (not excess) levels of cortisol. The diagnosis is made by history and an elevated urinary cortisol-to-cortisone ratio.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A mutation in the gene encoding 11β-hydroxysteroid dehydrogenase type 2 can also produce these findings, but patients with genetic insufficiency of this enzyme present at a much younger age.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Unilateral renal artery stenosis can produce hypertension, hypokalemia, and metabolic alkalosis. The pathophysiology of this presentation will lead to elevated renin and aldosterone levels, whereas this patient has a relatively low aldosterone level.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Elevated urinary and plasma metanephrines are seen in pheochromocytoma or paraganglioma. Although hypertension and constipation are compatible with this diagnosis, severe hypokalemia and metabolic alkalosis would not be expected. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Elevated cortisol exposure, either endogenous from a tumor or exogenous from medication, can produce a similar syndrome. However, patients with hypercortisolism will most often have additional findings consistent with glucocorticoid excess, such as hyperglycemia, acne, fat redistribution, and striae. Moreover, cortisol levels are highly variable and may be low or normal in conditions of hypercortisolism and are therefore not a preferred screening test.</p>\n</div>",
        "references": [
            "Mumford E, Unwin RJ, Walsh SB: Liquorice, Liddle, Bartter or Gitelman—how to differentiate?Nephrol Dial Transplant34(1): 38‒39, 2019",
            "Edelman ER, Butala NM, Avery LL,et al: Case 30-2020: a 54-year-old man with sudden cardiac arrest.N Engl J Med. 383(13): 1263‒1275, 2020",
            "Walker BR, Edwards CR: Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess.Endocrinol Metab Clin North Am23(2): 359‒377, 1994",
            "Chiodini I, Ramos-Rivera A, Marcus AO, et al: Adrenal hypercortisolism: a closer look at screening, diagnosis, and important considerations of different testing modalities.J Endocr Soc3(5): 1097–1109, 2019"
        ]
    },
    "26": {
        "question": "<div class=\"qtext\"><p>A 60-year-old man with CKD G3b/A1 attributed to ADPKD presents to the emergency department with worsening abdominal pain. Pain is localized to the left flank and has worsened over the last 3 days, accompanied by occasional fever and chills. Kidney function has been stable, and CT scan of the abdomen 2 months ago showed numerous cortical cysts in the kidneys, liver, and pancreas, stable in size over the last 2 years. Many of the cysts had measured density consistent with hemorrhage, although the patient was asymptomatic at the time of the study. Medications include lisinopril and atorvastatin. </p>\n<p>BP is 116/76 mm Hg, heart rate is 98/min, and temperature is 39°C. Physical examination reveals a protuberant abdomen with mild tenderness to deep palpation of the left upper quadrant and left flank.</p>\n<p>Laboratory data are significant for WBC count 14,000/µL (reference range, 4000‒11,000) and C-reactive protein 10.1 mg/dL (reference range, £0.8). Hemoglobin is 14.5 g/dL and unchanged from baseline (reference range, 14–18).</p>\n<p>A urinalysis and urine culture are sent. </p>\n<p><strong>Which of the following is the best next step in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "CT abdomen/pelvis"
            },
            {
                "label": "B.",
                "text": "Cyst aspiration and culture"
            },
            {
                "label": "C.",
                "text": "Ciprofloxacin"
            },
            {
                "label": "D.",
                "text": "Positron emission tomography (PET) scan"
            },
            {
                "label": "E.",
                "text": "Piperacillin-tazobactam"
            }
        ],
        "correct_answer": "Ciprofloxacin",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with ADPKD presenting with features of a cyst infection should receive antibiotic therapy likely to achieve good penetration into cysts.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The incidence of cyst infections in patients with ADPKD is low and estimated to be 0.01 episodes per patient per year; however, cyst infections may account for 11% of hospitalizations. Cyst infection is likely in patients presenting with fever, abdominal pain (especially in the area of a known cyst), and increased C-reactive protein (&gt;7 mg/dL). Initial empiric treatment with antibiotics is recommended. Gram-negative rods, such as <em>Escherichia coli</em>, are the most frequently identified pathogens, but culture data are often lacking. Current recommendations are for a 14-day course of treatment with a fluoroquinolone or trimethoprim-sulfamethoxazole, if local antibiotic resistance data are acceptable. These antibiotics penetrate kidney cysts, although evidence supporting recommendations for their use is scarce. Although piperacillin-tazobactam is widely used for management of abdominal infections or sepsis of unknown source, β-lactam antibiotics have a higher clinical failure rate for the management of cyst infections in patients with ADPKD.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">PET scan and cyst aspiration are highly sensitive for cyst infections but are generally not needed for diagnosis or treatment. PET should be ordered if the cause of infection remains uncertain or if signs and symptoms of infection persist despite appropriate antibiotic therapy. In these cases, abnormalities on PET can help confirm or reject the diagnosis and guide aspiration.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">CT and ultrasound are less reliable to identify sources of infection. Although CT has been proposed as a step in the diagnostic algorithm for patients with ADPKD presenting with fever and abdominal pain because it may be able to identify cyst hemorrhage, such a study is unlikely to be useful in this patient with a recent baseline CT showing hemorrhagic cysts. Urine culture data are not always revealing, because cysts may not communicate with the collecting system, and culture results are not needed to initiate empiric treatment of cyst infections. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In cases of persistent or recurrent cyst infection, radiologic cyst aspirations or surgical cystectomy may be needed. Cyst aspiration may also be needed if infected cysts are &gt;5 cm in diameter. </p>\n</div>",
        "references": [
            "Lantinga MA, Casteleijn NF, Geudens A,et al: Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review.Nephrol Dial Transplant32(1): 144‒150, 2017",
            "Sallée M, Rafat C, Zahar JR, et al: Cyst infections in patients with autosomal dominant polycystic kidney disease.Clin J Am Soc Nephrol4(7): 1183‒1189, 2009",
            "Suwabe T, Ubara Y, Sumida K, et al: Clinical features of cyst infection and hemorrhage in ADPKD: new diagnostic criteria.Clin Exp Nephrol16(6): 892‒902, 2012",
            "Jouret F, Hogan MC, Chebib FT: A practical guide for the management of acute abdominal pain with fever in patients with autosomal dominant polycystic kidney disease.Nephrol Dial Transplant2021 [online ahead of print]",
            "Neuville M, Hustinx R, Jacques J, et al: Diagnostic algorithm in the management of acute febrile abdomen in patients with autosomal dominant polycystic kidney disease.PLoS One11(8): e0161277, 2016"
        ]
    },
    "27": {
        "question": "<div class=\"qtext\"><p>A 65-year-old man with ESRD is seen for his monthly in-center HD visit. ESRD was attributed to long-standing type 2 diabetes and hypertension, and HD was initiated 4 months ago. The patient is a former smoker, and family history is positive for myocardial infarction in his father at age 58, but he has no personal history of cardiovascular disease. Medications include carvedilol, lisinopril, calcium acetate, B/C complex vitamin, and erythropoietin thrice weekly.</p>\n<p>On examination, BP is 142/72 mm Hg and heart rate is 76/min. Heart, lung, and abdominal examinations are unremarkable, and there is no edema. There is a well-functioning arteriovenous fistula in use for HD.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Hemoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">10.8 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">14–18</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.9 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Calcium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8.8 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8.6–10.2</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Phosphorus<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.9 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.0–4.5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Albumin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.8 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Kt/V<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.54</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&gt;1.2</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Total cholesterol<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">220 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;200, desirable<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Low-density lipoprotein<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">146 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;100, optimal<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">High-density lipoprotein<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">38 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&gt;40</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Triglycerides<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">178 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;100, optimal<br/></td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST appropriate medication to prescribe?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "No additional medication"
            },
            {
                "label": "B.",
                "text": "Atorvastatin"
            },
            {
                "label": "C.",
                "text": "Fenofibrate"
            },
            {
                "label": "D.",
                "text": "Simvastatin/ezetimibe"
            },
            {
                "label": "E.",
                "text": "Niacin"
            }
        ],
        "correct_answer": "No additional medication",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">No additional medication is required for this patient with ESRD and an abnormal lipid profile.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with CKD and ESRD have markedly increased (20–40 times greater) cardiovascular risk compared with age-matched controls. Risk factors include traditional (age, sex, smoking, diabetes), nontraditional (C-reactive protein, B-type natriuretic peptide, left ventricular hypertrophy, asymmetric dimethylarginine), and uremic (anemia, hypoalbuminemia, poor dialytic clearance) components.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">At least 3 major clinical trials have assessed statin use in patients with ESRD. The 4D trial randomized 1255 subjects with type 2 diabetes receiving maintenance HD to atorvastatin 20 mg daily or placebo. Low-density lipoprotein (LDL) levels decreased 42% in those receiving atorvastatin, but there was no effect on the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, and stroke. Similarly, the AURORA trial randomized 2776 patients undergoing HD to rosuvastatin 10 mg daily or placebo and again found a 43% decrease in LDL levels with rosuvastatin but no effect on a similar primary composite end point. Lastly, the SHARP trial randomized 9270 patients with CKD (67%) or ESRD (33%) to simvastatin 20 mg plus ezetimibe 10 mg or placebo, with decreased major cardiovascular events seen only in patients with CKD. Thus, there appears to be a limited role for statins for primary prevention in patients with ESRD, and KDIGO guidelines do not recommend initiating these medications in patients receiving dialysis. Guidelines do recommend that statins be continued in patients who are already taking this class of medication when dialysis is initiated. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Fibrates and niacin have not been systematically evaluated in patients with ESRD. Fenofibrate, additionally, is contraindicated at eGFR &lt;30 mL/min/1.73 m<sup>2</sup>.</p>\n</div>",
        "references": [
            "Collins AJ, Li S, Ma JZ, Herzog C: Cardiovascular disease in end-stage renal disease patients.Am J Kidney Dis38(4 Suppl 1): S26–S29, 2001",
            "Zoccali C, Tripepi G, Mallamaci F: Predictors of cardiovascular death in ESRD.Semin Nephrol25(6): 358–362, 2005",
            "Wanner C, Krane V, Marz W, et al: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.N Engl J Med353(3): 238–248, 2005",
            "Fellstrom BC, Jardine AG, Schmieder RE, et al: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.N Engl J Med360(14): 1395–1407, 2009",
            "Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group: KDIGO Clinical Practice Guideline for lipid management in chronic kidney disease.Kidney Int3(3): 259–305, 2013",
            "Streja E, Gosmanova EO, Molnar MZ, et al: Association of continuation of statin therapy initiated before transition to chronic dialysis therapy with mortality after dialysis initiation.JAMA Netw Open1(6): e182311, 2018"
        ]
    },
    "28": {
        "question": "<div class=\"qtext\"><p>A 43-year-old man presents to the nephrology clinic for ongoing management of IgA nephropathy. Four months ago, microscopic hematuria and 2+ proteinuria were detected during an insurance evaluation. An office BP at that time was 135/85 mm Hg. A 24-hour urine collection revealed 1.1 g protein (reference range, &lt;100 mg/24 h). Serum creatinine was 0.9 mg/dL (reference range, 0.7–1.3). Kidney biopsy revealed IgA nephropathy with mild mesangial hypercellularity, but no crescents, interstitial fibrosis, or tubular atrophy (MEST-C score M1, E0, S0, T0, and C0). Home BP monitoring was instituted, and hypertension was diagnosed based on an average BP of 138/83 mm Hg. Lisinopril 20 mg/day was initiated 1 month ago.</p>\n<p>Today, the patient feels well, and brings a home BP log with average readings of 130/78 mm Hg and heart rate of 65/min. Physical examination is unremarkable. Spot urine protein-to-creatinine ratio (UPCR) is 1.2 mg/mg (reference range, &lt;0.2).</p>\n<p><strong>Which ONE of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe losartan"
            },
            {
                "label": "B.",
                "text": "Repeat 24-hour urine albumin and creatinine"
            },
            {
                "label": "C.",
                "text": "Increase lisinopril dose"
            },
            {
                "label": "D.",
                "text": "No change in management"
            },
            {
                "label": "E.",
                "text": "Prescribe amlodipine"
            }
        ],
        "correct_answer": "Increase lisinopril dose",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in management for this patient with IgA nephropathy, whose BP is above optimal and proteinuria is estimated to be &gt;1 g/d, is to increase the dose of lisinopril.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The KDIGO Clinical Practice Guideline for Glomerulonephritis provides a 1B level of evidence for the use of renin-angiotensin-aldosterone inhibitors when proteinuria is &gt;1 g/day. A weaker, grade 2C recommendation is given to titrate ACEI or ARB as high as tolerated to achieve proteinuria &lt;1 g/day, primarily based on post hoc and subgroup analysis of the MDRD and AASK trials. KDIGO guidelines also make a grade 2B recommendation for a target systolic BP of &lt;120 mm Hg in patients with glomerular disease. Although there are several approaches to achieve the double aim of reducing BP and proteinuria, the most straightforward approach would be to titrate the dose of the currently prescribed ACEI. If this were unsuccessful, addition of a thiazide diuretic or aldosterone receptor blocker could be considered. Amlodipine would be a reasonable addition if BP did not reach goal with the combination of an ACEI and diuretic or if those medications were not tolerated. New data from the DAPA-CKD study suggest that add-on therapy with dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, is also effective in improving outcomes in patients with IgA nephropathy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In large clinical trials, such as ONTARGET, the addition of an ARB to an ACEI decreased albuminuria but increased the risk of AKI and hyperkalemia, so prescribing losartan would not be advisable.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Repeating a 24-hour urine collection to reassess urine albumin or protein excretion is unnecessary, as above, because there are no compelling data to support targeted albuminuria reduction. However, a 24-hour urine collection for sodium and creatinine may be used to assess compliance with dietary sodium restriction, because high sodium intake may blunt the proteinuria reduction benefit of ACEIs and ARBs. </p>\n</div>",
        "references": [
            "Cheung AK, Chang TI, Cushman WC, et al: Executive summary of the KDIGO 2021 Clinical Practice Guideline for the management of blood pressure in chronic kidney disease.Kidney Int99(3): 559–569, 2021",
            "Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO Clinical Practice Guideline for glomerulonephritis.Kidney Int2(suppl): 139–274, 2012",
            "Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study.Ann Intern Med123(10): 754–762, 1995",
            "Appel LJ, Wright Jr JT, Greene T, et al: Intensive blood-pressure control in hypertensive chronic kidney disease.N Engl J Med363(10): 918–929, 2010",
            "Mann JFE, Schmieder RE, McQueen M, et al: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.Lancet372(9638): 547–553, 2008",
            "Esnault VLM, Ekhlas A, Delcroix C, et al: Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.J Am Soc Nephrol16(2): 474–481, 2005",
            "Weaver RG, James MT, Ravani P, et al: Estimating urine albumin-to-creatinine ratio from protein-to-creatinine ratio: development of equations using same-day measurements.J Am Soc Nephrol31(3): 591–601, 2020",
            "Wheeler DC, Toto RD, Stefansson BV et al: A pre-specified analysis of the DAPA-CKD trial demonstrates the effect of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.Kidney Int100(1): 215–224, 2021"
        ]
    },
    "29": {
        "question": "<div class=\"qtext\"><p>A 53-year-old man is brought to the emergency department after being found down at home. Medical history includes squamous cell cancer of the head and neck, for which he currently receives chemotherapy and radiation, and appendectomy 8 years ago.</p>\n<p>On arrival, BP is 88/44 mm Hg, temperature is 39.1°C, oxygen saturation is 92% while breathing 3 L/min oxygen by nasal cannula, and body mass index (BMI) is 28 kg/m<sup>2</sup>. Physical examination is significant for somnolence and crackles in the right lower lung field.</p>\n<p>Laboratory data are notable for creatinine 8.2 mg/dL (reference range, 0.7–1.3) and potassium 7.6 mEq/L (reference range, 3.5–5.0). Chest x-ray shows right lower lobe pneumonia and mild pulmonary edema.</p>\n<p>The decision is made to start renal replacement therapy, but because of prior radiation therapy, his internal jugular veins are not suitable for HD catheter placement. </p>\n<p><strong>Which of the following is a CONTRAINDICATION to urgent start PD in this patient?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Severe hyperkalemia"
            },
            {
                "label": "B.",
                "text": "Prior abdominal surgery"
            },
            {
                "label": "C.",
                "text": "Pulmonary edema"
            },
            {
                "label": "D.",
                "text": "Sepsis"
            },
            {
                "label": "E.",
                "text": "High BMI"
            }
        ],
        "correct_answer": "Severe hyperkalemia",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Severe hyperkalemia is a contraindication to acute or urgent-start PD for this patient.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">PD is an effective way to manage many patients with AKI. High-volume PD can provide adequate clearance for many patients with AKI, avoids the need for venous access, and does not require the same specialized equipment and medical staff as is required for HD or CRRT. Acute PD also has the benefit of better hemodynamic tolerance compared with intermittent HD because it can be performed over 12–24 hours.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There are several absolute and relative contraindications to acute PD for the management of AKI. This patient would not be a good candidate for acute PD given the severity of his hyperkalemia. HD is the most appropriate modality for patients with life-threatening electrolyte or acid-base abnormalities because more rapid correction can be achieved. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s prior appendectomy would not preclude acute PD, although very recent abdominal surgery would be a contraindication to PD because of the risk of dialysate leakage. Additionally, patients with numerous prior abdominal surgeries are at increased risk for adhesions, which often makes PD challenging, but these would not be absolute contraindications.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s pulmonary edema would also not be a barrier to PD, because using high dextrose dialysate can be an effective way to achieve adequate UF. Concerns that acute PD could worsen other forms of respiratory compromise by impairment of diaphragmatic excursion have not been borne out by clinical trials. Sepsis would not preclude PD, although patients with peritonitis or intra-abdominal infections would not be appropriate candidates. This patient’s BMI places him in the overweight category, but such patients can also be treated with acute PD. Severe obesity has been proposed as a contraindication because of challenges to catheter placement and limitation of dwell volumes, but recent experience has demonstrated successful application of acute PD in such patients.</p>\n</div>",
        "references": [
            "Chionh CY, Coni SS, Finkelstein FO, et al: Use of peritoneal dialysis in AKI: a systematic review.Clin J Am Soc Nephrol8(10): 1649–1660, 2013",
            "Ponce D, Berbel MN, Regina de Goes C, et al: High-volume peritoneal dialysis in acute kidney injury: indications and limitations.Clin J Am Soc Nephrol7(6): 887–894, 2012",
            "Cullis B, Abdelraheem M, Abrahams G, et al: Finkelstein FO: Peritoneal dialysis for acute kidney injury.Perit Dial Int34(5): 494–517, 2014",
            "Caplin NJ, Zhdanova O, Tandon M, Thompson N, et al: Acute peritoneal dialysis during the COVID-19 pandemic at Bellvue Hospital in New York City.Kidney3601(12): 1345–1352, 2020",
            "Shimonov D, Srivatana: Peritoneal dialysis for acute kidney injury during the COVID-19 pandemic.Clin J Am Soc Nephrol15(12): 1829–1831, 2020"
        ]
    },
    "30": {
        "question": "<div class=\"qtext\"><p>A 42-year-old man is admitted with malaise, vomiting, and AKI. Four days prior to admission, he received methotrexate (MTX) 750 mg/m<sup>2</sup> followed by leucovorin rescue for the treatment of acute lymphoblastic leukemia with central nervous system (CNS) involvement. He subsequently developed a headache and took ibuprofen 600 mg 3–4 times daily. Over the next 24 hours, 2 L IV fluids is administered, with urine output of 135 mL/day. </p>\n<p>BP is 134/78 mm Hg and heart rate is 92/min. On examination, he is arousable but lethargic. Lung examination reveals fine bibasilar crackles, and there is trace lower extremity edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><strong> </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">134 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.9 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">19 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.4 mg/dL (baseline, 0.8)<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7–1.3</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Aspartate aminotransferase<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">103 U/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">10–40</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Alanine aminotransferase<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">142 U/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">10–40</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Urine pH<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">5.5</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.5–8.0</td>\n</tr>\n</tbody>\n</table>\n<p>MTX level is 0.4 µmol/L (expected, &lt;0.1 µmol/L at 72 hours after treatment).</p>\n<p><strong>Which of the following is the next BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Isotonic sodium bicarbonate"
            },
            {
                "label": "B.",
                "text": "Isotonic saline"
            },
            {
                "label": "C.",
                "text": "Folic acid"
            },
            {
                "label": "D.",
                "text": "N-acetylcysteine"
            },
            {
                "label": "E.",
                "text": "Hemodialysis"
            }
        ],
        "correct_answer": "Hemodialysis",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">HD is the next best step in management for this patient with oligoanuric AKI from MTX toxicity.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">MTX is a mainstay of therapy for many types of malignancies and rheumatologic diseases. High-dose MTX (doses &gt;500 mg/m<sup>2</sup>) is often used for high-risk leukemias and lymphomas with CNS involvement, as well as for osteosarcoma. MTX is predominantly excreted unchanged in the urine, so the risk of toxicity increases with decreased kidney function. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has developed severe AKI after receiving high-dose MTX, which is likely because of the direct tubular toxicity of MTX, possibly exacerbated by exposure to NSAIDs. He has clinical evidence of MTX toxicity with vomiting, encephalopathy, elevated transaminases, and an elevated serum MTX level. Initial therapy for MTX toxicity should include volume expansion and urine alkalinization to help with drug excretion. MTX is more soluble in alkaline urine, and maintaining urine pH &gt;7.0 will facilitate urinary elimination. Additional therapy includes glucarpidase, a recombinant enzyme that rapidly converts MTX to an inactive metabolite. Extracorporeal removal of MTX can be accomplished with HD, but clearance is limited by high protein binding and large volume of distribution. As a result, there is often a significant rebound in MTX levels after HD, and repeated treatments are necessary.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">If glucarpidase is not immediately available, and in the absence of urine output in response to IV fluids, HD should be administered. The initial prescription should use high blood and dialysate flows and a duration of at least 4–6 hours. Neither isotonic bicarbonate nor saline would be indicated in this oligoanuric patient who has not responded to fluid resuscitation and has signs of volume overload. Additionally, saline would not help with urine alkalinization. Neither folic acid nor <em>N</em>-acetylcysteine is indicated for MTX toxicity or AKI.</p>\n</div>",
        "references": [
            "Kitchlu A, Shirali AC: High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: what’s best?J Onco-Nephrol3(1): 11–18, 2019",
            "Fujikura E, Akiu M, Miyauchi K, et al: Blood purification therapies in methotrexate-induced acute kidney injury: four case reports.Ren Replace Ther3(48): 1–6, 2017",
            "Saland JM, Leavey PJ, Bash RO, et al: Effective removal of methotrexate by high-flux hemodialysis.Pediatr Nephrol17(10): 825–829, 2002"
        ]
    },
    "31": {
        "question": "<div class=\"qtext\"><p>A 52-year-old man is evaluated for AKI. He has taken omeprazole 20 mg twice daily for the last 3 weeks for indigestion. He is otherwise asymptomatic and has not observed any changes in the volume or character of his urine.</p>\n<p><span style=\"font-size: 0.9375rem;\">BP is 138/82 mm Hg and heart rate is 86/min. Physical examination, including heart, lungs, and abdomen, is unremarkable. No edema or rash is observed.</span></p>\n<p>Laboratory data reveal serum creatinine 2.9 mg/dL compared with 0.9 mg/dL from 2 months ago (reference range, 0.7–1.3). Urinalysis is positive for leukocyte esterase but negative for nitrites. Urine microscopy reveals 20 WBC/HPF, and eosinophils account for &gt;6% of the total urinary WBCs, which is considered a positive result at the reference laboratory. A urine culture shows no growth after 72 hours.</p>\n<p>Despite withdrawal of omeprazole, 5 days later, the creatinine remains 3.0 mg/dL. Acute interstitial nephritis (AIN) is suspected, and a kidney biopsy is recommended. The patient asks if a biopsy is necessary given the presence of urinary eosinophils. To address this question, the physician identifies a study of patients with pyuria and AKI, sufficiently similar to this patient, who had both a urine eosinophil test and a kidney biopsy performed within the same week. A table of results is constructed:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>467 patients with pyuria</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Kidney biopsy result (AIN)</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Kidney biopsy result (other)</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Total</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Urine eosinophils &gt;5%<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">18</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">42</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">60</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Urine eosinophils ≤5%<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">55</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">352</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">407</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Total</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">73</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">394</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">467</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Based on this study, what is the probability that a kidney biopsy performed in this patient will demonstrate AIN?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "30%"
            },
            {
                "label": "B.",
                "text": "4%"
            },
            {
                "label": "C.",
                "text": "16%"
            },
            {
                "label": "D.",
                "text": "25%"
            },
            {
                "label": "E.",
                "text": "86%"
            }
        ],
        "correct_answer": "30%",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The probability that a kidney biopsy in this patient will show AIN, based on these data, is 30%.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">AIN is an important cause of AKI, for which eosinophiluria has been proposed as a noninvasive diagnostic strategy. Nephrologists must have a sufficient understanding of the principles of diagnostic testing to understand the limitations of this test. In this study of patients similar to the case described, the positive predictive value (PPV) of urine eosinophil count &gt;5% is 30%. A PPV is defined as the probability that a patient with a positive test will have the disease in question. Thus, despite a clinical suspicion for AIN, 70% of patients will have an alternative diagnosis, such as glomerulonephritis, acute tubular necrosis, atheroembolic disease, or paraprotein deposition, among other possibilities. Because corticosteroids are not the best treatment for many of these conditions, kidney biopsy is often warranted. </p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; width: 75%; border: 1px solid black;\" width=\"609\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"20.19704433497537%\"><br/></td>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"27.586206896551722%\">\n<p><strong>Number of patients<br/> with disease</strong></p>\n</td>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"29.55665024630542%\">\n<p><strong>Number of patients without disease</strong></p>\n</td>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"22.660098522167488%\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"20.19704433497537%\">\n<p><strong>Positive test</strong></p>\n</td>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"27.586206896551722%\">\n<p>A</p>\n</td>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"29.55665024630542%\">\n<p>B</p>\n</td>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"22.660098522167488%\">\n<p>PPV = A/(A + B)</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"20.19704433497537%\">\n<p><strong>Negative test</strong></p>\n</td>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"27.586206896551722%\">\n<p>C</p>\n</td>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"29.55665024630542%\">\n<p>D</p>\n</td>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"22.660098522167488%\">\n<p>NPV = D/(D + C)</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"20.19704433497537%\"><br/></td>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"27.586206896551722%\">\n<p>Sensitivity = A/(A + C)</p>\n</td>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"29.55665024630542%\">\n<p>Specificity = D/(D + B)</p>\n</td>\n<td style=\"border: 1px solid black;\" valign=\"top\" width=\"22.660098522167488%\"><br/></td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">As demonstrated in this representative 2 ´ 2 table, sensitivity and specificity are descriptors of diagnostic test performance that are independent of the prevalence of the condition in the population being assessed. Sensitivity is defined as the proportion of patients who have the condition of interest who will have a positive test result. A negative result for a highly sensitive test is useful to exclude a diagnosis. Urine eosinophil count &gt;5% occurred in only 25% of patients found to have AIN; thus, the absence of eosinophiluria is insufficient to exclude the diagnosis. Specificity is defined as the proportion of patients without the condition of interest who will have a negative result. A test with a very high specificity can help establish a diagnosis. This study found the specificity of urine eosinophilia &gt;5% was 90%, which supports a diagnosis of AIN but does not establish the diagnosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Calculations of the PPV and negative predictive value (NPV) reveal the performance of a diagnostic test in the relevant population by taking prevalence into account. As described, the PPV is defined as the probability that subjects who have a positive test have the condition in question, referred to as true positives. It is influenced by the prevalence of a disease in a population. A positive test result for a highly prevalent condition will have a high PPV. NPV describes the probability that a subject with a negative test does not have the disease, referred to as true negatives. A negative test result in a population with a low prevalence of the condition in question has a high NPV. In this study in which the overall prevalence of AIN was 16%, the PPV and NPV of urine eosinophil count &gt;5% are 30% and 86%, respectively. Neither predictive value would be adequate to rule in or out the diagnosis of AIN.</p>\n</div>",
        "references": [
            "Muriithi AK, Nasr SH, Leung N: Utility of urine eosinophils in the diagnosis of acute interstitial nephritis.Clin J Am Soc Nephrol8(11): 1857–1862, 2013",
            "Lusica M, Rondon-Berrios H, Feldman L: Urine eosinophils for acute interstitial nephritis.J Hosp Med12(5): 343–345, 2017",
            "Trevethan R: Sensitivity, specificity, and predictive values: Foundations, Pliabilities, and pitfalls in research and practice.Front Public Health5: 307, 2017"
        ]
    },
    "32": {
        "question": "<div class=\"qtext\"><p>A 76-year-old man presents to the emergency department with fever, chills, and shortness of breath. Past medical history includes CKD stage G3a/A2 attributed to poorly controlled type 2 diabetes and hypertension.</p>\n<p>BP is 82/54 mm Hg, heart rate is 112/min, respiratory rate is 22/min, and oxygen saturation is 84% breathing room air. On examination, he is somnolent with labored breathing. Heart examination reveals tachycardia and lung examination reveals coarse breath sounds, decreased in the right base. There is no edema.</p>\n<p>Laboratory data on admission is significant for creatinine 1.3 mg/dL (baseline, 0.9; reference range, 0.7–1.3).</p>\n<p>Chest x-ray shows a dense, right lower lobe consolidation. EKG is unremarkable.</p>\n<p>The patient is intubated, and broad-spectrum antibiotics and IV fluids are administered. After 3 hours, BP remains 80/52 mm Hg.</p>\n<p><strong>Which of the following agents is the next BEST STEP in therapy?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Epinephrine"
            },
            {
                "label": "B.",
                "text": "Dopamine"
            },
            {
                "label": "C.",
                "text": "Dobutamine"
            },
            {
                "label": "D.",
                "text": "Norepinephrine"
            },
            {
                "label": "E.",
                "text": "Phenylephrine"
            }
        ],
        "correct_answer": "Norepinephrine",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Adding norepinephrine to this patient’s regimen is the next best step in therapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patent has developed AKI in the setting of septic shock. Management of septic shock focuses on treating the underlying infection, but hemodynamic support with volume resuscitation and vasoactive agents plays an important role in maintaining organ perfusion. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Numerous randomized, controlled trials (RCTs) have been conducted to compare mortality and morbidity with different vasoactive agents in critically ill patients with septic shock. Norepinephrine has emerged as the vasopressor of choice for most patients. A meta-analysis of 43 trials that assessed 17 vasopressors and inotropes showed that a combination of norepinephrine and dobutamine was associated with the lowest mortality, whereas dopamine was associated with the highest risk of arrythmia. Norepinephrine is recommended as the first-line vasoactive agent for septic shock because of its ease of use, rapid onset of action, and low cost. The target mean arterial pressure (MAP) is 60–65 mm Hg for most outcomes, although a target of 80–85 mm Hg decreased the risk of progressing to AKI stage 3 and requiring renal replacement therapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Epinephrine stimulates β1-, β2-, and α1-adrenergic receptors, thereby increasing cardiac output and MAP. Compared with norepinephrine, epinephrine causes more adverse events, including mesenteric ischemia, tachyarrythmias, and lactic acidosis. Phenylephrine is a pure α1-adrenergic agonist that augments vasoconstriction but requires 220% of the equivalent dose of norepinephrine to achieve its effect. The use of phenylephrine was associated with increased mortality in one observational cohort study. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Low-dose dopamine, often defined as &lt;5 μg/kg per minute, was previously thought to increase renal perfusion by activating vasodilatory dopamine receptors in the renal circulation. However, human studies have not shown any renal benefits for this strategy in the setting of septic shock, and there are risks associated with this medication, including an increased risk of cardiac arrhythmias and greater mortality in patients with cardiogenic shock.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Dobutamine is an inotrope that stimulates β1- and β2-adrenergic receptors. This agent increases cardiac output, which is usually high in the setting of septic shock, and acts as a vasodilator. Dobutamine alone would not be appropriate for this patient. Dobutamine in combination with norepinephrine has been effective in some trials. Vasopressin, which induces vasoconstriction via a non-adrenergic pathway, can be added to norepinephrine in refractory cases.</p>\n</div>",
        "references": [
            "Russell JA, Gordon AC, Williams MD, et al: Vasopressor therapy in the intensive care unit.Semin Respir Crit Care Med42(1): 59–77, 2021",
            "Asfar P, Meziani F, Hamel JF, et al: High versus low blood-pressure targets in patients with septic shock.N Engl J Med370(17): 1583–1593, 2014",
            "Lauschke A, Teichgraber UKM, Frei U, Eckardt KU: ‘Low-dose’ dopamine worsens renal perfusion in patients with acute renal failure.Kidney Int69(9): 1669–1674, 2006"
        ]
    },
    "33": {
        "question": "<div class=\"qtext\"><p>A 48-year-old woman with ESRD attributed to lupus nephritis receiving HD was admitted to the hospital with anemia caused by a lower gastrointestinal bleed. On admission, there was also concern for pneumonia, and she was prescribed ceftazidime. She has been receiving erythropoietin 10,000 units with each dialysis treatment, but Hb was 6.1 g/dL (reference range, 12–16). During HD today, she received 2 units of packed RBCs. She completed the treatment, achieving her usual target weight. Approximately 1 hour after completing dialysis, she developed sudden-onset shortness of breath and was found to have an oxygen saturation of 84% on room air. Chest x-ray revealed new bilateral interstitial opacities.</p>\n<p>Blood pressure is 112/84 mm Hg and heart rate is 106/min. Cardiac examination reveals a regular rhythm without abnormal sounds and normal jugular venous pressure. Lung examination reveals labored breathing and bibasilar crackles. There is no peripheral edema.</p>\n<p><strong>Which of the following is the MOST LIKELY cause of hypoxemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Transfusion-associated acute lung injury (TRALI)"
            },
            {
                "label": "B.",
                "text": "Transfusion-associated circulatory overload (TACO)"
            },
            {
                "label": "C.",
                "text": "Acute hemolytic transfusion reaction"
            },
            {
                "label": "D.",
                "text": "Pulmonary embolism"
            },
            {
                "label": "E.",
                "text": "Worsening pneumonia"
            }
        ],
        "correct_answer": "Transfusion-associated acute lung injury (TRALI)",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient is experiencing transfusion associated acute lung injury (TRALI), which is a severe complication of blood product transfusion that occurs in approximately 1 in 5000 transfusions.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">TRALI is a 2-step process. First, neutrophils are sequestered in the lung vasculature, often related to endothelial injury (this patient had a concurrent pneumonia). Neutrophils then become activated in response to factors present in the donor blood. The usual presentation is worsened hypoxemia that develops within 6 hours of blood product transfusion. Chest x-ray may show opacities consistent with pulmonary edema, but this relates to inflammation rather than cardiogenic pulmonary edema. Plasma-rich blood products, such as fresh frozen plasma, confer a higher risk of TRALI. Management is largely supportive to correct the hypoxemia, as well as discontinuing transfusion if it has not been completed. The blood bank should also perform a transfusion reaction investigation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Transfusion-associated circulatory overload (TACO) is a more frequent cause of post-transfusion hypoxemia than TRALI. However, in this case, TACO is unlikely, as this patient is below her target weight and has no edema or other signs of volume overload. Acute hemolytic transfusion reactions are very rare because of modern transfusion medicine safety protocols. Clinical features of such reactions often include chest or back pain, as well as laboratory evidence of hemolysis. In this case, although laboratory investigation should be performed, there are no features to suggest that she has experienced hemolysis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although patients receiving HD are at increased risk for pulmonary embolism compared to those without ESRD, bilateral pulmonary opacities and crackles would not be expected. Worsening of her existing pneumonia is also less likely to cause sudden-onset dyspnea and hypoxemia, particularly in the absence of other evidence of progression of infection. </p>\n</div>",
        "references": [
            "Tanhehco YC, Berns JS: Red blood cell transfusion risks in patients with end-stage renal disease.Semin Dial25(5): 539–544, 2012",
            "Afshar M, Netzer G: Update in critical care for the nephrologist: transfusion in nonhemorrhaging critically ill patients.Adv Chronic Kidney Dis20(1): 30–38, 2013"
        ]
    },
    "34": {
        "question": "<div class=\"qtext\"><p>A 60-year-old man presents to the clinic for kidney transplant evaluation. He has a history of hypertension and ESRD secondary to diabetes, for which he has been treated with in-center HD for 1 year. He has a remote history of smoking but quit more than 30 years ago. His current medications include amlodipine, lisinopril, and long-acting insulin.</p>\n<p>BP is 145/93 mm Hg and body mass index is 31 kg/m<sup>2</sup>. Physical examination is notable for a left upper extremity arteriovenous fistula (AVF), bilateral crackles at the lung bases, and 1+ bilateral pedal edema.</p>\n<p>The patient recently completed most of the routine testing and evaluation required in preparation for kidney transplant. He had a nuclear stress test that did not show evidence of ischemia. He also had a transthoracic echocardiogram that showed normal right and left ventricular systolic function (ejection fraction, 60%; reference range, 55–70), normal valvular function, left atrial dilation, and an estimated pulmonary artery systolic pressure (PASP) of 49 mm Hg (reference range, 18–25). He is currently asymptomatic.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Pulmonary function testing"
            },
            {
                "label": "B.",
                "text": "Right heart catheterization"
            },
            {
                "label": "C.",
                "text": "Increase ultrafiltration and repeat echocardiogram"
            },
            {
                "label": "D.",
                "text": "AVF ligation"
            },
            {
                "label": "E.",
                "text": "Polysomnography"
            }
        ],
        "correct_answer": "Increase ultrafiltration and repeat echocardiogram",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pulmonary hypertension (PH) is common in patients with CKD and is associated with worse post-transplant survival and allograft outcomes. However, the etiologies of PH are heterogeneous in patients with CKD, including intravascular volume expansion, left-to-right shunting from AVFs, and pulmonary disease. Therefore, diagnostic evaluation and treatment of the underlying etiology is necessary for cardiovascular optimization prior to kidney transplantation. In this patient, intravascular volume expansion may be a significant contributor to his PH. Therefore, more aggressive ultrafiltration for volume optimization followed by repeat echocardiography would be the best next step in management. Significant improvement or resolution of the PH would suggest intravascular volume expansion as the main etiology of PH, whereas minimal improvement would suggest an alternative etiology of PH that would require further evaluation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Because PH is associated with worse outcomes following kidney transplantation, proceeding with listing without further evaluation would not be the next best step in management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Right heart catheterization (RHC) is the gold standard for diagnosing pulmonary hypertension and evaluating its etiology. The 2012 AHA/ACC guidelines recommend considering RHC in kidney transplant candidates with right ventricular systolic pressure (RVSP) ³50 mm Hg or evidence of right ventricular pressure overload. This patient has a PASP &lt;50 mm Hg (RVSP and PASP are essentially equivalent in the absence of right ventricular outflow obstruction) and has clear signs of extravascular volume overload, which can contribute to PH. Therefore, invasive assessment of pulmonary pressure with RHC should not be performed prior to volume optimization with ultrafiltration.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">AVFs can cause high-output heart failure and PH through left-to-right shunting. There is no evidence presented in this case showing high flows through the AVF or high cardiac output to support the diagnosis, which makes it a less likely cause of PH compared with intravascular volume expansion. Even if high flow through the AVF were a contributing factor, it would be premature to ligate the fistula before assessing the response to increased ultrafiltration.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Polysomnography can identify obstructive sleep apnea (OSA) as an etiology of PH. However, the presence of signs of intravascular volume expansion and lack of symptoms of OSA make OSA a less likely cause of his PH compared with intravascular volume expansion.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pulmonary function testing (PFT) is considered part of the work-up of pulmonary hypertension in patients with suspected chronic lung disease. This patient was a prior smoker for a few years but denies any other respiratory symptoms, and there is evidence of volume overload on examination. Therefore, PFT would not be the next step in assessment. </p>\n</div>",
        "references": [
            "Caughey MC, Detwiler RK, Sivak JA, et al: Five-year outcomes of pulmonary hypertension with and without elevated left atrial pressure in patients evaluated for kidney transplantation.Transplantation104(10): 2113–2119, 2020",
            "Lentine KL, Villines TC, Axelrod D, et al: Evaluation and management of pulmonary hypertension in kidney transplant candidates and recipients: concepts and controversies.Transplantation101(1): 166–181, 2017",
            "Lentine KL, Costa SP, Weir MR, et al: Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.J Am Coll Cardiol60(5): 434–80, 2012",
            "Zlotnick DM, Axelrod DA, Chobanian MC, et al: Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction.Nephrol Dial Transplant25(9): 3090–3096, 2010"
        ]
    },
    "35": {
        "question": "<div class=\"qtext\"><p>A 50-year-old woman presents for follow-up in the kidney transplant evaluation clinic. She has a history of CKD stage 4 secondary to IgA nephropathy. Kidney function has slowly worsened over the last 5 years. Her current medications include lisinopril and amlodipine.</p>\n<p>BP is 125/75 mm Hg. Physical examination is unremarkable.</p>\n<p>Laboratory studies show a serum creatinine of 2.2 mg/dL (reference range, 0.5–1.1) with eGFR 25 mL/min/1.73 m<sup>2</sup> (reference range, ≥60).</p>\n<p>She previously completed her evaluation and has no contraindications to kidney transplantation. Her husband was found to be a suitable donor. The patient asks when kidney transplantation should be performed.</p>\n<p><strong>Which ONE of the following is the OPTIMAL time for this patient to undergo kidney transplantation?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "As soon as possible"
            },
            {
                "label": "B.",
                "text": "Once eGFR is <20 mL/min/1.73 m2"
            },
            {
                "label": "C.",
                "text": "After 90 days of dialysis"
            },
            {
                "label": "D.",
                "text": "After 12 months of dialysis"
            },
            {
                "label": "E.",
                "text": "Once uremic symptoms develop"
            }
        ],
        "correct_answer": "Once eGFR is <20 mL/min/1.73 m2",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients for whom pre-emptive kidney transplant is available should undergo transplantation once the eGFR falls below 20 mL/min/1.73 m<sup>2</sup>. Pre-emptive transplantation is associated with improved patient and allograft outcomes, so should not be delayed until after dialysis is initiated or uremic symptoms develop.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The renal replacement therapy options available for the treatment of ESRD are dialysis and kidney transplantation. Overall, kidney transplantation in patients with ESRD is associated with improved patient survival compared with dialysis. Several studies have shown that pre-emptive transplantation (before initiation of dialysis) is associated with improved patient and allograft survival compared with transplantation after dialysis. Furthermore, in patients who receive a kidney transplant after dialysis, longer time on dialysis is associated with worse post-transplant outcomes. Therefore, pre-emptive kidney transplantation is the preferred treatment for eligible patients with advanced CKD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The United Network for Organ Sharing (UNOS) rules state that eGFR should be &lt;20 mL/min/1.73 m<sup>2 </sup>for pre-emptive transplantation. This threshold is based on operative risks of kidney transplantation and data showing no additional benefit to pre-emptive transplantation in patients with eGFR &gt;20 mL/min/1.73 m<sup>2</sup> compared with &lt;20 mL/min/1.73 m<sup>2</sup>. The patient described in the scenario has an eGFR of 25 mL/min/1.73 m<sup>2</sup>, so she should not proceed with transplantation at this time. Transplantation should be delayed until eGFR is consistently &lt;20 mL/min/1.73 m<sup>2</sup>. The rate of progression is also important to consider because some patients with chronic tubulointerstitial disease may have very slow kidney function decline. Most patients with advanced CKD will undergo pre-emptive transplantation when eGFR is &lt;15 mL/min/1.73 m<sup>2</sup>. It is not necessary to delay pre-emptive transplantation until the emergence of uremic symptoms. To do so would risk the need to initiate dialysis to stabilize a patient prior to transplantation and might negate the advantage of pre-emptive transplantation.</p>\n</div>",
        "references": [
            "Meier-Kriesche H-U, Kaplan B: Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis.Transplantation74(10): 1377–1381, 2002",
            "Grams ME, Massie AB, Coresh J, Segev DL: Trends in the timing of pre-emptive kidney transplantation.J Am Soc Nephrol22(9): 1615–1620, 2011",
            "Akkina SK, Connaire JJ, Snyder JJ, et al: Earlier is not necessarily better in preemptive kidney transplantation.Am J Transplant8(10): 2071–2076, 2008",
            "Kasiske BL, Snyder JJ, Matas AJ, et al: Preemptive kidney transplantation: the advantage and the advantaged.J Am Soc Nephrol13(5): 1358–1364, 2002",
            "Mange KC, Joffe MM, Feldman HI: Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors.N Engl J Med344(10): 726–731, 2001"
        ]
    },
    "36": {
        "question": "<div class=\"qtext\"><p>A 68-year-old woman with a history of hypertension and nephrolithiasis presents to clinic for follow-up. She has passed a kidney stone every 3–5 years since age 50 but has never received medical preventative therapy. Analysis of the most recently passed stone revealed a composition of 60% calcium oxalate monohydrate, 30% calcium oxalate dihydrate, and 10% calcium phosphate. She was recently seen by her primary care physician and had a routine dual energy x-ray absorptiometry (DEXA) scan performed, which revealed a T-score of -1.5 at the spine and -2.0 at the hip. She has no history of fracture.</p>\n<p>On examination, she is a thin, well-appearing woman with a BP of 148/88 mm Hg. She has no flank tenderness. Her physical examination is otherwise unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Serum</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.9 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Total CO<sub>2</sub> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">25 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Creatinine </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.9 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Albumin</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.9 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Calcium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">9.5 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8.6–10.2</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> PTH</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">25 pg/mL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">10–65</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>24-Hour urine</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Volume</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.2 L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies with intake</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">211 mEq<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies with intake</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Calcium </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">390 mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Female &lt;250</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Oxalate</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">25 mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;40</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> Citrate</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">332 mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">250–1000</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> pH</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">6.0</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.5–8.0</td>\n</tr>\n</tbody>\n</table>\n<p><strong>In addition to dietary sodium restriction, which of the following is MOST appropriate next step in therapy?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Furosemide"
            },
            {
                "label": "B.",
                "text": "Potassium citrate"
            },
            {
                "label": "C.",
                "text": "Teriparatide"
            },
            {
                "label": "D.",
                "text": "Chlorthalidone"
            },
            {
                "label": "E.",
                "text": "Calcium carbonate"
            }
        ],
        "correct_answer": "Chlorthalidone",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate treatment, in addition to dietary sodium restriction, for this patient with calcium oxalate stones, hypercalciuria, and osteoporosis is chlorthalidone.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Osteoporosis (T-score ≤-2.5) and low bone mineral density (BMD) are common in patients who form calcium stones, with 30–40% having low BMD. The mechanisms underlying this association are complex and still poorly understood. However, environmental, genetic, and hormonal factors are implicated in the pathophysiology. One intriguing hypothesis posits that, in some patients, calcium leaches from bone leading to both deposition in the vasculature and increased calciuria, thus accounting for osteoporosis, cardiovascular disease, and nephrolithiasis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In both animal models and humans, chlorthalidone improves calcium balance, reduces stone formation, and increases BMD in subjects with hypercalciuria, especially when added to dietary modification. The mechanism for these benefits is suspected to be related to increased renal tubular calcium absorption and, surprisingly, reduced intestinal calcium absorption. This patient has increased urine calcium excretion, one of her major risk factors for kidney stone formation, which chlorthalidone would address. Given this patient’s elevated blood pressure, chlorthalidone is also a particularly attractive option. Although a recent trial of 416 recurrent calcium-containing stone formers found that hydrochlorothiazide did not prevent recurrence, the patients studied did not have hypercalciuria, as seen here.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Potassium citrate is an effective therapy for stone prevention, reducing free urinary calcium and inhibiting crystal aggregation. Although this patient has borderline low urine citrate excretion, citrate therapy may lead to an increase in urine pH, which in the setting of untreated hypercalciuria may predispose to calcium phosphate stone formation. Finally, although there is some evidence that potassium citrate improves calcium balance and bone mass in patients with osteopenia, further trials are needed to document this potential clinical benefit.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although furosemide would increase urine volume, it acts on the sodium-potassium-chloride cotransporter in the loop of Henle, prompting decreased paracellular transport of calcium and exacerbating hypercalciuria. Teriparatide is a bone formation stimulating agent analogous to PTH and would improve bone density in this patient but has also been associated with hypercalciuria. Although it is important for patients with osteoporosis and hypercalciuria to maintain adequate dietary calcium intake, pharmacologic calcium supplementation has been associated with increased kidney stone formation in postmenopausal women in some studies and would not address hypercalciuria in this patient. </p>\n</div>",
        "references": [
            "Sakhaee K, Maalouf NM, Kumar R, et al: Nephrolithiasis-associated bone disease: pathogenesis and treatment options.Kidney Int79(4): 393–403, 2011",
            "Krieger NS, Asplin JR, Granja I, et al: Chlorthalidone is superior to potassium citrate in reducing calcium phosphate stones and increasing bone quality in hypercalciuric stone-forming rats.J Am Soc Nephrol30(7): 1163–1173, 2019",
            "Pak CY, Heller HJ, Pearle MS, Odvina CV, et al: Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions.J Urol169(2): 465–469, 2003",
            "Moseley KF, Weaver CM, Appel L, et al: Potassium citrate supplementation results in sustained improvement in calcium balance in older men and women.J Bone Miner Res28(3): 497–504, 2013",
            "Jackson RD, LaCroix AZ, Gass M, et al: Calcium plus vitamin D supplementation and the risk of fractures.N Engl J Med354(7): 669–683, 2006",
            "Dhayat NA, Bonny O, Roth B et al: Hydrochlorothiazide and prevention of kidney-stone recurrence.N Engl J Med388(9): 781–791, 2023"
        ]
    },
    "37": {
        "question": "<div class=\"qtext\"><p>A 58-year-old man with a history of stage G5/A3 CKD secondary to diabetes is seen for ongoing kidney transplant evaluation. He has no uremic symptoms and has not yet initiated dialysis.</p>\n<p>During his transplant evaluation, an exophytic right kidney mass was incidentally discovered. A partial right nephrectomy was performed 6 weeks ago, and pathology demonstrated a 3.5-cm renal cell carcinoma, stage T1a, N0, M0, with negative margins.  </p>\n<p>The remainder of his kidney transplant evaluation is unremarkable, and a suitable potential living donor has been identified.</p>\n<p><strong>Which of the following is the BEST recommendation regarding this patient’s transplant candidacy?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Proceed with kidney transplant"
            },
            {
                "label": "B.",
                "text": "Decline as kidney transplant candidate"
            },
            {
                "label": "C.",
                "text": "Proceed with transplant after 2-year cancer-free waiting period"
            },
            {
                "label": "D.",
                "text": "Proceed with transplant after 5-year cancer-free waiting period"
            },
            {
                "label": "E.",
                "text": "Proceed with transplant following completion of adjuvant chemotherapy"
            }
        ],
        "correct_answer": "Proceed with kidney transplant",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with a small, incidentally detected renal cell carcinoma (RCC) that is completely resected may proceed with transplantation without the need for a cancer-free waiting period.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The timing of kidney transplant in candidates with pre-transplant malignancy requires balancing the expected benefit associated with timely transplantation compared with the potential risk of cancer recurrence and the impact of immunosuppression.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Small kidney masses are frequently found in potential kidney transplant candidates, and the majority are RCCs. Following partial or radical nephrectomy, stage 1a (&lt;4 cm), N0, M0 tumors have a low risk of metastasis and excellent recurrence-free survival, without the need for adjuvant chemotherapy. As such, following resection, no additional waiting time is needed prior to proceeding with transplantation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">For larger tumors, additional recurrence-free waiting time may be necessary. Tumors between 4 and 7 cm in diameter may require 0–2 years of waiting time depending on the tumor grade, and tumors &gt;7 cm typically require a waiting time of at least 2 years.</p>\n</div>",
        "references": [
            "Al-Adra DP, Hammel L, Roberts J, et al: Pretransplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement.Am J Transplant21(2): 460–474, 2021",
            "Bhindi B, Thompson RH, Lohse CM, et al: The probability of aggressive versus indolent histology based on renal tumor size: implications for surveillance and treatment.Eur Urol74(4): 489–497, 2018"
        ]
    },
    "38": {
        "question": "<div class=\"qtext\"><p>A 31-year-old man with a history of stage 5 CKD secondary to chronic tubulointerstitial disease presents for routine follow-up. He has been approved for kidney transplantation and is scheduled to receive a living unrelated donor kidney transplant in 6 weeks. Panel of reactive antibodies (PRA) is 0%, and he has 4/6 human leukocyte antigen (HLA) mismatches with the proposed living donor. He generally feels well but endorses mild fatigue that is stable from prior visits. He does not have hiccups, itching, dyspnea, chest pain, nausea, vomiting, anorexia, bleeding, or edema. Medications include amlodipine, calcium acetate, calcitriol, multivitamin, and sodium bicarbonate. </p>\n<p>On physical examination, BP is 129/75 mm Hg, heart rate is 84/min, respiratory rate is 16/min, and pulse oximetry is 98% on room air. He is pale, but has clear lungs, normal heart sounds, and no peripheral edema. A mature left upper extremity arteriovenous fistula (AVF) with thrill is present. The remainder of his examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">WBC count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">6000/µL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">4000–11,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Hemoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">6.8 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">14–18<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Reticulocyte count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">25,000/µL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">25,000–100,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Platelet count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">150,000/µL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">150,000–450,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><b>Serum</b><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">5.4 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  eGFR<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">8 mL/min/1.73 m<sup>2</sup><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">≥60<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Ferritin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">40 ng/mL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">24–336<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Transferrin\nsaturation<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">15%<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">20–50<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Lactate dehydrogenase<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">104 U/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">80–225<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Haptoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">105 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">83–267<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Vitamin B<sub>12</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">790 pg/mL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">200–800<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Folate<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">8.5 ng/mL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">1.8–9.0<br/></td>\n</tr>\n</tbody>\n</table>\n<p>Testing for fecal occult blood is negative. His Hb 3 months earlier at the time of his AVF surgery was 9.5 g/dL. </p>\n<p><strong>Which of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Administer IV iron"
            },
            {
                "label": "B.",
                "text": "Transfuse packed RBCs"
            },
            {
                "label": "C.",
                "text": "Initiate hemodialysis"
            },
            {
                "label": "D.",
                "text": "Administer PO iron"
            },
            {
                "label": "E.",
                "text": "Administer darbepoetin"
            }
        ],
        "correct_answer": "Administer IV iron",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has severe anemia likely secondary to CKD and relative or absolute iron deficiency, as identified by low transferrin saturation and ferritin. The most appropriate initial therapy is to initiate IV iron to treat his anemia prior to transplantation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Transfusion should be avoided or minimized whenever possible in potential transplant candidates because of risk of allosensitization. Pre-transplant transfusion significantly increases the risk of developing anti-HLA antibodies and is associated with longer waiting time, increased risk of rejection, and allograft failure. Although blood transfusion is traditionally considered for a Hb &lt;7 g/dL, the evidence base for this threshold is limited. In this patient, who is scheduled for a compatible living donor transplant, transfusion increases the potential for the development of donor-specific HLA antibodies and a positive cross match. Because this patient does not have risk factors for ischemic heart disease, is not actively bleeding, and is only mildly symptomatic, urgent transfusion is not warranted.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Erythropoiesis-stimulating agents (ESAs) such as darbepoetin have an established role for the treatment of anemia associated with CKD. However, their effectiveness is diminished when iron deficiency is present. As such, iron stores should be replenished prior to initiating ESAs. Current guidelines suggest achieving a target ferritin &gt;100 ng/mL and a transferrin saturation &gt;20%. Both IV and PO iron can effectively replete iron stores, and studies comparing the safety and efficacy of these 2 routes of administration have been equivocal in terms of safety, although gastrointestinal side effects are consistently greater with the PO route. The time to response is shorter with IV iron, making this the preferred approach in patients with severe anemia, such as this one.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient has advanced CKD and a functional dialysis access, he has no acute indication for initiating dialysis. The timing of dialysis initiation should be based on the presence of uremic symptoms or threatening laboratory parameters rather than the eGFR alone.</p>\n</div>",
        "references": [
            "Scornik JC, Bromberg JS, Norman DJ, et al: An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival.BMC Nephrol14: 217, 2013",
            "Leffell MS, Kim D, Vega RM et al: Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation.Transplantation97(5): 525–533, 2014",
            "Yabu JM, Anderson MW, Kim D, et al: Sensitization from transfusion in patients awaiting primary kidney transplant.Nephrol Dial Transplant28(11): 2908–2918, 2013",
            "Macdougall IC: Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions.Clin Kidney J10(suppl 1): i16–i24, 2017"
        ]
    },
    "39": {
        "question": "<div class=\"qtext\"><p>A 29-year-old man is evaluated for increased BP (144/82 mm Hg) found during a routine office visit. He reports occasional fatigue but does not have headaches, chest pain, dyspnea, or palpitations. He does not use over-the-counter medications, herbal products, or recreational drugs. His maternal grandfather had hypertension and coronary artery disease, but there is no family history of stroke. His only medication is sertraline.</p>\n<p>On physical examination, BP is 146/86 mm Hg, with a heart rate of 86/min and a body mass index (BMI) of 24.2 kg/m<sup>2</sup>. Fundoscopic examination reveals normal optic discs and blood vessels, and a cardiovascular examination reveals no heart murmurs or gallops, no abdominal masses or bruits, and normal peripheral pulses. </p>\n<p>Laboratory evaluation shows serum creatinine level of 0.9 mg/dL (reference range, 0.7–1.3), potassium level of 4.2 mEq/L (reference range, 3.5–5.0), and thyroid-stimulating hormone level of 2.1 mU/L (reference range, 0.5–4.0). Ambulatory BP monitoring shows an average daytime BP of 148/90 mm Hg and average nighttime BP of 126/80 mm Hg. </p>\n<p>Chlorthalidone 25 mg daily is initiated. Laboratory evaluation 2 weeks later shows creatinine 1.0 mg/dL and potassium 3.3 mEq/L. Chlorthalidone is changed to amlodipine 10 mg daily, and potassium is supplemented. After correction of hypokalemia, additional laboratory studies are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Morning, upright, normal diet </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Plasma renin activity</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.3 ng/mL/hr<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.2–3.6 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Plasma aldosterone concentration</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">22 ng/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">≤10</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>24-Hour urine</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">245 mEq<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies with intake</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.1 g<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies with intake</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Aldosterone</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">16 μg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">5–19</td>\n</tr>\n</tbody>\n</table>\n \n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Order adrenal CT scan"
            },
            {
                "label": "B.",
                "text": "Prescribe spironolactone"
            },
            {
                "label": "C.",
                "text": "Prescribe dexamethasone"
            },
            {
                "label": "D.",
                "text": "Order 24-hour urinary free cortisol"
            },
            {
                "label": "E.",
                "text": "Change amlodipine to amiloride"
            }
        ],
        "correct_answer": "Order adrenal CT scan",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with biochemical evidence of primary aldosteronism should undergo adrenal CT in preparation for adrenal vein sampling and possibly adrenalectomy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary aldosteronism is a common cause of secondary hypertension that is characterized by renin-independent aldosterone secretion. Patients with primary aldosteronism have a higher cardiovascular risk than those with essential hypertension, including increased risk of stroke, heart failure, atrial fibrillation, and coronary artery disease. Screening for primary aldosteronism is recommended in all patients with resistant hypertension and those with spontaneous or diuretic-induced hypokalemia. However, the prevalence of primary aldosteronism is likely greater than previously recognized, and a lower threshold for screening may be appropriate. The initial screening test is a paired morning ambulatory plasma renin activity (PRA) and plasma aldosterone concentration (PAC). The PRA is typically very low (&lt;1 ng/mL/h), and the PAC is typically elevated (&gt;15 ng/dL). A urinary aldosterone excretion of &gt;12 μg/day while consuming a high-sodium diet (urine sodium excretion &gt;200 mEq/day) is also evidence of primary aldosteronism when the PRA is low. Recently, many laboratories have begun reporting plasma renin concentration instead of PRA, and because there is no accepted conversion factor between these 2 parameters, it is unclear which threshold values to use for diagnosing primary aldosteronism. When primary aldosteronism is identified, and there is a high likelihood of cure, adrenal CT should be performed to distinguish a unilateral aldosterone-producing adenoma (APA) from bilateral adrenal hyperplasia. If an adenoma is identified, adrenal vein sampling should be performed to confirm that excessive aldosterone production lateralizes to the side of the adenoma. Criteria suggesting high likelihood of cure include (1) no more than 2 antihypertensive medications, (2) BMI ≤25 kg/m<sup>2</sup>, (3) hypertension diagnosed &lt;6 years ago, and (4) female gender. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient, for whom surgical resection of an APA could be curative, it would be inappropriate to prescribe spironolactone alone. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Dexamethasone is effective at treating hypertension caused by glucocorticoid-remediable aldosteronism (GRA), also known as familial hyperaldosteronism type I (FH type I). Patients with GRA have adrenocorticotropic hormone (ACTH)-sensitive aldosterone production in the zona fasciculata of the adrenal gland, leading to renin-independent aldosterone synthesis. GRA is inherited in an autosomal dominant manner. Affected patients have a family history of hypertension and stroke from ruptured intracranial aneurysms; many such patients are diagnosed in childhood. Although PRA is low and PAC is high, the absent family history in this case makes GRA less likely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ectopic ACTH release, typically from small cell carcinoma of the lung, can lead to a syndrome of apparent mineralocorticoid excess as a result of extremely high circulating levels of ACTH and cortisol. Cortisol levels may exceed the metabolic capacity of 11β-hydroxysteroid dehydrogenase enzyme type 2 isoform (11β-HSD2), which is present in the kidney and converts cortisol to cortisone, preventing cortisol-induced mineralocorticoid receptor activation. Markedly elevated ACTH levels may also inhibit 11β-HSD2. Elevated 24-hour urinary free cortisol or urinary cortisol-to-cortisone ratio suggests ectopic ACTH production or another syndrome of apparent mineralocorticoid excess. Chronic ingestion of glycyrrhizic acid, which is the active compound in licorice and can also found in chewing tobacco, may lead to the syndrome of apparent mineralocorticoid excess because of inhibition of 11β-HSD2. Cessation of licorice ingestion is usually the only treatment that is required. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Liddle syndrome is a rare genetic disorder that results from gain-of-function mutations in the genes that encode the subunits of the epithelial sodium channel . Patients usually present in childhood with hypertension, hypokalemia, and metabolic alkalosis. PRA, PAC, and 24-hour urinary aldosterone excretion are all low. Treatment with amiloride or triamterene is effective at correcting hypertension and hypokalemia.</p>\n</div>",
        "references": []
    },
    "40": {
        "question": "<div class=\"qtext\"><p>A 93-year-old woman is evaluated for recurrent, severe weakness. She initially experienced weakness and poor appetite several months ago and was found to be undernourished due to anorexia. Megestrol was prescribed to address anorexia and she responded favorably with an improvement in energy and appetite and a 4-kg weight gain. However, over the last month, she reports feeling weak again. Additionally, she reports fatigue and nausea. She does not describe shortness of breath, edema, or change in her urine output. She has long-standing stress urinary incontinence. Medical history includes CKD stage 3 attributed to hypertension and congestive heart failure with reduced ejection fraction, as well as osteoarthritis affecting multiple joints. Her medications include lisinopril, amlodipine, megestrol, diclofenac gel, and aspirin.</p>\n<p>On examination, BP is 110/61 mm Hg and heart rate is 78/min. She has mild temporal wasting and mild sarcopenia. Strength is 4/5 and equal throughout all extremities. There is no edema of her lower extremities, and lung, heart, and abdominal examinations are unremarkable. Mild pallor is present.</p>\n<p>Laboratory values are as follows:</p>\n<div style=\"margin-bottom: 20px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\"><strong><b>2 Months Ago</b></strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\"><b>Current</b><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\"><strong><b>Reference Range</b></strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Hemoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">10 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">10.8<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">12–16 <br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">139 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">131</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">3.5 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">5.6</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">3.5–5.0 <br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">109 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">110</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">98–106<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">25 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">15</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">23–28 <br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">20 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">24</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">8–20 <br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">1.0 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">1.1</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">0.5–1.1<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Glucose<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">104 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">109</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">70–99, fasting <br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Albumin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">2.5 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">3.2</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">3.5–5.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Urine potassium-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">10 mEq/g<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">Varies<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><strong>Which of the following tests is the most likely to reveal the cause of her hyperkalemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Dietary history"
            },
            {
                "label": "B.",
                "text": "24-Hour urine potassium"
            },
            {
                "label": "C.",
                "text": "Serum cortisol"
            },
            {
                "label": "D.",
                "text": "Bladder ultrasound"
            },
            {
                "label": "E.",
                "text": "Serum aldosterone"
            }
        ],
        "correct_answer": "Serum cortisol",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in the evaluation of this patient with hyperkalemia, hyponatremia, and a low serum bicarbonate is to check a morning serum cortisol level to evaluate for adrenal insufficiency.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Megestrol, a synthetic progestin approved for treatment of anorexia or weight loss in patients with acquired immunodeficiency syndrome (AIDS) and often used off-label for other forms of cachexia, has high affinity for the glucocorticoid receptor. Patients taking megestrol are at risk for both symptoms of cortisol excess (Cushing syndrome) and adrenal insufficiency, due to central suppression of the hypothalamic-pituitary axis (HPA). In one study, 33% of patients with cancer taking megestrol developed adrenal insufficiency within a month of medication initiation. The mechanism of adrenal insufficiency is unknown, but postulated mechanisms include high-affinity antagonism at the glucocorticoid receptor while suppressing the HPA, resulting in secondary adrenal insufficiency. Additional or alternative mechanisms may also be present because hyperkalemia, which is sometimes observed in megestrol-related hypoadrenalism, is not expected when hypoadrenalism results from suppression of the HPA. Adrenal function is initially evaluated by checking a morning serum cortisol level, followed by a cosyntropin stimulation test if the level is low. Aldosterone levels may be low, but measurement of cortisol is better established as a diagnostic test in this setting. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urinary retention can result in hyperkalemia and a non-anion gap metabolic acidosis that may mimic the effect of hypoaldosteronism, and clinical symptoms of bladder dysfunction may be subtle or nonexistent, but profound weakness, fatigue, and nausea would not be expected in the absence of more severe kidney impairment.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Either a specific dietary history or measurement of 24-hour potassium excretion could establish excessive intake as a potential cause of hyperkalemia. In this case, the relatively low urine potassium-to-creatinine ratio implicates impaired potassium excretion, and neither a dietary history nor a 24-hour urine would be likely to be informative.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient reports improvement in her energy and appetite with megestrol. Before discontinuing megestrol, it is important to determine whether adrenal insufficiency is present. This patient would benefit from shared decision-making about the risks and benefits of the drug before discontinuation.</p>\n</div>",
        "references": []
    },
    "41": {
        "question": "<div class=\"qtext\"><p>A 35-year-old man presents to the emergency department at 2:00 a.m. after a motor vehicle collision. His leg was pinned under the seat for 5 hours. He is unresponsive and has no known health care proxy. His wallet contains his work identification card and the contact information for his sister, who is unable to be reached. He wears a wedding ring. His electronic medical record indicates that he was seen 6 months ago by his primary care physician and was in excellent health at that time.</p>\n<p>His BP is 106/52 mm Hg, heart rate is 108/min, and oxygen saturation is 92% while receiving 5 L/min oxygen via nasal cannula. Examination of the lungs reveals bilateral crackles. There are extensive signs of trauma to the head, face, torso, and extremities.</p>\n<p>Laboratory data are as follows:</p>\n<div style=\"margin-bottom: 15px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">7.1 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">9 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">70 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">4.5 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Creatine kinase<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">450,000 U/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">55–170<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p>The EKG shows peaked T waves and prolonged QRS complexes.</p>\n<p>Isotonic sodium bicarbonate and calcium gluconate are administered, and an indwelling urinary catheter is placed. Over the next 5 hours, his urine output is 10 mL. The care team decides that acute HD is indicated.</p>\n<p><strong>Which ONE of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Review the electronic medical record for the presence of a portable medical order"
            },
            {
                "label": "B.",
                "text": "Contact the patient’s place of employment for his spouse’s contact information"
            },
            {
                "label": "C.",
                "text": "Request an ethics consult for this patient without decisional capacity"
            },
            {
                "label": "D.",
                "text": "Perform emergent HD without patient consent"
            },
            {
                "label": "E.",
                "text": "Medically manage the patient until his sister is available to give consent"
            }
        ],
        "correct_answer": "Perform emergent HD without patient consent",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with life-threatening electrolyte abnormalities should undergo emergent HD without patient consent.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although laws regarding patients without decisional capacity whose wishes are unknown vary by state, the consensus of medical and ethical societies is to act in the patient’s best interest (beneficence) and to perform the medical standard of care. In this case, it is likely that the patient will die without HD. If HD is performed and rhabdomyolysis improves, the patient’s condition may improve sufficiently for capacity to be restored. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Requesting an ethics consult will take time and may not be warranted if the next of kin or a surrogate will be available soon. Additionally, because spouses are considered higher-level surrogates in most states, and there is a possibility that the patient is married, marital status would need to be confirmed before allowing his sister, rather than his spouse, to consent for non-emergent procedures. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Waiting for a prolonged period for any surrogate to give consent is likely not feasible in the immediate setting, given the patient’s life-threatening hyperkalemia. Options for medical management of rhabdomyolysis complicated by anuric AKI and severe hyperkalemia are limited.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A portable medical order, or physician order for life-sustaining treatment (POLST), is only used for patients at the end of life. In this patient who was previously healthy, there would be no indication for a POLST to be created.</p>\n</div>",
        "references": []
    },
    "42": {
        "question": "<div class=\"qtext\"><p>A 64-year-old man with a history of ESRD due to ADPKD status post kidney transplant 1 year ago presents for routine follow-up. His immediate post-transplant course was uncomplicated, and he was discharged after 5 days. Three weeks after discharge, he was admitted with community-acquired pneumonia, and an induced sputum culture was positive for <em>Streptococcus pneumoniae</em>. He had an episode of mild acute rejection 2 months after transplant that was managed successfully with high-dose corticosteroids. He has also had several instances of supratherapeutic tacrolimus trough levels and chronic diarrhea, which required decreased dosing of tacrolimus and mycophenolate, respectively. Current medications include tacrolimus, mycophenolate, and prednisone.</p>\n<p>Of note, he has a history of cannabis use, which he discontinued immediately prior to transplant (confirmed by blood testing). At this visit, he admits that 2 weeks after transplant, he resumed smoking marijuana and taking oral cannabidiol (CBD) 1–2 times per week.</p>\n<p>His peak eGFR following transplantation was 79 mL/min/1.73 m<sup>2</sup>, and his current eGFR is 62 mL/min/1.73 m<sup>2</sup>.</p>\n<p><strong>Which of the following events is MOST LIKELY attributable to this patient’s use of cannabis products?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Acute rejection"
            },
            {
                "label": "B.",
                "text": "Supratherapeutic tacrolimus trough"
            },
            {
                "label": "C.",
                "text": "Pneumococcal pneumonia"
            },
            {
                "label": "D.",
                "text": "Chronic diarrhea"
            },
            {
                "label": "E.",
                "text": "eGFR decrease"
            }
        ],
        "correct_answer": "Supratherapeutic tacrolimus trough",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely adverse event attributable to cannabis use in this patient is supratherapeutic tacrolimus trough levels.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cannabis refers to the products of the <em>Cannabis sativa</em> plant, such as the flowers or buds, which are commonly referred to as marijuana. Cannabis can be consumed by inhalation or ingestion and is the most widely used illicit substance (by federal statute) in the United States. Extensively touted for medicinal and intoxicating properties, cannabis is being legalized in an increasing number of states. Cannabis contains numerous components that may be biologically important, but the 2 dominant components are tetrahydrocannabinol (THC), which produces psychoactive effects, and CBD, which is reported to have analgesic and anxiolytic properties. CBD is almost ubiquitously available and is marketed to treat pain, insomnia, and many other somatic complaints. A pharmaceutical CBD preparation has been approved for the treatment of intractable seizures in patients with Lennox-Gastaut syndrome. CBD inhibits the function of cytochrome P450 3A4 (CYP3A4), which is responsible for the metabolism of multiple medications including tacrolimus, resulting in supratherapeutic drug levels and toxicity. The use of CBD is widespread and increasing, so it is inevitable that practicing nephrologists will encounter questions about its use and its effect on the kidneys. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Outcomes data are scant and short term, but to date, 1-year mortality and graft survival appear no different between cannabis users and nonusers. There are no data associating cannabis use with allograft rejection.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Similarly, there are no data associating cannabis use with pneumococcal pneumonia or worsened mycophenolate-associated gastrointestinal symptoms. Inhalational use of cannabis has been linked to fungal pneumonia in transplant recipients and other immunocompromised patients. The Centers for Disease Control and Prevention recommends that solid organ transplant recipients refrain from smoking marijuana.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Single center data do not show an association between marijuana use and decreased eGFR or changes in graft function in kidney transplant recipients. Additionally, there are no data linking cannabis use to rapid decreases in eGFR as seen in this patient. </p>\n</div>",
        "references": []
    },
    "43": {
        "question": "<div class=\"qtext\"><p>A 56-year-old woman with CKD stage G3b due to hypertension presents to clinic for a follow-up visit. Her medications include amlodipine, carvedilol, and torsemide. She has no specific complaints.</p>\n<p>On examination, her BP is 154/90 mm Hg and her body mass index (BMI) is 31 kg/m<sup>2</sup>. The remainder of the examination is normal.</p>\n<p>Her laboratory results are as follows:</p>\n<div style=\"margin-bottom: 20px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Hemoglobin <br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">10.3 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">12–16<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">142 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.5 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">21 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">eGFR<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">32 mL/min/1.73 m<sup>2</sup><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">≥60<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Calcium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">8.5 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">8.6–10.2<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Phosphorus<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.8 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.0–4.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Albumin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">4.2 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">PTH<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">98 pg/mL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">10–65<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><strong>If this patient were to adopt a plant-based diet, which of the following consequences would be MOST LIKELY?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Improvement of metabolic acidosis"
            },
            {
                "label": "B.",
                "text": "Development of hyperkalemia"
            },
            {
                "label": "C.",
                "text": "Worsening of hyperparathyroidism"
            },
            {
                "label": "D.",
                "text": "Development of hyperphosphatemia"
            },
            {
                "label": "E.",
                "text": "Development of hypoalbuminemia"
            }
        ],
        "correct_answer": "Improvement of metabolic acidosis",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely outcome of changing to a predominantly plant-based diet in this patient with moderate CKD and probable mild metabolic acidosis would be increased serum bicarbonate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Plant-based diets are gaining in popularity. In a randomized, placebo-controlled trial, Goraya and colleagues<em> </em>studied the effects of fruit and vegetable (F/V) supplementation, sodium bicarbonate tablets, or usual care in CKD stage 3 patients with presumed hypertensive nephropathy and metabolic acidosis. Both F/V and bicarbonate supplementation improved the serum bicarbonate level and decreased the rate of CKD progression compared with usual care. The F/V group had the added benefit of better BP control and more weight loss.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this study, which excluded patients with high baseline potassium levels, hyperkalemia rates were not different between the F/V and the bicarbonate groups. Although this study investigated adding F/V rather than adopting a completely plant-based diet, this patient has a low baseline potassium level, takes a potassium-excreting diuretic, and does not take any medication that impairs potassium secretion, all of which reduce the risk of developing hyperkalemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In a crossover study, Moe and colleagues demonstrated that a diet high in plant-based protein was less likely to result in an increased serum phosphorus level than diets high in animal-based protein containing the same amount of phosphorus. Recognizing that a 100% plant-based (vegan) diet may not be acceptable to many individuals, Moorthi and colleagues found that a 70% plant protein diet did not increase serum phosphorus levels, despite a decrease in urinary phosphorus excretion compared with a more animal protein-heavy diet. The most likely explanation for these findings is that plant phosphorus is bound in phytate, and humans lack the enzyme phytase needed to liberate the phosphorus, such that less is bioavailable. Also notable in these studies was that PTH did not rise with a diet high in plant protein.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">To date, there are no studies that show a significant association between plant-based diets and hypoalbuminemia.</p>\n</div>",
        "references": []
    },
    "44": {
        "question": "<div class=\"qtext\"><p>A 76-year-old man with stage 3 non-small cell lung cancer is evaluated for increased serum creatinine after initiating cisplatin therapy. He denies shortness of breath, edema, or hematuria.</p>\n<p>On exam, BP is 110/64 mm Hg and heart rate is 72/min without orthostatic changes. There is trace pretibial edema bilaterally.</p>\n<p>Laboratory data are as follows:</p>\n<div style=\"margin-bottom: 15px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">WBC count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3200/µL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">4000–11,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Hemoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">9.6 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">14–18<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Platelet count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">162,000/µL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">150,000–450,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><b>Serum</b><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">137 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.9 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">1.7 mg/dL (baseline, 0.7)<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Magnesium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">1.3\nmEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">1.6–2.6<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><b>Urine</b><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Protein-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">0.6 mg/mg (baseline, 0.2)<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">&lt;0.2<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p>Urinalysis with microscopy is unremarkable, and urine output is 1200 mL/day.</p>\n<p><strong>Which ONE of the following is the MOST appropriate intervention to limit cisplatin-associated AKI?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Isotonic saline"
            },
            {
                "label": "B.",
                "text": "Isotonic saline plus furosemide"
            },
            {
                "label": "C.",
                "text": "Mannitol"
            },
            {
                "label": "D.",
                "text": "Magnesium"
            },
            {
                "label": "E.",
                "text": "N-acetylcysteine"
            }
        ],
        "correct_answer": "Isotonic saline",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Infusion of isotonic saline before chemotherapy is the most effective way to minimize cisplatin-associated nephrotoxicity. The alkylating agent cisplatin causes kidney injury by several mechanisms, including direct proximal tubular toxicity, renal arteriolar vasoconstriction, and inflammation. Cisplatin is filtered and secreted by organic cation transporters in the proximal tubule, and increased concentrations cause tubular injury in the S3 segment. The risk of cisplatin nephrotoxicity rises as the cumulative dose increases. Carboplatin has less nephrotoxicity and is sometimes substituted for cisplatin when possible.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Toxicity may manifest as AKI, Fanconi syndrome, or thrombotic microangiopathy, especially when combined with agents such as bleomycin or gemcitabine. Furosemide and mannitol do not prevent toxicity, although furosemide may be useful in patients with hypervolemia.</p>\n<p><em>N</em>-acetylcysteine has not been shown to be effective in preventing cisplatin-associated AKI. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A single, underpowered trial showed that pretreatment with magnesium IV decreased cisplatin-associated AKI in patients with ovarian cancer; this result has not been replicated in larger trials. Separately, hypomagnesemia from urinary magnesium wasting is commonly observed with cisplatin, and this deficit may exacerbate cisplatin nephrotoxicity. Magnesium supplementation would be appropriate in this patient but would not preclude administration of isotonic saline. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Isotonic saline infusion and forced diuresis with saline followed by furosemide or mannitol were compared in a randomized controlled trial for preventing cisplatin nephrotoxicity. There was a trend toward increased toxicity in the mannitol arm and no difference in the isotonic saline alone versus isotonic saline plus furosemide arms. Therefore, the current standard of care to prevent cisplatin-associated AKI is isotonic saline only.</p>\n</div>",
        "references": []
    },
    "45": {
        "question": "<div class=\"qtext\"><p>A 74-year-old-woman is referred to the emergency department by her primary care physician due to abnormal laboratory tests that had been ordered to investigate progressively severe fatigue over the last few months. </p>\n<p>Her physical examination is normal except for lower extremity ecchymoses. There is no edema. </p>\n<p>Laboratory data are as follows:</p>\n<div style=\"margin-bottom: 15px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><b>Blood</b><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  WBC count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">6000/µL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">4000–11,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Hemoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">11 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">12–16<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Platelet count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">112,000/µL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">150,000–450,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><b>Serum</b><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">138 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.4 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">132 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">98–106<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">16 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">2.5 mg/dL (baseline, 0.6)<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.5–1.1<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Glucose<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">95 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">70–99, fasting<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Calcium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">10.7 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">8.6–10.2<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Phosphorus<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">2.2 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.0–4.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Albumin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.0 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Uric Acid<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.5 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.0–7.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><b>Urine\n                        (random)</b><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">25 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">40 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">80 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  pH<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">4.7<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">4.5–8.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Protein-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">7.5 mg/mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">&lt;0.2<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Albumin-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">20 mg/g<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">&lt;30<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"></p>\n<p>The urinalysis reveals a urine pH of 5, specific gravity 1.011, trace blood, trace protein, and 1+ glucose. Urine microscopy reveals occasional RBCs, occasional WBCs, and rare granular casts.</p>\n<p><strong>Which of the following is the MOST LIKELY diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Acute tubular necrosis (ATN)"
            },
            {
                "label": "B.",
                "text": "Membranoproliferative glomerulonephritis"
            },
            {
                "label": "C.",
                "text": "Hyperparathyroidism"
            },
            {
                "label": "D.",
                "text": "Membranous nephropathy"
            },
            {
                "label": "E.",
                "text": "Light chain proximal tubulopathy"
            }
        ],
        "correct_answer": "Light chain proximal tubulopathy",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Proximal renal tubular acidosis (RTA) in the setting of non-albumin (“tubular”) proteinuria and AKI are features of light chain proximal tubulopathy. Proximal RTA is suggested by the low serum bicarbonate level without an increase in the serum anion gap, along with an acidic urine pH, and the presence of a urine cation gap that implies the presence of ammonium or another unmeasured cation. The relatively low serum anion gap and hypercalcemia, anemia, and thrombocytopenia are all consistent with a plasma cell dyscrasia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Plasma cell dyscrasias can cause kidney damage by a variety of mechanisms, most commonly AKI from myeloma cast nephropathy. In this condition, light chains filtered by the glomerulus precipitate in acidic distal urine with Tamm-Horsfall protein, causing tubular obstruction and injury and presenting with fractured casts on biopsy. Alternatively, light chains may cause proximal tubular injury during reabsorption, causing AKI with Fanconi syndrome, which manifests as proximal RTA, hypophosphatemia, normoglycemic glycosuria, hyperuricosuria, aminoaciduria, and low-molecular-weight proteinuria. The diagnosis of light chain proximal tubulopathy should be considered in patients with Fanconi syndrome and paraproteinemia, hypercalcemia, or anemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ATN can present with tubular proteinuria without concurrent albuminuria, but there is no history of obvious causes of ATN in this case. Furthermore, the other features of this case including Fanconi syndrome are more consistent with light chain proximal tubulopathy than ATN.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">MPGN has been associated with malignancy, paraproteinemia, infections, and autoimmune conditions. However, the proteinuria seen in MPGN would be glomerular, not tubular, and urine albumin excretion should be 50%–75% of urine protein excretion.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Membranous nephropathy can be a paraneoplastic syndrome but would be expected to cause nephrotic-range proteinuria with predominant albuminuria, which is not present in this case. The urine studies suggesting 7.5 g/d of total proteinuria but only 20 mg/d of albuminuria is a clue to the presence of light chains in the urine as the major source of protein. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary hyperparathyroidism can cause RTA, hypercalcemia, and hypophosphatemia but would not account for the other features of this case.</p>\n</div>",
        "references": []
    },
    "46": {
        "question": "<div class=\"qtext\"><p>A 59-year-old man with ESRD due to FSGS status post deceased donor kidney transplant 1 year ago returns to clinic for evaluation of poorly controlled hypertension and acute allograft dysfunction. He has been maintained on tacrolimus, mycophenolate, and prednisone. Medical history also includes long-standing type 2 diabetes, hypertension, hyperlipidemia, hypothyroidism, and a 30-year history of smoking (quit before transplant). Additional medications include aspirin, atorvastatin, levothyroxine, and nifedipine.</p>\n<p>Previously, the patient’s BP had been well controlled, but over the last few weeks, his average home BP readings have been 180/100 mm Hg. Carvedilol and doxazosin have been prescribed, but he remains hypertensive.  </p>\n<p>BP is 190/110 mm Hg. On physical examination, jugular venous pressure is normal, and he has no edema. A bruit is heard over the kidney transplant, and the allograft is nontender.</p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">140 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.3 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">105 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">98–106<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">29 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">30 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">2.0 mg/dL (baseline, 0.9)<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Tacrolimus, whole blood trough<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">5.0 ng/mL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">5.0–10.0, 3 months post-transplant<br/></td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis shows no blood or protein, and no WBCs or RBCs are noted on urine microscopy.</p>\n<p>Ultrasound demonstrates a 2.3 x 5.1 x 2.0-cm perinephric fluid collection without septations superior and lateral to the kidney, early intrarenal <em>parvus tardus</em> waveforms, a main renal artery peak systolic velocity of 240 cm/s (reference range, 60–100), and no hydronephrosis.</p>\n<p><strong>Which of the following tests is MOST LIKELY to identify the cause of this patient’s worsening hypertension and allograft dysfunction?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Kidney biopsy"
            },
            {
                "label": "B.",
                "text": "Angiography"
            },
            {
                "label": "C.",
                "text": "Antegrade nephrostogram"
            },
            {
                "label": "D.",
                "text": "Perinephric fluid aspiration"
            },
            {
                "label": "E.",
                "text": "Adrenal vein sampling"
            }
        ],
        "correct_answer": "Angiography",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient, who likely has transplant renal artery stenosis (TRAS) or iliac artery stenosis proximal to the arterial anastomosis, should undergo renal angiography for further evaluation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">TRAS is suggested by new-onset hypertension, abdominal bruit, hypokalemia, AKI, and abnormal sonographic Doppler signals (increased main renal artery peak systolic velocity and <em>parvus et tardus</em> [small and late] spectral waveforms). Hypertension and hypokalemia derive from increased renin production by the stenotic kidney, causing increased angiotensin II and aldosterone production. Angiography would confirm the presence of TRAS or proximal iliac arterial stenosis prior to intervention.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A kidney biopsy is commonly performed to evaluate for intrinsic causes of AKI (e.g., rejection, BK virus nephropathy). However, based on the history, physical examination findings, and ultrasound, an intrinsic cause of AKI is less likely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ureteral stenosis typically presents early in the post-transplant course and would likely present with hydronephrosis and signs of obstruction. This diagnosis could be confirmed with an antegrade nephrostogram but is not necessary if obstruction is not suspected.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient has a small perinephric fluid collection. Such collections are not infrequent after transplantation and can be caused by seromas, lymphoceles, urinomas, hematomas, or abscesses. However, given its relatively small size, location, and characteristics, it is unlikely to be contributing to this patient’s graft failure or hypertension, so aspiration is not necessary.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Adrenal vein sampling may be useful in patients with primary aldosteronism in which lateralization must be documented prior to adrenalectomy. Although primary aldosteronism is a common cause of secondary hypertension, it is less likely in this patient with a clear alternative explanation.</p>\n</div>",
        "references": []
    },
    "47": {
        "question": "<div class=\"qtext\"><p>A 29-year-old woman with type 1 diabetes mellitus and stage 4 CKD is evaluated for consideration of kidney transplantation. She has had diabetes for &gt;15 years and has retinopathy and neuropathy. She has had variable glycemic control and has suffered episodes of hypoglycemia by fingerstick measurement (as low as 45 mg/dL) without associated symptoms. Her eGFR has fallen to 15 mL/min/1.73 m<sup>2</sup> (reference range, ≥60). She notes fatigue and some anorexia but no nausea, hiccups, itching, bleeding, chest pain, or dyspnea. She has been referred for creation of an HD access. Both parents are interested in kidney donation but are 68 years old with hypertension, requiring 2 medications to achieve BP control. She has no siblings and is unaware of other potential donors but has not approached friends or cousins. She also asks about the feasibility of seeking a transplant outside the United States or making an appeal on social media for an altruistic donor. Her medications include insulin, amlodipine, sevelamer, and atorvastatin. Lisinopril was stopped because of hyperkalemia. </p>\n<p>On examination, the patient appears slightly pale. Her BP is 135/84 mm Hg and pulse is 84/min. Superficial arm veins are small but visible. The lungs are clear, and the heart is regular without rub or gallop. Mild pretibial edema is present. Light touch sensation is diminished to the level of the knees bilaterally. There is no asterixis.</p>\n<p>Laboratory data are as follows:</p>\n<div style=\"margin-bottom: 20px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Hemoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">8.8 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">12–16<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.8 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.5–1.1<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Refer for deceased donor kidney transplant"
            },
            {
                "label": "B.",
                "text": "Encourage social media request for an altruistic donor"
            },
            {
                "label": "C.",
                "text": "Refer for simultaneous kidney and pancreas transplant (SKPT)"
            },
            {
                "label": "D.",
                "text": "Evaluate her parents for live kidney donation"
            },
            {
                "label": "E.",
                "text": "Explore kidney transplantation outside the United States"
            }
        ],
        "correct_answer": "Refer for simultaneous kidney and pancreas transplant (SKPT)",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has type 1 diabetes complicated by retinopathy, neuropathy, and episodes of hypoglycemic unawareness. Hence, she would benefit from SKPT.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">None of the other options include pancreas transplantation, which would be indicated for this patient. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A living donor kidney transplant, such as from an altruistic donor, is preferrable to a deceased donor kidney transplant, but would not address diabetes with complications, and patient outcomes in this setting are superior with SKPT. Altruistic donation appears to be increasingly common, but ethical concerns persist, particularly regarding donor outcomes. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Traveling across national borders to obtain an organ transplant is often referred to as “transplant tourism (TT),” and the practice remains fraught with medical and ethical concerns. As with other kidney transplant strategies, TT would not address diabetes and its complications.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although there is evidence that both older persons and those with well controlled hypertension taking £2 medications may be suitable kidney donors, this patient’s<a href=\"#_msocom_1\" id=\"_anchor_1\" language=\"JavaScript\" name=\"_msoanchor_1\"></a> parents are not ideal donors given their age and history of hypertension. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pancreas after kidney transplant (PAK) is a good option in patients with a well-functioning prior kidney transplant, but this patient has no immediately available living donors. In addition, patient survival with SKPT is superior to that of living donor kidney transplant recipients with type 1 diabetes.</p>\n</div>",
        "references": []
    },
    "48": {
        "question": "<div class=\"qtext\"><p>A 32-year-old man with ESRD due to FSGS status post living kidney transplant from his mother 2 years ago is seen for routine follow-up. He has well-controlled hypertension, and his post-transplant course has been uneventful. His immunosuppressive regimen consists of tacrolimus and mycophenolate mofetil. Creatinine has been at his baseline level of 0.9 mg/dL (reference range, 0.7–1.3), and tacrolimus trough is usually 5–7 ng/mL (reference range, 5–10).</p>\n<p>He is recently married and is planning to have children within the year. He is concerned about infertility with his history of kidney disease and immunosuppression.</p>\n<p><strong>Which one of the following is the MOST APPROPRIATE next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "No change in management"
            },
            {
                "label": "B.",
                "text": "Change tacrolimus to belatacept"
            },
            {
                "label": "C.",
                "text": "Advise against pregnancy until 3 years after transplant"
            },
            {
                "label": "D.",
                "text": "Change mycophenolate to everolimus"
            },
            {
                "label": "E.",
                "text": "Change tacrolimus to sirolimus and prednisone"
            }
        ],
        "correct_answer": "No change in management",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">No change in management is required for this patient, who has a well-functioning allograft 2 years after transplantation and a fertility rate equivalent to men in the general population.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Male patients with progressive CKD have increased rates of infertility. After kidney transplant (KT), however, fertility recovers with reestablishment of normal serum testosterone levels and semen quality within months. Generally, pregnancies fathered by men with KT fare as well as pregnancies fathered by men who do not have transplants. Studies suggest that optimal pregnancy outcomes occur if men wait at least 2 years after KT and have good allograft function. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sirolimus can impact male fertility by impairing sperm development, resulting in low sperm counts and decreased testosterone levels, so there would be no reason to change to a sirolimus- or everolimus-based immunosuppressive regimen. Calcineurin inhibitors (CNI) may be used for male and female patients of reproductive age with KT. Studies in rats show that cyclosporine decreases sperm count, testosterone level, and fertility while increasing luteinizing and follicle-stimulating hormones. However, in humans, there is no evidence that CNI adversely affect male fertility or fetal development. There are no recommendations regarding CNI trough levels for men with regard to fertility and pregnancy outcomes. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mycophenolate mofetil has been associated with birth defects and pregnancy loss in women taking the medication, but such data are limited when the father is taking mycophenolate at the time of conception. A recent study found no increased risk for adverse pregnancy outcomes in which the father had exposure to mycophenolate. The European Medicines Agency and the manufacturer’s medication label warn that men should use contraception and avoid sperm donation during and up to 90 days after mycophenolate treatment, but this recommendation is based on hypothetical risk rather than clinical trials or observations. Any risk for adverse pregnancy outcome would need to be weighed against an adverse patient outcome that could be precipitated by a change in immunosuppression. It is reasonable to inform prospective fathers of this hypothetical risk, but based on current information, it is not necessary to advise against conception or discontinue mycophenolate in the absence of an alternative indication.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Currently, there is insufficient information available about belatacept and fertility or pregnancy outcomes to justify a change in immunosuppression in this patient with a well-functioning allograft.</p>\n</div>",
        "references": []
    },
    "49": {
        "question": "<div class=\"qtext\"><p>A 55-year-old woman with CKD G3b/A1, hypertension, type 2 diabetes mellitus, and nephrolithiasis is referred for outpatient evaluation. Her medications include lisinopril, metformin, empagliflozin, and glipizide.</p>\n<p>BP is 120/80 mm Hg and heart rate is 70/min. Her lungs are clear to auscultation, and there is no lower extremity edema. </p>\n<p>Laboratory data are as follows: </p>\n<div style=\"margin-bottom: 20px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 40%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">1.5 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">0.5–1.1<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 40%;\">Calcium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">10.3 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">8.6–10.2<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 40%;\">Albumin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">4.0 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">3.5–5.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 40%;\">Total protein<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">8.0 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">5.5–9.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 40%;\">Phosphorus<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">3.0 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">3.0–4.5 <br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 40%;\">PTH, intact<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">165 pg/mL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">10–65<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 40%;\">25-Hydroxyvitamin D<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">35 ng/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">30–60<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><strong>Which ONE of the following is the MOST likely cause of elevated PTH?</strong></p>\n<p></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Primary hyperparathyroidism"
            },
            {
                "label": "B.",
                "text": "Secondary hyperparathyroidism"
            },
            {
                "label": "C.",
                "text": "Pseudohypoparathyroidism"
            },
            {
                "label": "D.",
                "text": "Tertiary hyperparathyroidism"
            },
            {
                "label": "E.",
                "text": "Familial hypercalcemic hypocalciuria"
            }
        ],
        "correct_answer": "Primary hyperparathyroidism",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of increased PTH is primary hyperparathyroidism.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The parathyroid glands are essential to maintain normal calcium and phosphorus homeostasis. Synthesis and release of PTH are influenced by several factors: </p>\n<ol>\n<li style=\"margin-bottom: 15px;\">Negative feedback exerted by ionized calcium binding to the calcium-sensing receptor (CaSR)</li>\n<li style=\"margin-bottom: 15px;\">Inhibition by 1,25-dihydroxycholecalciferol (calcitriol), both directly and indirectly</li>\n<li style=\"margin-bottom: 15px;\">Stimulation by phosphate, both directly and indirectly</li>\n<li style=\"margin-bottom: 15px;\">Inhibition by fibroblast growth factor-23</li>\n</ol>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The major actions of PTH are stimulation of bone resorption; renal tubular calcium reabsorption and phosphate excretion; and enhanced gastrointestinal absorption of calcium (through hydroxylation of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The differential diagnosis of an elevated intact PTH concentration includes primary hyperparathyroidism, secondary hyperparathyroidism, tertiary hyperparathyroidism, and familial hypocalciuric hypercalcemia (FHH).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Secondary hyperparathyroidism is common in CKD. The pathophysiology of this condition includes stimulation of PTH secretion and parathyroid gland hyperplasia from vitamin D deficiency, decreased parathyroid gland vitamin D receptor (VDR) density, and phosphate retention. Serum calcium levels are generally normal to low. Long-standing secondary hyperparathyroidism may evolve into tertiary hyperparathyroidism, characterized by excessive parathyroid hyperplasia or neoplasia causing hypercalcemia. Both secondary and tertiary hyperparathyroidism are associated with phosphate retention and hyperphosphatemia. In this vignette, the presence of hypercalcemia and low-normal serum phosphorus level strongly favor primary hyperparathyroidism, despite the presence of CKD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pseudohypoparathyroidism encompasses a rare group of disorders characterized by unresponsiveness to PTH. Individuals present in childhood with hypocalcemia, hyperphosphatemia, and elevated PTH.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">FHH is caused by inactivating mutations of CaSR. Patients present with mild hypercalcemia and normal or only mildly elevated PTH. Urinary calcium excretion is low (&lt;250 mg/24 h in women; &lt;300 mg/24 h in men). The metabolic abnormalities in this patient are not inconsistent with FHH, but the degree of elevation of PTH is more than is typically seen in FHH. Urinary calcium measurement, and more recently genetic evaluation, can be obtained when the routine clinical data cannot distinguish between FHH and primary hyperparathyroidism and to determine whether surgery is appropriate.</p>\n</div>",
        "references": []
    },
    "50": {
        "question": "<div class=\"qtext\"><p>A 50-year-old man with CKD G3b/A1, hypertension, and glucose-6-phosphate dehydrogenase (G6PD) deficiency is admitted to the hospital for a new diagnosis of acute myeloid leukemia. He is scheduled for induction chemotherapy with cytarabine and daunorubicin. </p>\n<p>Admission laboratory data are as follows: </p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 40%;\">WBC count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">50,000/µL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">4000–11,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 40%;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">4.5 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 40%;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">24 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 40%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">1.9 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 40%;\">Calcium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">8.8 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">8.6–10.2<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 40%;\">Phosphorus<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">3.5 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;\">3.0–4.5<br/></td>\n</tr>\n</tbody>\n</table>\n<p>He is at intermediate risk for tumor lysis syndrome. </p>\n<p><strong>In addition to volume expansion, which ONE of the following is the MOST appropriate treatment for preventing tumor lysis syndrome?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Allopurinol"
            },
            {
                "label": "B.",
                "text": "Sodium bicarbonate"
            },
            {
                "label": "C.",
                "text": "Furosemide"
            },
            {
                "label": "D.",
                "text": "Rasburicase"
            },
            {
                "label": "E.",
                "text": "Probenecid"
            }
        ],
        "correct_answer": "Allopurinol",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient at intermediate risk for tumor lysis syndrome (TLS) should receive allopurinol prophylaxis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">TLS is an oncologic emergency characterized by the release of potassium, phosphate, and nucleic acids from massive tumor cell lysis. The risk of TLS depends on tumor type but is also influenced by other factors such as CKD. In general, solid tumors have a low risk for TLS, but there are exceptions, such as chemosensitive bulky tumors. Acute leukemias with WBC count 25,000–100,000/µL are intermediate risk. Highly aggressive lymphomas such as Burkitt and acute leukemias with WBC count &gt;100,000/µL are high risk. CKD magnifies the baseline risk. Patients with intermediate risk, such as this one, should receive prophylaxis with allopurinol and IV volume expansion (usually referred to as “hydration”). Low-risk patients are managed with hydration alone. High-risk patients without contraindications should receive rasburicase (discussed below) in addition to hydration. All patients should be monitored for the development of TLS.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The standard recommended dosing schedule for allopurinol is 300 mg/m<sup>2</sup>/day, up to a maximum of 800 mg daily. A dose reduction up to 50% can be considered in patients with decreased kidney function. Allopurinol 100 mg thrice daily is the most appropriate dose for preventing TLS in this patient and is much higher than the typical initial daily dose for gout prevention. Febuxostat is an alternative urate-lowering agent that has shown efficacy in the prevention and treatment of TLS and is an alternative for patients intolerant of allopurinol.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Uric acid is more soluble at alkaline pH. However, urinary alkalinization is not recommended for TLS prophylaxis because it may increase the risk for calcium phosphate precipitation. Sodium bicarbonate IV would be a reasonable option for volume expansion in the presence of a non-anion gap metabolic acidosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Routine use of diuretics for TLS prevention is not recommended unless clinical signs of volume overload are present. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Rasburicase, a recombinant urate oxidase, is highly efficacious for both TLS prophylaxis and treatment. This agent is an appropriate choice for patients at high risk for TLS. Rasburicase is contraindicated in patients with G6PD deficiency because it may precipitate hemolytic anemia. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Probenecid is a uricosuric agent that has been used to prevent gout in patients with hyperuricemia and normal kidney function. It is not recommended for prevention or treatment of TLS in which AKI due to uricosuria is a primary concern.</p>\n</div>",
        "references": []
    },
    "51": {
        "question": "<div class=\"qtext\"><p>A 47-year-old man with ESRD undergoing thrice weekly HD presents to his dialysis center with worsening pain in both legs and hands over the last several weeks. He has a history of hyperphosphatemia and hyperparathyroidism, both of which have worsened over the last 3 months. Medications include sevelamer and cinacalcet.</p>\n<p>On examination, BP is 152/78 mm Hg, heart rate is 90/min, and weight is 120 kg. Heart, lung, and abdomen are normal, and there is no peripheral edema. There is a functioning arteriovenous fistula in the left arm.</p>\n<p>An x-ray of the hands shows periosteal resorption at multiple sites. A technetium-labeled sestamibi scan of the parathyroid glands does not identify an adenoma.</p>\n<p>The patient agrees to subtotal (3/4 gland) parathyroidectomy and is prescribed calcitriol prior to surgery. Cinacalcet is discontinued.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.9761%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\"><strong>Preoperative</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\"><strong>1-Hour Postoperative</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;; width: 25.0000%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.9761%;\">Calcium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">8.8 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">7.9<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;; width: 25.0000%;\">8.6–10.2<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.9761%;\">Calcium, ionized<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">0.89 mmol/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;; width: 25.0000%;\">1.12–1.23<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.9761%;\">Phosphorus<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">7.1 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;; width: 25.0000%;\">3.0–4.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.9761%;\">PTH<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">1200 pg/mL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">75<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;; width: 25.0000%;\">130–585, dialysis patients<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.9761%;\">Alkaline phosphatase<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">420 U/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">600<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;; width: 25.0000%;\">30–120<br/></td>\n</tr>\n</tbody>\n</table>\n<p>The patient has been extubated and does not report any paresthesias, muscle weakness, or tetany, and none is observed on examination. EKG shows normal sinus rhythm with a corrected QT interval within normal limits.</p>\n<p><strong>Which of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Calcium carbonate PO"
            },
            {
                "label": "B.",
                "text": "HD with 3.5 mEq/L (1.75 mmol/L) calcium dialysate"
            },
            {
                "label": "C.",
                "text": "No additional management"
            },
            {
                "label": "D.",
                "text": "Calcium gluconate IV"
            },
            {
                "label": "E.",
                "text": "Calcitriol IV"
            }
        ],
        "correct_answer": "Calcium gluconate IV",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with developing hungry bone syndrome (HBS) should receive IV calcium gluconate, typically given as a bolus followed by a continuous infusion, to prevent severe, symptomatic hypocalcemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">HBS presents as hypocalcemia after parathyroidectomy and is due to increased osteoblast activity leading to an acute net influx of calcium into bone with a rapid decrease in PTH. This patient has multiple risk factors for developing HBS. As opposed to patients with primary hyperparathyroidism, a recent study showed that younger patients (47.5 versus 54.5 years of age) with secondary hyperparathyroidism were more prone to develop HBS. Increased body weight was also shown to be a risk factor, the proposed mechanism being a larger amount of overall bone tissue as a depository for calcium influx. Both higher alkaline phosphatase (415 versus 221 U/L) and the degree to which serum calcium decreased postoperatively were additional risk factors for HBS.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Preoperative calcitriol has been shown to reduce postoperative IV calcium requirements and length of stay following parathyroidectomy in patients with CKD by increasing gut absorption of calcium via intestinal transient receptor potential vanilloid-6 (TRPV-6). Patients are often treated with 2.25–4 μg/day postoperatively, with gradual titration over the next several weeks, but in patients with a functioning gut, there is no specific indication to convert from PO to IV calcitriol.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">It is necessary to monitor patients with frequent ionized calcium levels during the first 48 hours after surgery, particularly in those with multiple risk factors for HBS. Given this patient’s risk factors and immediate decrease in calcium with increase in alkaline phosphatase, a more aggressive monitoring and treatment strategy would be preferred. At-risk patients may require 6–12 g/day of elemental calcium. IV calcium with initial bolus dosing to immediately raise the serum calcium followed by a continuous infusion for maintenance would be appropriate in this case.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Adding PO calcium carbonate or replacing sevelamer with a calcium-based phosphate binder and titrating PO calcitriol would be appropriate long-term management for HBS but would not be the next best step to obviate the high risk of immediate hypocalcemia. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">HBS is anticipated, and the ionized calcium is already low, so additional management with IV calcium is necessary.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">HD with a high calcium dialysate would increase the serum calcium transiently and can be helpful to maintain calcium in the normal range, but most patients will require IV calcium, and treatment with IV calcium should not be delayed for dialysis. </p>\n</div>",
        "references": []
    },
    "52": {
        "question": "<div class=\"qtext\"><p>A 57-year-old woman undergoes a hysteroscopy complicated by uterine perforation and extravasation of irrigant solution. She has a successful surgical repair and is then extubated in the post-anesthesia care unit. Her pain is treated with IV morphine. She has incisional pain and mild nausea.</p>\n<p>On physical examination, BP is 124/72 mm Hg, heart rate is 92/min, respiratory rate is 14/min, and temperature is 37.6°C. She is no acute distress. There is an expected degree of tenderness at the site of the surgical incision. There is no edema.</p>\n<p>Laboratory data are as follows:</p>\n<div style=\"margin-bottom: 20px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.9761%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\"><strong>1 Day Preoperative</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\"><strong>1 Hour Postoperative </strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;; width: 25.0000%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.9761%;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">137 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">121</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;; width: 25.0000%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.9761%;\">Creatinine <br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">0.8 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">0.7</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;; width: 25.0000%;\">0.5–1.1<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.9761%;\">Glucose<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">86 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">75</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;; width: 25.0000%;\">70–99, fasting<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.9761%;\">Osmolality<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">289 mOsm/kg H<sub>2</sub>O<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 22.4522%;\">282</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 30%;; width: 25.0000%;\">275–295<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><strong>Which ONE of the following is the MOST appropriate treatment?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Isotonic saline"
            },
            {
                "label": "B.",
                "text": "Hypertonic saline"
            },
            {
                "label": "C.",
                "text": "Discontinue morphine"
            },
            {
                "label": "D.",
                "text": "No additional intervention"
            },
            {
                "label": "E.",
                "text": "Furosemide"
            }
        ],
        "correct_answer": "No additional intervention",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">No additional intervention is needed at this time for this asymptomatic patient with evidence of irrigant solution absorption. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Irrigant solutions containing glycine or sorbitol are used in a variety of endoscopic procedures. Extravasation can result in significant absorption of these effective osmoles, leading to hyponatremia. The effect on serum osmolality depends on the amount and osmolality of the solution absorbed. Glycine and sorbitol irrigant solutions are hypotonic with an osmolality of 200 and 165 mOsm/kg H<sub>2</sub>O, respectively. The most common clinical consequences are nausea, hypotension, and reduced urine output, but a variety of cardiovascular and neurologic signs and symptoms has been reported. Severity of presentation appears to correlate with the volume absorbed. In this case, the patient sustained a marked fall in the serum sodium caused by absorption of the irrigant solution but only a slight decrease in the serum osmolality from her baseline and was minimally symptomatic.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The differential diagnosis for euvolemic hyponatremia also includes the syndrome of inappropriate antidiuresis (SIAD), for which she is at risk due to exposure to morphine, as well as pain, nausea, and surgical stress, all of which can stimulate antidiuretic hormone secretion. In this case, SIAD is excluded by the absence of hypo-osmolality. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypertonic saline has been used in patients with neurologic complications and significant hypo-osmolality or in those with a drop in serum sodium level by &gt;5 mEq/L when mental status cannot be assessed due to anesthesia but would not be indicated in this asymptomatic patient. Neither would isotonic saline be indicated in this patient without evidence of hypovolemia. Loop diuretics have been used in patients with irrigant absorption with concomitant volume overload and pulmonary edema, neither of which is present here. In the absence of neurologic symptoms, AKI, or volume disturbance, serum sodium can be allowed to correct without intervention as the retained solute (glycine or sorbitol) is taken up intracellularly, metabolized, and excreted.</p>\n</div>",
        "references": []
    },
    "53": {
        "question": "<div class=\"qtext\"><p>A 60-year-old man with hypertension, hyperlipidemia, and lung cancer currently undergoing chemotherapy with carboplatin and paclitaxel is admitted to the hospital with nausea, vomiting, and inability to tolerate PO intake for 2 days. He had an upper gastrointestinal endoscopy that showed gastritis 2 weeks ago and was prescribed pantoprazole. Other medications include lisinopril and atorvastatin.</p>\n<p>On examination, BP is 112/76 mm Hg with a pulse of 85/min while supine and 100/65 mm Hg with a pulse of 96/min while standing. Temperature is 37°C. Chest is clear, heart sounds are normal, and lower extremities show no edema. </p>\n<p>Laboratory data are as follows:</p>\n<div style=\"margin-bottom: 15px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">WBC count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">7500/μL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">4000–11,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">Hemoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">9.8 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">14–18<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">Platelet count <br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">180,000/μL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">150,000–450,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\"><strong>Serum</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">  Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">130 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">  Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">3.3 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">  Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">100 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">98–106<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">  Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">30 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">  BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">50 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">  Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">2.6 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">  Albumin</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">3.2 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">3.5–5.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\"><strong>Urine (random)</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">  Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">65 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">Varies with intake<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">  Creatinine   <br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">50 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">Varies with intake<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">  Urea<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">70 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">Varies with intake<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p>Urinalysis shows specific gravity 1.020, 1+ protein, trace blood, no leukocyte esterase, and no casts.</p>\n<p>One month ago, hemoglobin level was 10.7 g/dL, platelet count was 230,000/μL, and serum creatinine level was 0.8 mg/dL.</p>\n<p><strong>Which of the following is the MOST LIKELY cause of AKI?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hypoperfusion"
            },
            {
                "label": "B.",
                "text": "Acute tubular necrosis (ATN)"
            },
            {
                "label": "C.",
                "text": "Acute interstitial nephritis (AIN)"
            },
            {
                "label": "D.",
                "text": "Thrombotic microangiopathy"
            },
            {
                "label": "E.",
                "text": "Glomerulonephritis"
            }
        ],
        "correct_answer": "Hypoperfusion",
        "abim_content_category": "Acute Kidney Disease and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypoperfusion, or prerenal AKI, is the most likely diagnosis for this patient with a history of vomiting, inability to eat or drink, and positive orthostatic vital signs.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The fractional excretion of sodium (FENa) is calculated as follows:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">FENa = [(urine Na/serum Na) ÷ (urine creatinine/serum creatinine)]×100%</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A FENa threshold of 1% is frequently used to diagnose or exclude prerenal AKI, but this calculation has low sensitivity and specificity. For example, the FENa may be &lt;1% in patients with prerenal AKI, cardiorenal syndrome, hepatorenal syndrome, renal artery stenosis, acute glomerulonephritis, acute interstitial nephritis, contrast-associated AKI, and rhabdomyolysis. Conversely, the FENa may be &gt;1% in patients with renal hypoperfusion who also have preexisting or concomitant tubular dysfunction, such as in those with advanced CKD. In these cases, the measured FENa may be lower than the patient’s baseline but still &gt;1%, obscuring the diagnosis of prerenal AKI. Medications such as diuretics or platinum-based chemotherapeutic agents increase natriuresis, which can mask prerenal physiology. In these cases, fractional excretion of urea (FEurea), calculated in analogous fashion to FENa, shows modest improvement in sensitivity and specificity, with results &lt;35% proposed to represent cases of prerenal azotemia. In this case, the clinical history and examination strongly suggest hypoperfusion, and this diagnosis is supported by the calculated FEurea of 7.3%. The misleading FENa of 2.6% is explained by the tubular toxicity of carboplatin, which although less toxic than cisplatin, can induce sodium wasting. The high FENa may also result from the metabolic alkalosis, causing obligate excretion of sodium as a counter-ion with the increased filtered bicarbonate load.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ATN is a well-known complication of cisplatin therapy but is less common with carboplatin. Prolonged prerenal AKI can also result in ATN. The absence of renal tubular epithelial cells or granular casts on urinalysis do not suggest this diagnosis. AIN should be included in the differential diagnosis of any patient with AKI, but definitive diagnosis requires kidney biopsy; in addition, this case has historical, examination, and laboratory data that suggest prerenal AKI as the more likely diagnosis. Paclitaxel and other taxanes may cause thrombotic microangiopathy, but platelet count is within the normal range and there is only trace blood on urinalysis, arguing against significant hemoglobinuria from intravascular hemolysis. Glomerulonephritis would be unusual with minimal hematuria and albuminuria and no casts.</p>\n</div>",
        "references": []
    },
    "54": {
        "question": "<div class=\"qtext\"><p>A 66-year-old woman with a prior kidney transplant presents with allograft dysfunction.  She has ADPKD and received a living donor kidney transplant 16 years ago. After induction with antithymocyte globulin, she was then maintained on tacrolimus, mycophenolate mofetil, and prednisone for approximately 10 years. Six years ago, due to multiple squamous and basal cell skin cancers involving the face, scalp, and arms, her maintenance immunosuppression was transitioned to everolimus and prednisone.  </p>\n<p>Over the last 5 years, she has had a progressive decline in her allograft function. A biopsy performed 2 years ago revealed transplant glomerulopathy, with moderate to severe interstitial fibrosis and tubular atrophy. She used PD prior to her first transplant but experienced peritonitis and now prefers HD or repeat transplantation. She currently has no uremic symptoms. Six months ago, her creatinine was 4.4 mg/dL, and her everolimus trough was 3.5 ng/mL. She has been referred to a vascular surgeon for creation of an arteriovenous fistula.</p>\n<p>BP is 138/76 mm Hg with a pulse of 76/min. Physical examination reveals normal heart, lung, and abdominal findings, with the exception of a well-healed scar in the right lower quadrant. A bruit is auscultated over the allograft but is unchanged and has been present on prior examinations. The allograft is nontender. There is no peripheral edema and no palpable adenopathy. There are substantial actinic changes in sun-exposed skin and scars related to prior treatment of skin cancers.</p>\n<p>Current laboratory results are as follows:</p>\n<div style=\"margin-bottom: 20px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">136 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">4.4 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">104 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">98–106<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">22 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">81 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">Creatinine <br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">4.6 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">0.5–1.1<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">eGFR<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">12 mL/min/1.73 m<sup>2</sup><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">≥60<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6831%;\">Everolimus trough (whole blood)<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;\">2.9 ng/mL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.3045%;\">Therapeutic: 3.0–8.0<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><strong>Which of the following is the next BEST STEP in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Start hemodialysis"
            },
            {
                "label": "B.",
                "text": "Refer for repeat kidney transplant"
            },
            {
                "label": "C.",
                "text": "Perform kidney biopsy"
            },
            {
                "label": "D.",
                "text": "Increase dose of everolimus"
            },
            {
                "label": "E.",
                "text": "Perform transplant renal angiogram"
            }
        ],
        "correct_answer": "Refer for repeat kidney transplant",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The best next step to manage this patient with a failing allograft is referral to a transplant center to preemptively list for a repeat kidney transplant.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients are eligible for waitlisting and accumulation of waiting time once eGFR reaches ≤20 mL/min/1.73 m<sup>2</sup>, and this eligibility extends to repeat transplant candidates. Timely referral for waitlisting may minimize pretransplant dialysis exposure, increase the opportunity for preemptive transplantation, and optimize post-transplant outcomes. Mortality is high for patients with failing kidney transplants who return to dialysis, but this risk is significantly attenuated with preemptive re-transplantation. Despite a prior relationship with a transplant center, only 15% of patients with a failing allograft undergo preemptive waitlisting or transplantation. Because this patient has advanced allograft dysfunction, repeat transplantation should be considered. Her history of skin cancers is not a contraindication to repeat transplant. However, she is at increased risk of subsequent skin cancer. As a result, she will require close monitoring by a dermatologist and careful management of immunosuppression and should adhere to sun protective measures.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient has no indication to start dialysis now. She has no uremic symptoms, is not volume overloaded, and does not have dialysis indications based on her laboratory data.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A kidney biopsy is not indicated. A prior biopsy demonstrated evidence of advanced chronic allograft injury (transplant glomerulopathy, interstitial fibrosis, and tubular atrophy). A biopsy at this point is likely to again show chronic changes that would not substantially alter management. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The therapeutic range for immunosuppressive agents such as everolimus is predominately based on studies performed in patients also being treated with calcineurin inhibitors and have not included many patients with long-functioning allografts affected by advanced glomerulopathy and tubulointerstitial fibrosis. In this patient, there is unlikely to be significant benefit to her kidney function by increasing the everolimus dose, and this is less important than timely referral for transplant. With advanced chronic allograft dysfunction, the aim of immunosuppression is to maintain allograft function and avoid development of new anti-human leukocyte antigen (anti-HLA) antibodies while also minimizing complications of excessive immunosuppression.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Bruits related to the transplant renal artery are relatively commonly found, but not all bruits signify clinically significant stenosis. It would be reasonable to investigate for transplant renal artery stenosis, but this should not delay either referral for a second transplant or preparation for renal replacement therapy. The preferred initial investigation is duplex ultrasonography rather than transplant renal angiography.</p>\n</div>",
        "references": []
    },
    "55": {
        "question": "<div class=\"qtext\"><p>A 54-year-old man with membranous nephropathy presents to clinic for follow-up. He was diagnosed with primary membranous nephropathy by kidney biopsy 8 months ago and was prescribed lisinopril. Tacrolimus, prednisone, and omeprazole were added 2 months ago when proteinuria failed to improve with conservative management. At the time of diagnosis, his urine protein-to-creatinine ratio was 6 mg/mg, serum creatinine level was 0.7 mg/dL, and serum albumin level was 2.1 g/dL. His urinalysis was otherwise bland with no cells or casts. On follow-up today, he complains of leg swelling that has not improved and bilateral flank pain. He denies any fevers or chills.</p>\n<p>On examination, BP is 130/80 mm Hg, heart rate is 80/min, and temperature is 36.5°C. Lungs are clear, heart sounds are normal, and the abdomen is soft with no tenderness. There is tenderness to percussion of the costovertebral angles bilaterally and 3+ leg edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 23.1847%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 17.4522%;\"><strong>Current Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 20%;\"><strong>2 Months Ago</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;; width: 25.0000%;; width: 20.0000%;\"><strong>8 Months Ago</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 19.3631%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 23.1847%;\"><strong>Serum</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 17.4522%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 20%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;; width: 25.0000%;; width: 20.0000%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 19.3631%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 23.1847%;\">  BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 17.4522%;\">40 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 20%;\">21<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;; width: 25.0000%;; width: 20.0000%;\">19</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 19.3631%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 23.1847%;\">  Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 17.4522%;\">2.6 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 20%;\">1.0</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;; width: 25.0000%;; width: 20.0000%;\">0.7</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 19.3631%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 23.1847%;\">  Albumin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 17.4522%;\">2.3 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 20%;\">1.9</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;; width: 25.0000%;; width: 20.0000%;\">2.1</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 19.3631%;\">3.5–5.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 23.1847%;\">  Tacrolimus, whole blood<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 17.4522%;\">6 ng/mL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 20%;\">4.2</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;; width: 25.0000%;; width: 20.0000%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 19.3631%;\">5–15<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 23.1847%;\"><strong>Urine (random)</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 17.4522%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 20%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;; width: 25.0000%;; width: 20.0000%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 19.3631%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 23.1847%;\">  Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 17.4522%;\">68 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 20%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;; width: 25.0000%;; width: 20.0000%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 19.3631%;\">Varies with intake<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 23.1847%;\">  Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 17.4522%;\">42 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 20%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;; width: 25.0000%;; width: 20.0000%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 19.3631%;\">Varies with intake<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 23.1847%;\">  Protein-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 17.4522%;\">8 mg/mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 20%;\">8.4<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.0123%;; width: 25.0000%;; width: 20.0000%;\">6</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 19.3631%;\">&lt;0.2<br/></td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis shows specific gravity 1.010, 4+ protein, 2+ blood, negative leukocyte esterase, 10–15 RBCs/HPF, and 1–2 WBCs/HPF.</p>\n<p><strong>Which of the following is the MOST LIKELY cause of AKI?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Renal vein thrombosis"
            },
            {
                "label": "B.",
                "text": "Calcineurin inhibitor toxicity"
            },
            {
                "label": "C.",
                "text": "Hypoperfusion"
            },
            {
                "label": "D.",
                "text": "Acute interstitial nephritis"
            },
            {
                "label": "E.",
                "text": "Membranous nephropathy progression"
            }
        ],
        "correct_answer": "Renal vein thrombosis",
        "abim_content_category": "Acute Kidney Disease and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely diagnosis in this patient with nephrotic syndrome from high-risk membranous nephropathy, AKI, hematuria, and flank pain is bilateral renal vein thrombosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with severe, nephrotic-range proteinuria, especially those with membranous nephropathy and hypoalbuminemia, are at risk of thrombosis due to urinary loss of proteins C and S and antithrombin III. The renal veins are common sites of thrombosis in these diseases, possibly because this vascular bed has the lowest concentration of these anticoagulant proteins, having just been lost by glomerular filtration. Bilateral renal vein thrombosis may be asymptomatic or present with AKI, flank pain, and hematuria from increased renal venous pressure. Ultrasound or CT would confirm the diagnosis, and treatment would include anticoagulation. Some authorities recommend prophylactic anticoagulation in patients with serum albumin persistently &lt;2.8 g/dL, as risk of venous thromboembolism increases significantly below this threshold.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Calcineurin inhibitor toxicity would not typically present with hematuria, and bilateral flank pain would not be expected. Although calcineurin inhibitor nephrotoxicity can occur even when concentrations are within the accepted therapeutic range, AKI due to tacrolimus would be more likely with elevated trough levels.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypoperfusion, or prerenal AKI, would be expected to show a bland urine sediment rather than hematuria. Additionally, the urine sodium and fractional excretion of sodium are relatively high and do not support hypoperfusion as the cause of AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute interstitial nephritis is frequently in the differential diagnosis of AKI but usually does not cause flank pain. In this case, renal vein thrombosis is more likely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Finally, the tempo of worsening creatinine suggests AKI rather than CKD progression. Proteinuria has remained relatively stable, albeit in the nephrotic range. Thus, progression of membranous nephropathy would be an unlikely cause of worsening kidney function.</p>\n</div>",
        "references": []
    },
    "56": {
        "question": "<div class=\"qtext\"><p>A 48-year-old woman with advanced CKD secondary to diabetic kidney disease is evaluated for kidney transplant. Her current eGFR is 11 mL/min/1.73 m<sup>2</sup>. She has no uremic symptoms. Current medications include lisinopril, glipizide, aspirin, atorvastatin, calcitriol, and calcium acetate. She has completed routine pretransplant evaluation and is deemed a suitable candidate for kidney transplantation. She has an approved living kidney donor and surgery is scheduled for next week.</p>\n<p>During her evaluation, a varicella antibody screen returned negative. She has never received a varicella vaccine and has not had known prior infection with varicella, including chickenpox or shingles.</p>\n<p><strong>Which of the following is MOST APPROPRIATE vaccination strategy?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "No varicella vaccination before or after transplant"
            },
            {
                "label": "B.",
                "text": "Perform transplant and administer varicella vaccine in 3 months"
            },
            {
                "label": "C.",
                "text": "Perform transplant and prescribe post-transplant antiviral prophylaxis"
            },
            {
                "label": "D.",
                "text": "Administer varicella vaccine and then proceed to transplant after 4 weeks"
            },
            {
                "label": "E.",
                "text": "Administer varicella vaccine and proceed to transplant as scheduled"
            }
        ],
        "correct_answer": "Administer varicella vaccine and then proceed to transplant after 4 weeks",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient should receive varicella vaccine prior to transplant, and surgery should be planned for at least 4 weeks after completing vaccination.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary varicella infection may lead to severe infection following transplant. The varicella vaccine is a live attenuated virus and is recommended for all non-immune patients. Live viral vaccines should be administered at least 4 weeks prior to initiating immunosuppression to minimize the risk of vaccine-related viral infection. Because this patient is not receiving dialysis and has an approved living donor, it is preferable to complete necessary vaccinations prior to proceeding with preemptive transplantation. It is not required to wait longer than 4 weeks for transplant following vaccination, as further delay prolongs the time to transplant unnecessarily. Immunity should be confirmed by serologic testing. A recombinant zoster vaccine to prevent shingles is not approved for primary prevention of varicella (chickenpox).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In general, live attenuated vaccines, including varicella vaccine, should not be given after transplant due to the risk of the attenuated strain causing infection and disease.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Antiviral prophylaxis is inferior to pretransplant varicella vaccination. If a waitlisted patient receives a transplant shortly after varicella vaccination, a period of postoperative antiviral prophylaxis is recommended.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Because vaccine responses are often diminished in immunosuppressed transplant patients, efforts should be made to provide all recommended vaccines prior to transplant whenever possible.</p>\n</div>",
        "references": []
    },
    "57": {
        "question": "<div class=\"qtext\"><p>A 67-year-old woman with a history of CKD stage 4, diabetes, hypertension, and heart failure with preserved ejection fraction presents to the emergency department with nausea, fatigue, pruritus, and weight loss over the last 3 weeks. She was last seen by her nephrologist 1 year ago, at which time her estimated GFR was 20 mL/min/1.73 m<sup>2</sup>. </p>\n<p>On physical examination, she is in no distress. She is afebrile with a BP of 155/90 mm Hg and heart rate of 79/min. Her body mass index (BMI) is 34 kg/m<sup>2</sup>.<sup> </sup>Her cardiac and lung examinations reveal a normal rhythm and scant crackles at both bases. She has 2+ lower extremity edema bilaterally. Asterixis is present. </p>\n<p>Laboratory data are as follows:</p>\n<p></p>\n<div style=\"margin-bottom: 15px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">137 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">5.0 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">97 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">98–106<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">20 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">105 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Creatinine <br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">4.5 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.5–1.1<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">eGFR<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">9 mL/min/1.73 m<sup>2</sup><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">≥60<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p>She is admitted in order to initiate dialysis for symptomatic uremia. After discussion with her nephrologist, she decides to initiate PD as an urgent start. A PD catheter is placed laparoscopically. After 24 hours, low volume PD is initiated. </p>\n<p><strong>Which ONE of the following complications is this patient more likely to experience with urgent start compared to conventional PD?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Peri-catheter leak"
            },
            {
                "label": "B.",
                "text": "Inadequate clearance"
            },
            {
                "label": "C.",
                "text": "Peritonitis"
            },
            {
                "label": "D.",
                "text": "Transition to hemodialysis"
            },
            {
                "label": "E.",
                "text": "Death"
            }
        ],
        "correct_answer": "Peri-catheter leak",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient is more likely to experience a peri-catheter leak with urgent start PD as opposed to conventional PD. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urgent start PD is defined as the initiation of therapy &lt;14 days after placement of the PD catheter. It is increasingly recognized as a treatment option for patients presenting with severe AKI or progressive CKD who are not prepared for either HD or PD. Observational data suggest that urgent start therapy is both safe and effective, with comparable outcomes to urgent start HD and planned PD. Although urgent start PD and urgent start HD have similar rates of mortality, bacteremia rates are significantly lower in patients with urgent start PD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">However, these data also suggest that the decreased interval between catheter insertion and use is associated with higher rates of mechanical complications, especially peri-catheter leaks, with rates ranging from 0% to 33% depending on the method of catheter placement and the study setting. This patient has a BMI &gt;30 kg/m<sup>2</sup> and diabetes, both of which are associated with higher rates of leak. Although persistent leaks may require catheter removal, most leaks are minor and can be managed conservatively without surgical intervention. To minimize the risk of peri-catheter leak, dialysate exchanges are performed with low volumes and in the supine position during the first month of PD. Urgent start PD requires sufficient outpatient infrastructure to allow patients to dialyze supine during weekdays while dialysis staff educate patients about performing PD at home.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The available data suggest that regardless of the initial PD prescription, patients initiating PD urgently do not experience inadequate clearance at 90 days. Rates of peritonitis have not been found to be significantly different between urgent start and conventional PD. Technique survival and transition to HD are not associated with timing of PD initiation; in fact, some studies suggest that patients are less likely to undergo HD with earlier PD initiation. Finally, although all patients urgently starting dialysis have a high risk of mortality, no difference in mortality has been described between urgent start PD and conventional PD.</p>\n</div>",
        "references": []
    },
    "58": {
        "question": "<div class=\"qtext\"><p>A 58-year-old woman is referred for evaluation of nephrotic syndrome. She has a history of acute myelocytic leukemia and had an allogenic hematopoietic stem cell transplant (HSCT) from her human leukocyte antigen (HLA)-identical sibling 2 years ago. She received cyclosporine for 3 months following HSCT. Six months later, she developed mucosal ulcerations, and a mucosal form of graft-versus-host disease (GVHD) was diagnosed. She was treated with corticosteroids and cyclosporine, and then these agents were tapered. She was well for 1 year, but in recent weeks, she has noted the onset of lower extremity edema.</p>\n<p>On examination, she is afebrile, and her BP is 125/82 mm Hg. She has oral ulcerations and lower extremity edema.</p><p>Laboratory data are as follows:<br/></p>\n<div style=\"margin-bottom: 15px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Hemoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">11.2 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">14–18<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Platelet count</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">111,000/µL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">150,000–450,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">1.5 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.5–1.1<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Albumin<sub></sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">2.1 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Urine protein-to-creatinine\nratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">10.4 mg/mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">&lt;0.2<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p>The urine sediment is notable for fatty casts and oval fat bodies with an occasional RBC.</p>\n<p>A kidney biopsy is normal by light microscopy. Representative images of IF (anti-IgG) and EM are shown: </p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv7m2q30.png\" width=\"75%\"/>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv7m2q30b.png\" width=\"75%\"/>\n<figcaption><em>Image from </em><em>J Am Soc Nephrol 22(10): 1804–1808, 2011</em></figcaption>\n</figure>\n<p><strong>Which of the following is the MOST likely diagnosis?</strong></p>\n</figure></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Minimal change disease"
            },
            {
                "label": "B.",
                "text": "Membranous nephropathy"
            },
            {
                "label": "C.",
                "text": "Thrombotic microangiopathy"
            },
            {
                "label": "D.",
                "text": "Focal segmental glomerulosclerosis"
            },
            {
                "label": "E.",
                "text": "Proliferative glomerulonephritis"
            }
        ],
        "correct_answer": "Membranous nephropathy",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Nephrotic syndrome is a rare complication of HSCT. When it occurs, membranous nephropathy (MN) is the most common cause.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The IF demonstrates diffuse granular immune deposits along the basement membrane, and EM demonstrates subepithelial deposits and diffuse effacement of foot processes, the cardinal features of MN.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although the pathogenesis of MN in this setting is unknown, it is likely that GVHD plays an important role. Indeed, in animal models of GVHD, kidney involvement is a common complication, with subepithelial IgM and IgG deposits. However, in these models, autoantibodies can be demonstrated, including anti-DNA antibodies, which are typically not seen in human GVHD. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Minimal change disease (MCD) is the second most common cause of nephrotic syndrome seen in this setting and should be suspected when light microscopy is normal. Here, however, the IF and EM images demonstrate diffuse electron-dense deposits, which are not seen with MCD. The clinical presentations of MN and MCD in this setting are indistinguishable, and the diagnosis cannot be confirmed without a kidney biopsy. Patients who have MCD tend to be younger than those with MN, and the time from withdrawal of immunosuppressive agents to the development of nephrotic syndrome is usually shorter with MCD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Focal segmental glomerulosclerosis has been described in this clinical setting but would be inconsistent with the kidney biopsy findings.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Thrombotic microangiopathy can occur following HSCT, related to medications or as a manifestation of GVHD, but this process typically occurs earlier in the clinical course, usually in the first 20–100 days. In addition, this disorder typically presents with a microangiopathic hemolytic anemia with thrombocytopenia, AKI, and mild proteinuria rather than nephrotic syndrome.</p>\n<p>Rarely, proliferative glomerulonephritis has been reported in this setting, but the clinical history of nephrotic syndrome and the telltale signs of subepithelial deposits on biopsy make glomerulonephritis unlikely. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">When nephrotic syndrome occurs in the setting of GVHD, the treatment is directed at GVHD, although use of additional agents such as rituximab has been reported.</p>\n</div>",
        "references": []
    },
    "59": {
        "question": "<div class=\"qtext\"><p>A 51-year-old man is evaluated after his third episode of symptomatic nephrolithiasis in 3 years. He passed all 3 stones spontaneously. Stone analysis of the most recent showed that it was 95% calcium oxalate dihydrate and 5% calcium oxalate monohydrate. He has been advised to drink enough to make at least 2 L of urine daily, limit sodium to 2 g daily, and avoid “high oxalate foods.” He has no other medical problems and takes no medications. He weighs 85 kg.</p>\n<p>Laboratory studies show the following:</p>\n<div style=\"margin-bottom: 20px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><b>24-Hour\nUrine</b></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Volume<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">2.3 L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies with intake<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">1.8 g<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">15–25 mg/kg body weight<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">2.2 g<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies with intake<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Calcium<sub></sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">150 mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Male &lt;300<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Citrate<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">590 mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">250–1000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Oxalate<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">65 mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">&lt;40<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Uric acid<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">540 mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">250–750<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><strong>In addition to more consistent fluid intake and sodium restriction, which ONE of the following should be recommended?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Start chlorthalidone"
            },
            {
                "label": "B.",
                "text": "Increase lemonade consumption"
            },
            {
                "label": "C.",
                "text": "Add a serving of dairy to each meal"
            },
            {
                "label": "D.",
                "text": "Increase dietary protein intake"
            },
            {
                "label": "E.",
                "text": "Eliminate dietary oxalate"
            }
        ],
        "correct_answer": "Add a serving of dairy to each meal",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In addition to a consistently high fluid intake and restriction of dietary sodium, the most appropriate recommendation for this patient is to add a serving of dairy to each meal. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Oxalate is found in many foods in small amounts. It is also generated from endogenous metabolism and then excreted in the urine. The risk of calcium oxalate stone formation increases as urine oxalate excretion increases. The relative contribution of endogenous and exogenous oxalate to urinary oxalate is uncertain. Although there is general agreement that increasing dietary oxalate increases urinary oxalate, the impact of dietary oxalate on stone risk appears to be relatively small except in patients who follow fad diets or have food fetishes that include large amounts of high-oxalate food. There is scant evidence that low-oxalate diets reduce the risk of stone formation. Although decreasing the intake of foods that are very high in oxalate is reasonable, elimination of oxalate from the diet is not practical.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Individuals with idiopathic calcium oxalate nephrolithiasis have a higher rate of oxalate absorption and urinary excretion than control subjects given the same amount of exogenous oxalate. Dietary calcium can decrease oxalate absorption in the gut by forming insoluble calcium oxalate salts in the intestinal lumen. In contrast, when less calcium is available in the intestinal lumen to bind oxalate, oxalate absorption increases, which in turn increases urinary oxalate excretion. Higher urine calcium is a common finding in stone formers, but restricting dietary calcium is not recommended because this does not decrease urinary calcium. Hence, this patient should instead increase the intake of foods that contain calcium. A typical serving of dairy, such as a glass of milk, contains 200–300 mg of calcium, which can be expected to reduce oxalate absorption. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">High sodium intake increases calcium excretion and therefore contributes to calcium stone formation. A diet high in animal protein has been associated with an increased incidence of stone disease by promoting hypercalciuria, hypocitraturia, and urinary acidification, which are risk factors for calcium stones.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Thiazides are used to treat hypercalciuria, which is not seen here. One recent trial showed no benefit to the use of thiazide diuretics in patients with recurrent calcium stones in the absence of hypercalciuria.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Lemonade can increase urinary citrate slightly but has never been proven to decrease the risk of nephrolithiasis. In addition, this patient does not have low urinary citrate.</p>\n</div>",
        "references": []
    },
    "60": {
        "question": "<div class=\"qtext\"><p>A 45-year-old man with ESRD due to diabetic nephropathy receiving PD is diagnosed with an incidental cystic lesion in the left kidney on abdominal CT scan, originally done to evaluate abdominal pain, which has since resolved. He has no history of gross hematuria, fever, or weight loss, and family history is negative for kidney cancer or cystic disease. He continues to make approximately 1 L of urine daily. The patient is listed for kidney transplantation.</p>\n<p>The cyst is 2 cm in largest diameter located in the upper pole of the left kidney. The walls of the cyst are thickened but smooth in contour; several septations are present, with mild enhancement and nodularity. The radiology report classifies the cyst as Bosniak class III. There are no prior radiology reports for comparison.</p>\n<p><strong>Which of the following is the MOST appropriate next step in the management of this case?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Nephrectomy"
            },
            {
                "label": "B.",
                "text": "Kidney biopsy"
            },
            {
                "label": "C.",
                "text": "Urine cytology"
            },
            {
                "label": "D.",
                "text": "Repeat CT scan in 6 months"
            },
            {
                "label": "E.",
                "text": "MRI of left kidney"
            }
        ],
        "correct_answer": "Nephrectomy",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with a complex kidney cyst that has a high likelihood of being malignant should undergo nephrectomy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney cysts can be classified based on characteristics that are identified by CT scan, and these classifications can help guide caregivers in management. The classification is called the Bosniak cyst classification after the radiologist who first described these findings. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Class I is a simple cyst that is thin-walled. This is a normal finding and has no risk of malignancy. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Class II is a thin-walled cyst that is minimally complex. It may have a few thin-walled septations. This is also normal and has no risk of malignancy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Class IIF is also thin-walled but has features that suggest that follow-up imaging is indicated, such as calcifications, a large number of septations, or some nodularity. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Class III shows indeterminate cystic masses that have thickened walls and some enhancement by CT scan. Roughly 40%–50% of these lesions are malignant.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Class IV lesions are nearly all malignant. These cysts have radiologic enhancement and may appear as a solid mass with a cystic or necrotic component. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has a complex kidney cyst classified as Bosniak III based on thickened walls, as well as multiple septations and enhancement. If prior images exist and could confirm that this cyst is stable, then active surveillance is reasonable. If no previous imaging studies are available or if the character of the cyst has changed, a more aggressive approach is needed. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney biopsy has gained more acceptance in recent years, particularly for lesions that are &lt;4 cm, but in this patient who has already has ESRD, a definitive procedure with nephrectomy would be advised, particularly if this patient is a transplant candidate. The need for nephron-sparing surgery in this setting is less pressing (although he does have a significant daily urine volume).  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">MRI evaluation, with or without contrast, will add little to the existing information and would not change management. </p>\n</div>",
        "references": []
    },
    "61": {
        "question": "<div class=\"qtext\"><p>A 61-year-old woman is referred for the incidental finding of a homogeneous 3.3-cm adrenal mass on abdominal CT scan.</p>\n<p>She has recently diagnosed hypertension, but she feels generally well. She has recently gained 7 kg, which she attributes to overindulgence during the winter holidays. She does not report headaches, weakness, weight loss, fever, chills, or sweats. Her medications include amlodipine, the dose of which was increased from 5 to 10 mg/day last month. Her father has been treated for hypertension since the age of 40. She does not use illicit drugs or alcohol. </p>\n<p>On examination, she has a BP of 152/89 mm Hg, pulse of 72/min, and body mass index of 32 kg/m<sup>2</sup>. She has no dorsocervical fat pad, her pulmonary and cardiovascular systems are benign, and she has no edema. No striae are observed.</p>\n<p>Her laboratory values reveal:</p>\n<div style=\"margin-bottom: 20px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><b>Serum or Plasma, 8 a.m.</b></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.9\n                    mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Aldosterone</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">9\n                    ng/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">\n<p>≤10, supine or seated &lt;21, standing\n                </p></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Metanephrines<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">Normal<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Normal<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Cortisol,\n                    overnight suppression test (1-mg)<sub></sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">7.1 μg/dl<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">&lt;1.8<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><b>Urine,\n                        24-hour</b><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Metanephrines<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">Normal<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Normal<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Catecholamines<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">Normal<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Normal<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><strong>Which of the following is the next BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Repeat hormonal testing annually"
            },
            {
                "label": "B.",
                "text": "Surgical resection with preoperative glucocorticoids"
            },
            {
                "label": "C.",
                "text": "Repeat CT scan in 3–6 months"
            },
            {
                "label": "D.",
                "text": "Surgical resection with preoperative α-adrenergic blockade"
            },
            {
                "label": "E.",
                "text": "CT-guided fine needle aspiration (FNA)"
            }
        ],
        "correct_answer": "Surgical resection with preoperative glucocorticoids",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Surgical resection with preoperative glucocorticoids is appropriate for a patient with an adrenal mass and positive biochemical testing. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">As technology has advanced, so has the incidence of incidentally discovered adrenal masses, from 0.4% with lower-resolution CT scans in the 1980s to &gt;4% in the current era. With the discovery of an adrenal mass, a clinician must determine whether a mass is malignant or functional. In this case, the mass is homogeneous, unilateral, and &lt;4 cm, all of which are characteristic of benign adenomas. An overnight 1-mg dexamethasone suppression test result of &gt;5 µg/dL of cortisol is consistent with autonomous cortisol production. When coupled with the recent onset of hypertension and obesity, a diagnosis of Cushing syndrome can be established. Surgical removal of the adrenal mass is recommended for patients such as this. Glucocorticoids should be administered perioperatively to avoid adrenal insufficiency and hemodynamic crisis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Repeat radiologic testing in 3–6 months is appropriate for masses that are not functional by biochemical testing and do not have overtly malignant features. Many malignancies would grow during this period and could thereby be identified. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Yearly hormonal testing is reasonable if the initial biochemical evaluation is negative; however, the yield and cost effectiveness of this approach is not known. CT-guided FNA could be considered if imaging is consistent with metastatic disease and a tissue diagnosis is needed. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A pheochromocytoma should be excluded prior to FNA or resection. In this patient, hormonal testing has excluded this diagnosis, so α-adrenergic blockade is not necessary. α-Adrenergic blockade before excision of a pheochromocytoma is important to avoid unopposed α-adrenergic stimulation and hypertensive crisis.</p>\n</div>",
        "references": []
    },
    "62": {
        "question": "<div class=\"qtext\"><p>A 67-year-old man with advanced chronic obstructive pulmonary disease (COPD) initiates HD for acute oliguric AKI in the setting of severe pneumonia. He begins dialysis with a polysulfone dialyzer via an internal jugular dialysis catheter at a blood flow rate of 300 mL/min, a dialysate flow rate of 600 mL/min, and an ultrafiltration rate of 5 mL/min. The dialysate sodium is 137 mEq/L, potassium is 3 mEq/L, total base is 35 mEq/L, and calcium is 2.5 mEq/L.</p>\n<p>His pre-dialysis BP is 126/80 mm Hg. Thirty minutes after the start of HD, he becomes increasingly somnolent and hypopneic. On examination, systolic BP is now 100 mm Hg. The jugular venous pressure is 6 cm H<sub>2</sub>O. The lung examination reveals crackles at the right base. The cardiac examination shows normal S1, increased P2, and a grade 2 holosystolic murmur at the right sternal border. There is no pericardial friction rub. He has 1+ leg edema.</p>\n<p>A 16-beat run of monomorphic ventricular tachycardia is observed, and HD is discontinued. His BP and mentation gradually improve to baseline after blood is returned.</p>\n<p>His laboratory parameters include the following:</p><div style=\"margin-bottom: 20px;\"><table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\"> </td><td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\"><strong></strong><strong>Before\nHD</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\"><strong>Immediately\nAfter HD</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\"><strong>Serum</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">  Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">135\nmEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">136\nmEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">  Potassium<sub></sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">5.7\nmEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">4.3\nmEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">  Chloride<sub></sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">101\nmEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">98–106<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">  Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">24\nmEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">32\nmEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">  BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">64\nmg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">  Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">5.6\nmg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\"><span>  Calcium, ionized</span><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">1.25\nmmol/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">1.12–1.23<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\"><span>  Lactate </span><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">3\nmmol/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">0.7–2.1<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\"><strong>Arterial blood gas</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">  pH<sub></sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">7.33<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">7.38–7.44<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">  pCO<sub>2</sub><sub></sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">76\nmm Hg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">38–42<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">  pO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">64\nmm Hg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">75–100<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><strong>Which of the following is the MOST likely cause of this patient’s decompensation?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Acute respiratory acidosis"
            },
            {
                "label": "B.",
                "text": "Type A dialyzer reaction"
            },
            {
                "label": "C.",
                "text": "Volume depletion from ultrafiltration"
            },
            {
                "label": "D.",
                "text": "Dialysis disequilibrium syndrome"
            },
            {
                "label": "E.",
                "text": "Air embolism"
            }
        ],
        "correct_answer": "Acute respiratory acidosis",
        "abim_content_category": "Acute Kidney Disease and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s decline in mental status and intradialytic hemodynamic instability are most likely related to the development of acute respiratory acidosis and hypercarbia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Typical dialysate bicarbonate concentrations are about 36 mEq/L, which is 50% more than this patient’s pre-dialysis serum bicarbonate concentration. The abrupt influx of bicarbonate causes metabolic alkalosis that suppresses respiration, resulting in CO<sub>2</sub> retention. Most subjects increase their minute ventilation and offset the resulting rise in blood carbon dioxide levels, but patients with chronic lung disease may be limited in this response. In this patient with advanced COPD, the acute rise in bicarbonate contributed to the rise in pCO<sub>2</sub>. Initial dialysis treatments in individuals with COPD may require a downward adjustment in the dialysate bicarbonate concentration. In contrast, if the patient requires chronic HD, he may require higher dialysate bicarbonate to approximate the absent renal bicarbonate retention compensation for chronic respiratory acidosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ultrafiltration is unlikely to have caused this scenario because the symptoms started early in the treatment following modest ultrafiltration of only 150 mL. Dialysis disequilibrium syndrome occurs in individuals starting dialysis who have more pronounced azotemia, typically with BUN levels &gt;175 mg/dL. Symptoms may include headache, agitation, and disorientation that persist for several hours following dialysis. Severe cases may progress to seizures and coma. The degree of this man’s azotemia and the rapid resolution of symptoms after cessation of dialysis make dialysis disequilibrium less likely. Type A dialyzer reactions typically occur within the first few minutes of dialysis and are usually accompanied by itching, wheezing, and, in severe cases, hypotension; these are often anaphylactoid reactions to specific components of dialysis membranes or sterilizing solutions. The delayed onset of symptoms and absence of concurrent allergic manifestations make a type A dialyzer reaction less likely. Type B dialyzer reactions most commonly occur 20–40 minutes into dialysis. Symptoms of type B dialyzer reactions include chest and back pain, nausea, and, in some cases, hypotension. Type B dialyzer reactions resolve with supportive care, and unlike type A reactions, usually do not require discontinuation of dialysis. Type B reactions are complement-mediated and thought to be related to a reaction between complement and components of the dialysis circuit, particularly cellulose-based dialyzers that are generally no longer used. These reactions are exceedingly rare with modern polysulfone dialyzers.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Air embolism is an extremely rare complication of hemodialysis that occurs when air bubbles are introduced into the dialysis circuit. Patients present with chest pain, tachycardia, cyanosis, and hypoxemia. These symptoms often worsen with blood return, and blood lines should be clamped to prevent further air entry.</p>\n</div>",
        "references": []
    },
    "63": {
        "question": "<div class=\"qtext\"><p>A 27-year-old woman is evaluated for frequent urination. She notes frequent and heavy urination, with volumes exceeding 3 L/day. She reports drinking water continuously throughout the day and night. Eight years ago, she was diagnosed with bipolar disorder and has been managed successfully with lithium. Three months ago, she sustained a traumatic brain injury in a motor vehicle collision. A CT scan of the head was unremarkable at the time. </p>\n<p>On exam, BP is 118/64 mm Hg, with heart rate of 78/min. Heart, lung, abdominal, and neurological examination is normal, and there is no edema.</p>\n<p>Laboratory studies show a serum sodium level of 137 mEq/L (reference range, 136–145) and osmolality 281 mOsm/kg H<sub>2</sub>O (reference range, 275–295). Urine osmolality is 140 mOsm/kg H<sub>2</sub>O. Urine volume is 4 L/day with solute excretion 720 mOsm/day.</p>\n<p>Fluid is withheld, and urine osmolality is measured repeatedly over 6 hours.</p>\n<div style=\"margin-bottom: 20px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>Time</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>7 a.m.</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>8 a.m.</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>9 a.m.</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>10 a.m.</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>11 a.m.</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>12 p.m.</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>1 p.m.</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>Urine osmolality (mOsm/kg H<sub>2</sub>O)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>140</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>210</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>304</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>364</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>410</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>490</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 1px 1px 5px;\">\n<p>602</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><strong>Which ONE of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Inadequate solute intake"
            },
            {
                "label": "B.",
                "text": "Osmotic diuresis"
            },
            {
                "label": "C.",
                "text": "Partial nephrogenic diabetes insipidus"
            },
            {
                "label": "D.",
                "text": "Partial central diabetes insipidus"
            },
            {
                "label": "E.",
                "text": "Primary polydipsia"
            }
        ],
        "correct_answer": "Primary polydipsia",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely diagnosis in this patient with high water intake, polyuria, and intact urinary concentrating ability is primary polydipsia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary polydipsia has been reported in up to 20% of patients hospitalized with psychiatric conditions. Patients with polydipsia are often asymptomatic, but some complain of frequency or excessive urination. Patients with psychiatric disorders may also have conditions or take medications, such as lithium, that predispose to polyuria, so laboratory evaluation may be necessary to establish a diagnosis. Patients with primary polydipsia often have serum sodium levels &lt;140 mEq/L or frank hyponatremia, whereas those with diabetes insipidus (DI) typically have sodium levels &gt;140 mEq/L or frank hypernatremia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Polyuria is defined as urine output &gt;3 L daily. Urine osmolality &lt;150 mOsm/kg H<sub>2</sub>O reflects a water diuresis, whereas osmolality &gt;300 mOsm/kg H<sub>2</sub>O indicates an osmotic diuresis. This patient produces large quantities of dilute urine consistent with either primary polydipsia or DI. The differential diagnosis of DI includes nephrogenic DI due to chronic lithium use and central DI attributable to traumatic brain injury. The cause of polyuria can be determined from the urine osmolality during the urine concentration test (also commonly called the water deprivation test), which consists of water restriction followed by desmopressin challenge (if necessary).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">After water restriction, an increase in urine osmolarity to &gt;500 mOsm/kg H<sub>2</sub>O should occur in patients with preserved ability to respond to antidiuretic hormone (ADH), including those with primary polydipsia or those receiving large volumes of hypotonic fluids. In this case, during water deprivation, the rise in urine osmolality indicates the normal physiologic response to the osmotic release of endogenous ADH. In complete central or nephrogenic DI, no increase in urine osmolality is observed. In partial central DI, the urine osmolality increases after water deprivation but does not reach the expected threshold of &gt;500 mOsm/kg H<sub>2</sub>O. Administration of desmopressin subsequently leads to a further increase in the urine osmolality to &gt;500 mOsm/kg H<sub>2</sub>O. Conversely, in partial nephrogenic DI, the urine osmolality remains less than isotonic during water deprivation and may increase up to 45% after administration of desmopressin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The total daily solute excretion normally is about 600–900 mOsm/day. Patients experiencing an osmotic or solute diuresis will demonstrate much greater daily solute excretion, often &gt;1000 mOsm/day. Beer potomania and “tea and toast” diet are conditions of inadequate solute intake resulting in hyponatremia. This patient’s daily solute excretion is within the normal range. </p>\n</div>",
        "references": []
    },
    "64": {
        "question": "<div class=\"qtext\"><p>A 24-year-old woman with recurrent self-induced vomiting is evaluated for hypokalemic metabolic alkalosis. She is initially treated with 0.9% sodium chloride and potassium IV with only transient improvement in the hypokalemia and alkalosis. Despite intensive psychiatric interventions, she continues to self-induce emesis intermittently.</p>\n<p>On examination, she appears chronically ill and emaciated. Her BP is 102/70 mm Hg, and her pulse is 102/min. Her oropharynx shows pharyngitis, and she has dental erosions. There is no edema.</p>\n<p>Laboratory studies are as follows:</p><div style=\"margin-bottom: 20px;\"><table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong><b>Result</b></strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong><b>Reference\n                            Range</b></strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><b>Serum</b><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">136\n                    mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">2.7\n                    mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">98\n                    mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">98–106<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">34\n                    mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">2\n                    mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">0.3\n                    mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.5–1.1<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Calcium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">7.7\n                    mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">8.6–10.2<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Albumin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">2.6\n                    g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Magnesium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">1.7\n                    mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">1.6–2.6<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><b>Arterial blood gas </b><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  pH<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">7.51\n                    mm Hg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">7.38–7.44<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  pCO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">44\n                    mm Hg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">38–42<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  pO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">96\n                    mm Hg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">75–100<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><b>Urine</b><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  pH<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">5.5<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies\n                    with intake<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">14\n                    mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies\n                    with intake<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">&lt;10\n                    mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies\n                    with intake<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><strong>Which of the following medications is MOST likely to help correct this patient’s persistent hypokalemic metabolic alkalosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Omeprazole"
            },
            {
                "label": "B.",
                "text": "Acetazolamide"
            },
            {
                "label": "C.",
                "text": "Magnesium oxide"
            },
            {
                "label": "D.",
                "text": "Potassium bicarbonate"
            },
            {
                "label": "E.",
                "text": "Spironolactone"
            }
        ],
        "correct_answer": "Omeprazole",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Omeprazole is the medication most likely to correct this patient’s electrolyte abnormalities.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has metabolic alkalosis due to hydrogen chloride loss and volume depletion because of persistent vomiting. Hypokalemia results from several factors. Initially, before volume depletion ensues, obligate renal potassium excretion occurs with bicarbonaturia. Sodium is also lost in this fashion, and if vomiting persists, patients will develop chloride depletion, metabolic alkalosis, and hypokalemia. In addition, secondary hyperaldosteronism due to hypovolemia will perpetuate the metabolic alkalosis and contribute to the potassium losses.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Increased urinary excretion of sodium bicarbonate without chloride in the setting of a mild degree of hypovolemia is characteristic of the so-called “generation phase” of metabolic alkalosis. Urine studies in the generation phase show a urine sodium level &gt;15 mEq/L, a urine chloride &lt;15 mEq/L, and a urine pH &gt;6.5. As hypovolemia and chloride depletion worsen, most of the filtered sodium, chloride, and bicarbonate are reabsorbed along the nephron, leading to urine that is nearly devoid of these solutes. The chloride depletion maintains the metabolic alkalosis, and the urine during this “maintenance phase” is characterized by urine sodium and chloride levels that are often &lt;10 mEq/L and a urine pH that is paradoxically acidic.    </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Correction of the chloride and volume depletion with saline results in increased bicarbonate excretion and resolution of the alkalosis. If there are ongoing hydrogen chloride losses, such as in this patient who continues to vomit, additional strategies are needed to address the metabolic derangement.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Proton-pump inhibitors (PPIs) blunt gastric acid secretion and can limit loss of hydrogen and chloride in the setting of chronic vomiting or persistent nasogastric tube suctioning. This, in turn, can limit the severity of chloride depletion and metabolic alkalosis. Treatment for eating disorders requires a multidisciplinary approach, and use of a PPI would only address the metabolic alkalosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Spironolactone is useful to combat transient sodium retention and edema formation that occurs when bulimia or other eating disorders are abruptly ceased,but would not be appropriate for a patient with ongoing purging and volume depletion.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Potassium bicarbonate is a source of alkali and would worsen the metabolic alkalosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acetazolamide may help correct metabolic alkalosis, but it is associated with increased excretion of urinary bicarbonate and potassium. As a result, this may potentially worsen this patient’s hypokalemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Magnesium depletion can cause treatment-resistant hypokalemia, but supplementation of magnesium alone will not correct this patient’s hypokalemic metabolic alkalosis.</p>\n</div>",
        "references": []
    },
    "65": {
        "question": "<div class=\"qtext\"><p>A 35-year-old woman is evaluated for kidney cysts. She has a history of frequent urinary tract infections during her childhood and young adult years. She was recently admitted for pyelonephritis, which resolved with IV antibiotics. She is not taking any prescription or nonprescription medications. She does not have a history of kidney stones. There is no family history of kidney disease.</p>\n<p>Her BP is 122/74 mm Hg. A physical examination reveals normal findings and the following laboratory test values:</p>\n<div style=\"margin-bottom: 15px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong><b>Result</b></strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Serum<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">138 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.3 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Chloride<sub></sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">103 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">98–106<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">24 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Creatinine<sub></sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">1.5 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.5–1.1<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Urine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Protein-to-creatinine\nratio</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">1.4 mg/mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">&lt;0.2<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p>The urine dipstick demonstrates 2+ protein, and the urine sediment is notable for occasional WBCs and renal tubular epithelial cells.</p>\n<p>A coronal view of her kidneys by CT scan is shown below.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv7m2q37.png\" width=\"75%\"/>\n<figcaption><em>Image courtesy of Neera Dahl MD, Yale School of Medicine</em></figcaption>\n</figure>\n<p>The CT report describes small kidneys with bilateral scarring and cortical thinning centered over the inferior renal calyces. A clustering of cysts is noted in the bilateral lower poles.</p>\n<p><strong>Which of the following is the MOST LIKELY diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "ADPKD"
            },
            {
                "label": "B.",
                "text": "Reflux nephropathy"
            },
            {
                "label": "C.",
                "text": "Medullary sponge kidney"
            },
            {
                "label": "D.",
                "text": "Hypokalemia"
            },
            {
                "label": "E.",
                "text": "Simple cysts"
            }
        ],
        "correct_answer": "Reflux nephropathy",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient most likely has reflux nephropathy, which can be associated with secondary FSGS.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">She presents with hypertension, moderate proteinuria, CKD without edema, and small kidneys with scarring and cyst-like changes. This constellation of findings is consistent with vesicoureteral reflux and secondary FSGS. Scarring in the poles is more common because the compound papillae are usually found in this region; this formation makes them concave and more susceptible to damage from elevated pressure in the setting of urinary obstruction. In contrast, the simple or convex papillae, which are primarily in the nonpolar regions, have oblique orifices that close when the pressure increases in the renal pelvis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The small kidney size and the absence of a family history of kidney disease are not consistent with ADPKD. Medullary sponge kidney may be associated with kidney cysts and urinary tract infections but is also associated with medullary calcification and a history of kidney stones and not associated with proteinuria or loss of kidney function. Simple kidney cysts are possible, but the clustering of cysts in an area of scarring makes this unlikely. In addition, it would be unusual to have numerous simple cysts at a young age.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Chronic hypokalemia is associated with cyst formation and CKD. Most patients reported to have hypokalemic nephropathy have severe, chronic hypokalemia, sometimes related to an eating disorder. Although this patient’s serum potassium is mildly reduced, there is no reason to suspect chronic severe hypokalemia. Hypokalemia would also fail to explain her history of recurrent infections and kidney scarring.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Appropriate treatment of this patient would include use of an ACEI or ARB for management of BP and proteinuria. Given her history of recurrent urinary infections and the scarring seen on imaging, urologic evaluation for reflux would also be reasonable. Infection prophylaxis might also be a consideration. The incidence of ESRD due to reflux nephropathy may be decreasing in the United States.</p>\n</div>",
        "references": []
    },
    "66": {
        "question": "<div class=\"qtext\"><p>A 54-year-old woman is admitted to the hospital with an ischemic left foot, for which she undergoes a femoral-popliteal bypass. Two days after surgery, she returns to the operating room for a left transmetatarsal amputation. She receives propofol anesthesia for both procedures. After the second surgery, she is noted to be increasingly lethargic and is unable to be extubated.</p>\n<p>Her past medical history is notable for a Roux-en-Y gastric bypass, type 2 diabetes, and stage 3 CKD. Her current medications include subcutaneous heparin, aspirin 325 mg daily, omeprazole 20 mg daily, cefazolin 1 g IV every 12 hours for 3 doses, and insulin by sliding scale.</p>\n<p>Her examination reveals stable vital signs and no localizing neurologic findings. Her wounds are intact without features of infection. The cardiac, pulmonary, abdominal, and skin examinations are unremarkable.</p>\n<p>Her laboratory studies are notable for the following results:</p>\n<div style=\"margin-bottom: 15px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong><b>Result</b></strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">143 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">23 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">38 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Creatinine<sub></sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.1 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.5–1.1<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Bilirubin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">0.8 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.3–1.2<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Aspartate\naminotransferase<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">42 U/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">10–40<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Alanine\naminotransferase<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">43 U/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">10–40<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Ammonia</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">936 μg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">40–70<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p>A CT scan of the brain reveals moderate cerebral edema. Ultrasound of the liver yields normal findings.</p>\n<p>CRRT is initiated.</p>\n<p><strong>Which of the following is the most likely cause of hyperammonemia in this patient?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Ischemic hepatitis"
            },
            {
                "label": "B.",
                "text": "Propofol toxicity"
            },
            {
                "label": "C.",
                "text": "Zinc deficiency"
            },
            {
                "label": "D.",
                "text": "Copper deficiency"
            },
            {
                "label": "E.",
                "text": "Salicylate toxicity"
            }
        ],
        "correct_answer": "Zinc deficiency",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Zinc deficiency should be considered as a cause of hyperammonemia in this patient with a history of bariatric surgery.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ammonia is primarily produced in the intestine through metabolism of intraluminal amino acids and bacterial degradation of urea. Ammonia is eliminated by conversion to urea in the liver and to glutamine in the brain and skeletal muscle. Hyperammonemia results from both decreased intrinsic hepatic function and defects in the urea cycle. Although most individuals with urea cycle enzyme deficiencies present in infancy, mild defects, particularly in ornithine carbamoyltransferase, can present in adulthood with hyperammonemia precipitated by stress. Zinc is an essential co-factor for enzymes in the urea cycle, and zinc deficiency in patients with a history of gastric bypass surgery has been identified as a risk factor for acquired hyperammonemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Copper deficiency can also occur after gastric bypass surgery and may present with a variety of signs and symptoms, including cytopenias and myeloneuropathy, but hyperammonemia has not been reported.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ischemic hepatitis is associated with severe liver hypoperfusion, usually in the setting of shock, and is manifested by marked transaminase elevation.  Although ischemic hepatitis can result in acute liver failure and hyperammonemia, neither the clinical scenario nor the modest elevations of the transaminases support a diagnosis of ischemic hepatitis in this patient.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Salicylate toxicity can cause neurologic dysfunction including cerebral edema but does not result directly in hyperammonemia. Hyperammonemia is seen in Reye syndrome, and salicylate exposure has been proposed as a contributing factor, but the other characteristic features of this illness, which include marked elevation of transaminases, acute fatty liver, and a viral prodrome, are lacking.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Propofol infusion syndrome occurs in the setting of continuous propofol infusion and is characterized by rhabdomyolysis, metabolic acidosis, and multiple organ dysfunction, including the heart, liver, and kidneys. It is not reported to occur when propofol exposure is limited to anesthesia during surgery.</p>\n</div>",
        "references": []
    },
    "67": {
        "question": "<div class=\"qtext\"><p>A 22-year-old man is noted to have a rise in serum creatinine. He has a history of Caroli syndrome, which led to liver fibrosis, and he received a liver transplant 3 years ago. His medical history is also notable for portal hypertension and transfusion-associated hepatitis B. </p>\n<p>His medications include mycophenolate, tacrolimus, and prednisone for immunosuppression and tenofovir alafenamide (TAF) for hepatitis B treatment. His family history is negative for kidney disease. </p>\n<p>On examination, his blood pressure is 140/75 mm Hg, and he has a well-healed scar from the liver transplant, a mildly protuberant abdomen, and no edema.</p>\n<p>Laboratory studies show normal serum albumin, aminotransferases, bilirubin, and electrolytes. His creatinine has gradually risen over the last 2 years from 1.0 mg/dL after transplantation to 1.8 mg/dL currently (reference range, 0.7–1.3). Hepatitis B DNA is undetectable. The tacrolimus trough level is 3.2 ng/mL (target range, 5–10 at &gt;3 months post transplantation) and has been consistently in this range. His urinalysis is remarkable only for +1 protein with a bland urinary sediment.</p>\n<p>Kidney ultrasound shows mildly enlarged kidneys with increased cortical echogenicity and innumerable small cysts.</p>\n<p><strong>Which of the following is the MOST likely cause of this patient’s decline in kidney function?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Autosomal recessive polycystic kidney disease (ARPKD)"
            },
            {
                "label": "B.",
                "text": "Hepatitis B-associated nephropathy"
            },
            {
                "label": "C.",
                "text": "Tenofovir-associated tubulopathy"
            },
            {
                "label": "D.",
                "text": "Tacrolimus toxicity"
            },
            {
                "label": "E.",
                "text": "ADPKD"
            }
        ],
        "correct_answer": "Autosomal recessive polycystic kidney disease (ARPKD)",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Progressive CKD is most likely related to ARPKD, which is associated with Caroli syndrome. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Caroli disease is a congenital disorder characterized by segmental dilation of the large intrahepatic bile ducts; when there is also congenital hepatic fibrosis with portal hypertension, the disorder is known as Caroli syndrome. Kidney involvement, in the form of ARPKD, is encountered in up to 60% of patients with Caroli disease, and this association has led investigators to classify this disorder as a hepatorenal fibrocystic disease. In fact, the association of this disorder with inherited kidney cystic diseases has led to further characterization of this disorder as a “ciliopathy.”</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">When Caroli syndrome involves the kidneys, it typically manifests as ARPKD. This disorder appears to be secondary to mutations in the gene <em>PKHD1</em> (polycystic kidney and hepatic disease gene-1), which is located on the short arm of chromosome 6 and encodes the gene fibrocystin. Although ARPKD typically leads to advanced CKD and has a high mortality rate in infancy, older children and adolescents can present with milder kidney disease and complications from congenital hepatic fibrosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ADPKD is not known to be associated with Caroli syndrome, and the imaging characteristics are more consistent with ARPKD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute calcineurin toxicity is unlikely with the relatively low tacrolimus trough and a gradual but significant rise in the creatinine only 3 years post-transplant as described in this case. Calcineurin effects on the tubules often result in hyperkalemia and hypomagnesemia. Chronic calcineurin nephropathy is a possibility but would not explain the imaging findings, and kidney biopsy would be needed to establish this diagnosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Tenofovir toxicity is most commonly recognized as a proximal tubulopathy (Fanconi syndrome), but AKI or CKD are also possible, with modest proteinuria and no evidence of proximal tubular defects. TAF appears to be less likely to cause tubular injury than tenofovir disoproxil fumarate. In this case, the imaging findings make ARPKD the most likely diagnosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hepatitis B virus (HBV) infection is associated with a variety of glomerular diseases, including membranous nephropathy, MPGN, polyarteritis nodosa, and mesangioproliferative glomerulonephritis. AKI and CKD can also occur if there is severe acute or chronic liver impairment. The effective suppression of HBV and the absence of evidence for glomerulonephritis make HBV-associated nephropathy unlikely.</p>\n</div>",
        "references": []
    },
    "68": {
        "question": "<div class=\"qtext\"><p>A 59-year-old man is evaluated for refractory hypertension. He was diagnosed with hypertension and type 2 diabetes 15 years ago. His BPs have not been at goal for many years, but has recently worsened. The patient gained weight after starting insulin a few months ago despite exercising for 30 minutes daily. Clinic BP averages 150–160/90–100 mm Hg, and similar values are obtained at home. Recent ambulatory BP monitoring shows an average BP of 148/90 mm Hg. There is no history of headaches, paroxysmal hypertension, palpitations, sweating, or family history of hypertension. He does not smoke, drink alcohol, or use illicit drugs. He does not take NSAIDs. He has been adherent to a sodium-restricted diet. Antihypertensive medications include losartan, chlorthalidone, and nifedipine at the maximally-tolerated doses, as well as insulin, metformin, and atorvastatin.</p>\n<p>On examination, BP is 154/94 mm Hg, and body mass index is 38 kg/m<sup>2</sup>. Funduscopic examination shows grade 2 hypertensive retinopathy and mild diabetic retinopathy. The remainder of the examination is normal.</p>\n<p>Laboratory data are as follows:</p>\n<div style=\"margin-bottom: 20px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><strong>Serum</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">142 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.8 mEq/L</td><td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">108 mEq/L</td><td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">98–106<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">25 mEq/L</td><td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">32 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">1.2 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Aldosterone<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">9.1 ng/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">≤10 supine or seated, &lt;21 standing<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Renin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">1.1 ng/mL/h<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.3–2.5 supine, 0.2–3.6 upright<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><strong>Urine</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Albumin-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">462 mg/g<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">&lt;30<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">58 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies with intake<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Potassium <br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">38 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies with intake<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Creatinine <br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">81 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies with intake<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><strong>Which of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Perform renal artery Duplex ultrasonography"
            },
            {
                "label": "B.",
                "text": "Prescribe hydralazine"
            },
            {
                "label": "C.",
                "text": "Measure plasma free metanephrines"
            },
            {
                "label": "D.",
                "text": "Prescribe eplerenone"
            },
            {
                "label": "E.",
                "text": "Measure urine aldosterone excretion following sodium loading"
            }
        ],
        "correct_answer": "Prescribe eplerenone",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Prescribing eplerenone would be the next best step in management for this patient with obesity and resistant hypertension. Spironolactone is another option but is more likely to result in side effects. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Resistant hypertension is defined as BP that remains above target on adequate doses of ≥3 antihypertensive medications, one of which should be a diuretic. The results of this patient’s ambulatory BP monitoring exclude pseudo-resistance. Evaluation of resistant hypertension also includes discontinuing or minimizing contributing agents such as NSAIDs and screening for secondary causes of hypertension, if appropriate. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Managing resistant hypertension begins with lifestyle modification such as increasing exercise, limiting alcohol intake, stopping smoking, and reaching a healthy weight. After confirming adherence to a 3-drug regimen with optimal doses including a diuretic, adding a mineralocorticoid antagonist (MRA) is the next step in management, particularly in patients with obesity and albuminuria without contraindications. Low-dose MRAs are generally well tolerated in patients with eGFR &gt;45 mL/min/1.73 m<sup>2</sup> and serum potassium level &lt;4.5 mEq/L. When BP remains above goal despite an MRA and 3 other first-line medications, such as a dihydropyridine calcium channel blocker, ACEI or ARB, and long-acting thiazide diuretic, the addition of an α1-adrenergic antagonist, a direct-acting vasodilator (hydralazine or minoxidil), or a centrally-acting α2-agonist (clonidine) is a reasonable pharmacologic approach. b-Blockers are not typically recommended as antihypertensive agents, unless other indications, such as angina, heart failure, or tachycardia, are present. Carvedilol, an agent with both α- and b-adrenergic antagonism, is another potential add-on agent.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hydralazine would be a reasonable step if BP remains above goal after addition of an MRA such as eplerenone. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Screening for secondary hypertension is indicated for some patients with resistant hypertension. However, screening for pheochromocytoma with plasma free metanephrines would not be indicated in the absence of typical symptoms such as palpitations, headache, or sweating in a patient with an already defined cause for secondary hypertension, such as diabetic kidney disease.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Screening for renovascular hypertension would not be indicated in the absence of clinical clues suggesting the diagnosis. These include unexplained discrepancy in kidney size, atherosclerosis, history of heavy smoking, systolic-diastolic abdominal bruit, or decreased kidney function after angiotensin blockade. Furthermore, the plasma renin activity is normal despite prescription of losartan and chlorthalidone. Finally, clinical trials have failed to show any benefit to intervention for atherosclerotic renal artery stenosis beyond medical therapy. Therefore, ultrasonography would not be indicated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary aldosteronism is unlikely because the aldosterone-to-renin ratio is &lt;20 and the absolute level of the serum aldosterone is &lt;15 ng/dL. Although recent data suggest that these screening labs may underestimate the prevalence of primary aldosteronism, surgical cure is unlikely in the presence of long-standing hypertension in a man taking multiple antihypertensive medications. Therefore, measurement of urinary aldosterone excretion after sodium loading (aldosterone suppression testing) is not indicated.</p>\n</div>",
        "references": []
    },
    "69": {
        "question": "<div class=\"qtext\"><p>A 63-year-old man with a history of chronic myeloid leukemia, hypertension, and peripheral vascular disease is evaluated for hyponatremia. Nine months ago, he underwent allogeneic hematopoietic stem cell transplantation. He was recently diagnosed with graft-versus-host disease. Medications include prednisone, tacrolimus, aspirin, atorvastatin, and hydrochlorothiazide. Review of systems is notable for nausea and anorexia.</p>\n<p><span style=\"font-size: 0.9375rem;\">On examination, BP is 138/88 mm Hg, and heart rate is 66/min. Abdominal examination reveals tenderness in the right upper quadrant without distention. He also has scleral icterus and jaundice.</span></p>\n<p><span style=\"font-size: 0.9375rem;\">Laboratory data are as follows:</span></p>\n<div style=\"margin-bottom: 20px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><strong>Serum</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">119 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">92 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">98–106<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">4.7 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">22 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  BUN<sub></sub><sub></sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">9 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">0.6 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Glucose<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">88 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">70–99, fasting<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Osmolality<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">286 mOsm/kg H<sub>2</sub>O<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">275–295<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Aspartate aminotransferase<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">1102 U/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">10–40<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><span>  Alanine aminotransferase</span><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">964 U/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">10–40<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Alkaline phosphatase<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">755 U/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">30–120<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Total bilirubin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">10.2 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.3–1.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Direct bilirubin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">7.7 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.1–0.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Albumin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.1 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><strong>Urine</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><span>  Sodium</span><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">53 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies with intake<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Osmolality<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">302 mOsm/kg H<sub>2</sub>O<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies with intake<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><strong>Which ONE of the following is the MOST LIKELY diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hypovolemia"
            },
            {
                "label": "B.",
                "text": "Low solute intake"
            },
            {
                "label": "C.",
                "text": "Syndrome of inappropriate antidiuretic hormone"
            },
            {
                "label": "D.",
                "text": "Pseudohyponatremia"
            },
            {
                "label": "E.",
                "text": "Hydrochlorothiazide effect"
            }
        ],
        "correct_answer": "Pseudohyponatremia",
        "abim_content_category": "Salt and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with isosmotic hyponatremia most likely has pseudohyponatremia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has a low serum sodium but normal serum osmolality. The differential diagnosis of isosmotic hyponatremia includes pseudohyponatremia, infusion of nonconductive irrigation solutions, or accumulation of effective osmoles such as glucose in a patient with preexisting hypotonic hyponatremia. In this case, there is no history of exposure to an exogenous solute, and because the serum glucose is normal, pseudohyponatremia is most likely. The history and laboratory data show evidence of hepatocellular and cholestatic liver disease, which has most likely caused accumulation of lipoprotein X, a cause of pseudohyponatremia. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Many laboratory analyzers use indirect ion potentiometry to measure serum sodium; an aliquot of plasma is diluted for the assay to limit the volume of blood needed. The resulting value is then multiplied by a correction factor to yield the result. This correction factor assumes that plasma water is 93% of total plasma volume, with the remaining 7% of serum accounted for by solid phase particles such as proteins and lipids. This calculation is inaccurate when normal plasma water is displaced by abnormally large amounts of circulating paraprotein or lipid, because the magnitude of the dilution is underestimated. In severe hepatic cholestasis, as seen in this patient, lipoprotein X can accumulate from reflux of unesterified cholesterol and phospholipids into the circulation. This circulating lipid leads to a reduction in the fraction of total plasma volume occupied by plasma water. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Direct ion potentiometry does not require sample dilution and therefore will give an accurate assay of plasma sodium. This is the method commonly used to test blood gas samples. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with syndrome of inappropriate antidiuretic hormone (SIADH), thiazide-induced hyponatremia, hypovolemic hyponatremia, and hypo-osmolal hyponatremia due to low solute intake would all show both low serum sodium and osmolality. </p>\n</div>",
        "references": []
    },
    "70": {
        "question": "<div class=\"qtext\"><p>A 23-year-old man is evaluated for hypertension. He was first informed of elevated BP during a physical examination in high school, but he did not seek medical evaluation until now. His father was diagnosed with hypertension at a young age, but he is unaware of further details. He does not take any medications and does not use NSAIDs, herbal supplements, alcohol, tobacco, or illicit drugs. </p>\n<p>On examination, BP is 164/84 mm Hg in both arms, with a heart rate of 78/min and weight of 66 kg. Heart and lungs are normal, and there is no edema. There is no abnormal radial-femoral pulse delay.</p>\n<p>Laboratory data obtained at 8:00 a.m. are as follows:</p>\n<div style=\"margin-bottom: 15px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><span>Potassium</span><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.2 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">0.8 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Aldosterone<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">25 ng/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">≤10 supine or seated, &lt;21 standing<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">Renin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">0.2 ng/mL/h<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.3–2.5 supine, 0.2–3.6 upright<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p>Direct genetic testing confirms the presence of hybrid 11b-hydroxylase and aldosterone synthase genes.</p>\n<p><strong>Which ONE of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prednisone"
            },
            {
                "label": "B.",
                "text": "Sodium restriction"
            },
            {
                "label": "C.",
                "text": "Labetalol"
            },
            {
                "label": "D.",
                "text": "Amiloride"
            },
            {
                "label": "E.",
                "text": "Chlorthalidone"
            }
        ],
        "correct_answer": "Prednisone",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has glucocorticoid-remediable aldosteronism (GRA), which is best managed with corticosteroids.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">GRA is a rare, autosomal dominant form of hyperaldosteronism in which aldosterone hypersecretion may be suppressed with physiologic doses of glucocorticoids. Patients with GRA have adrenocorticotrophic hormone (ACTH)-sensitive aldosterone production in the zona fasciculata of the adrenal gland. The mutation in patients with GRA is a fusion of the promoter region of the gene for CYP11B1 (11b-hydroxylase) and the coding sequences for CYP11B2 (aldosterone synthase), resulting in ACTH-dependent activation of aldosterone synthase.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">GRA should be suspected in individuals with early-onset hypertension, especially when there is a family history of early-onset hypertension and hemorrhagic stroke. Hypokalemia, either spontaneous or after initiation of a thiazide diuretic, may be present in less than half of cases but can be another clue to the diagnosis. The absence of hypokalemia has been attributed to the circadian rhythm of ACTH release, which leads to an increase in aldosterone secretion for only part of the day. The plasma aldosterone level is typically modestly elevated, and plasma renin activity is suppressed. However, the aldosterone-to-renin ratio is typically not as high as in primary aldosteronism caused by an adrenal adenoma. Genetic testing for the chimeric gene can replace the need for a dexamethasone suppression test. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The primary therapy for this condition is the administration of glucocorticoid in the lowest dose that effectively suppresses ACTH secretion and thereby suppresses aldosterone secretion. Minimization of the glucocorticoid dose is crucial to minimize side effects.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Treatment with thiazide diuretics may cause marked hypokalemia secondary to the increased sodium delivery to the aldosterone-sensitive distal nephron. Alternatively, treatment with mineralocorticoid receptor antagonists or amiloride may be effective, but these agents are typically used only if hypertension cannot be controlled with glucocorticoids alone.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Labetalol would not address the pathophysiologic defect in GRA, and dietary sodium restriction may be helpful, but neither of these options would effectively manage this patient’s hypertension. </p>\n<p>Patients with GRA are at increased risk for cerebral aneurysms, and it has been recommended that patients undergo screening magnetic resonance angiography at puberty and every 5 years thereafter.</p>\n</div>",
        "references": []
    },
    "71": {
        "question": "<div class=\"qtext\"><p>A 71-year-old man presents to the emergency department after a fall. His wife notes that he has become progressively more confused during the past 2 weeks, and his gait has become unsteady.</p>\n<p>On examination, BP is 112/70 mm Hg, with heart rate of 82/min without postural change. There are no demonstrable injuries related to the fall. Heart and lungs are normal, and there is no edema. Neurologic exam reveals confusion, decreased coordination, and inability to stand or walk independently.</p>\n<p>Laboratory data reveal the following:</p>\n<div style=\"margin-bottom: 20px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><strong>Serum</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><span>  Sodium</span><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">117 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">3.8 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">88 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">98–106<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">24 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">12 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">0.8 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Glucose<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">91 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">70–99, fasting<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Osmolality<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">253 mOsm/kg H<sub>2</sub>O<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">275–295<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><strong>Urine</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">52 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies with intake<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">98 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies with intake<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Osmolality<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">493 mOsm/kg H<sub>2</sub>O<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">Varies with intake<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><strong>Which ONE of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Fluid restriction"
            },
            {
                "label": "B.",
                "text": "Isotonic saline"
            },
            {
                "label": "C.",
                "text": "Tolvaptan"
            },
            {
                "label": "D.",
                "text": "Desmopressin"
            },
            {
                "label": "E.",
                "text": "Hypertonic saline"
            }
        ],
        "correct_answer": "Hypertonic saline",
        "abim_content_category": "Salt and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with symptomatic hypo-osmolar hyponatremia should be treated with hypertonic saline.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hyponatremia with hypo-osmolality in euvolemic patients indicate a state of water overload. After excluding myxedema coma or adrenal insufficiency, the differential diagnosis includes the syndrome of inappropriate antidiuresis or water intoxication. This patient’s inappropriately concentrated urine is consistent with the syndrome of inappropriate antidiuretic hormone secretion (SIADH).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Treatment of symptomatic hyponatremia requires increasing the serum sodium by approximately 4–6 mEq/L within 6 hours to relieve symptoms. This can usually be accomplished empirically by administering a 100- or 150-mL bolus of hypertonic (3%) saline. Additional boluses may be needed based on follow-up laboratory data. The recommended goal of management is to increase the sodium by a cumulative total of 6–8 mEq in the first 24 hours, 12–14 mEq/L by 48 hours, and 14–16 mEq/L by 72 hours in patients with chronic hyponatremia to avoid overcorrection. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Vasopressin receptor antagonists that block ADH<a href=\"#_msocom_1\" id=\"_anchor_1\" language=\"JavaScript\" name=\"_msoanchor_1\"></a> , loop diuretics that decrease urine osmolality, and fluid restriction alone are all treatments for SIADH, but would be most appropriate for chronic management of patients without neurologic symptoms.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Desmopressin is a vasopressin agonist that results in urinary concentration and water retention, which would exacerbate hyponatremia. Desmopressin has been used with hypertonic saline to prevent overcorrection of hyponatremia but would not be appropriate as primary therapy for symptomatic hyponatremia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Isotonic saline might be effective for hyponatremia caused by hypovolemia, but this patient shows no evidence of hypovolemia by physical examination, orthostatic vital signs, or urine chemistry. Normal saline administration would be expected to worsen hyponatremia caused by SIADH, so it would not be the next best step in therapy.</p>\n</div>",
        "references": []
    },
    "72": {
        "question": "<div class=\"qtext\"><p>A 61-year-old man with type 2 diabetes is evaluated for resistant hypertension. He was diagnosed with hypertension 15 years ago. His BP has been poorly controlled despite adherence to his medication regimen and a sodium-restricted diet. His family history is significant for hypertension in several relatives, most of whom were diagnosed between the ages of 40 and 50 years. Recent home BP readings are 150/80–160/90 mm Hg. Medications include ramipril, amlodipine, and labetalol.</p>\n<p>Physical examination reveals BP 154–158/86–92 mm Hg in both arms, with a heart rate of 62/min. The heart and lung examinations are normal, and there is no edema.</p>\n<p>Laboratory data reveal the following:</p>\n<div style=\"margin-bottom: 15px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><strong>Serum</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">139 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">4.7 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">104 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">98–106<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">23 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">17 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">1.3 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><b>Urine</b><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Albumin-to-creatinine ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">182 mg/g<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">&lt;30 mg/g<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><strong>Which ONE of the following is the MOST APPROPRIATE addition to this patient’s antihypertensive regimen?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Furosemide"
            },
            {
                "label": "B.",
                "text": "Chlorthalidone"
            },
            {
                "label": "C.",
                "text": "Verapamil"
            },
            {
                "label": "D.",
                "text": "Losartan"
            },
            {
                "label": "E.",
                "text": "Clonidine"
            }
        ],
        "correct_answer": "Chlorthalidone",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Prescribing chlorthalidone is the most appropriate next step in management for this patient with uncontrolled hypertension. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On average, 3–4 medications are required to control BP in patients with hypertension and diabetes. Most patients with resistant hypertension have improved BP when diuretics are added to the regimen, even when edema is absent. Although either thiazide-type or loop diuretics can be used to control volume expansion and achieve BP target, thiazides are preferred when eGFR is &gt;30 mL/min/1.73 m<sup>2</sup>. Recent data suggests that thiazides may improve BP even in stage 4 CKD. Long-acting thiazide diuretics such as chlorthalidone or indapamide may be more effective than shorter-acting agents such as hydrochlorothiazide. Low-dose chlorthalidone is often favored over hydrochlorothiazide for treating hypertension, as chlorthalidone reduced cardiovascular events in the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Loop diuretics are generally less effective than thiazide diuretics in treating hypertension in patients with relatively preserved kidney function. The shorter half-life of loop diuretics relative to thiazides may in part account for this observation. Activation of the renin-angiotensin-aldosterone system results in sodium retention once the loop diuretic effect diminishes. Chronic use of thiazide diuretics also results in decreased peripheral vascular resistance. Use of loop diuretics, either alone or in combination with thiazides, may be advantageous in patients with eGFR &lt;30 mL/min/1.73 m<sup>2</sup>. Twice-daily administration of furosemide or use of a longer acting loop diuretic, such as torsemide, may enhance BP control, but long-term outcome studies are lacking. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Non-dihydropyridine calcium channel blockers such as diltiazem and verapamil may decrease proteinuria but are less effective antihypertensive agents than dihydropyridines. Diltiazem and verapamil also cause bradycardia and are not recommended for use in combination with β-blockers.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Similarly, clonidine interacts with β-blockers to cause bradycardia and should not be used in this patient with a relatively low heart rate. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Losartan, added to a maximal dose of lisinopril, would not be expected to provide additional BP reduction and could worsen hyperkalemia. In addition, although the combination of an ACEI and an ARB may reduce albuminuria, such “dual blockade” regimens have been associated with adverse clinical outcomes, such as increased rates of AKI, in clinical trials such as ONTARGET (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trail) and TRANSCEND (The Telmisartan Randomized Assessment Study in ACE-intolerant Subjects with Cardiovascular Disease). Routine use of this strategy is not recommended because of the increased risk for complications and the lack of evidence demonstrating improved outcomes such as decreased progression to ESRD or improved survival.</p>\n</div>",
        "references": []
    },
    "73": {
        "question": "<div class=\"qtext\"><p>A 56-year-old man with a history of chronic alcohol use and traumatic brain injury is admitted to the ICU for septic shock. His creatinine on admission was 2.3 mg/dL (baseline, 0.9) which stabilized over the next 2 days, and urine output improved with IV fluids and norepinephrine.</p>\n<p>He developed seizures on hospital day 4, ultimately controlled with phenytoin, diazepam, and propofol. He was then maintained on phenytoin daily and propofol infusion and received diazepam as needed for sedation during mechanical ventilation. On hospital day 7, he developed bradycardia and hypotension requiring increased doses of norepinephrine and the addition of phenylephrine.</p>\n<p>On examination, BP is 82/44 mm Hg, and pulse is 50/min. The patient is unresponsive on mechanical ventilation, and there is 2+ edema.</p>\n<p>Laboratory data are as follows:</p>\n<div style=\"margin-bottom: 15px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\"><strong><b>Admission</b></strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\"><b>Day 7</b><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\"><strong><b>Reference Range</b></strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Sodium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">132 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">138<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">136–145<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Potassium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">4.3 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">5.9</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">3.5–5.0<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Chloride<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">98 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">96</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">98–106<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Total CO<sub>2</sub><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">21 mEq/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">14</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">23–28<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">45 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">73</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">8–20<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">2.3 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">4.0</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Glucose<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">138 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">121</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">70–99, fasting<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Calcium<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">8.6 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">7.9</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">8.6–10.2<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Phosphorus<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">4.1 mg/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">5.9</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">3.0–4.5<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Lactic acid<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">2.9 mmol/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">0–2.1<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Creatine kinase<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">332 U/L<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">1912</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">55–170<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 28.9013%;\">Osmolality<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 21.7357%;\">295 mOsm/kg H<sub>2</sub>O<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;; width: 25.0000%;\">314</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 24.1242%;\">275–295<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p>EKG shows sinus bradycardia with coved ST segment elevations in V1–V2.</p>\n<p><strong>Which ONE of the following is the MOST LIKELY cause of clinical deterioration?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Propofol toxicity"
            },
            {
                "label": "B.",
                "text": "Acute coronary syndrome"
            },
            {
                "label": "C.",
                "text": "Propylene glycol toxicity"
            },
            {
                "label": "D.",
                "text": "Phenytoin toxicity"
            },
            {
                "label": "E.",
                "text": "Sepsis"
            }
        ],
        "correct_answer": "Propofol toxicity",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s clinical deterioration may be explained by propofol-related infusion syndrome, characterized by AKI, high anion gap metabolic acidosis, increased serum creatine kinase, Brugada-type EKG changes, hyperkalemia, and cardiovascular compromise (bradycardia with refractory hypotension). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Propofol-related infusion syndrome is rare but often fatal when it occurs. Predisposing factors include critically ill patients who require vasopressor support, propofol doses &gt;4–5 mg/kg/h, and infusion duration &gt;48 hours. Toxicity has been attributed to disruption of intracellular energy production, which leads to lactic acidosis, rhabdomyolysis, and cardiac instability. Mortality up to 60% has been reported. Treatment of propofol-related infusion syndrome is discontinuing the infusion and providing supportive care.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Propylene glycol is a solvent used as a vehicle for both diazepam and lorazepam. High-dose infusions of either agent can lead to propylene glycol toxicity. Toxicity of propylene glycol causes increased anion gap metabolic acidosis because of accumulation of both <span style=\"font-size: 12px;\">D</span>- and <span style=\"font-size: 12px;\">L</span>-isomers of lactic acid and an increase in the osmolal gap, but typically not the other features of this case.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute coronary syndrome may cause bradycardia and ST segment elevation, increased serum creatine kinase, and cardiogenic shock. However, the coved ST segment elevations on EKG in a patient receiving high-dose propofol are more consistent with the Brugada-type electrophysiologic changes of propofol-related infusion syndrome.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although sepsis is a common cause of AKI, acidosis, and hypotension in a critically ill patient, the bradycardia and metabolic derangements seen here are more consistent with propofol-related infusion syndrome.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Phenytoin toxicity is associated with neurologic rather than metabolic complications.</p>\n</div>",
        "references": []
    },
    "74": {
        "question": "<div class=\"qtext\"><p>A 51-year-old woman is evaluated for resistant hypertension. She presented 5 months ago to her primary care physician with a 3-week history of headaches, tinnitus, dizziness, and shortness of breath. BP was 182/94 mm Hg, increased from 124/72 mm Hg 1 year previously. Her 50-year-old brother and 75-year-old father both developed hypertension in their 30s. Medications include amlodipine, carvedilol, indapamide, and hydralazine.</p>\n<p>On examination, BP in the right arm is 174/88 mm Hg, BP in the left arm is 169/85 mmHg, heart rate is 84/min, and body mass index (BMI) is 34 kg/m<sup>2</sup>. On auscultation, there are left-sided carotid and epigastric bruits.</p>\n<p>Laboratory data show serum creatinine level of 0.9 mg/dL (reference range, 0.5–1.1), potassium level of 3.6 mEq/L (reference range, 3.5–5.0), and total CO<sub>2</sub> level of 29 mEq/L (reference range, 23–28). Urinalysis is normal. Duplex Doppler ultrasound of the left carotid artery reveals turbulence and increased flow velocity.</p>\n<p><strong>Which ONE of the following is the best NEXT STEP in evaluating hypertension?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Plasma aldosterone-to-renin ratio"
            },
            {
                "label": "B.",
                "text": "Digital subtraction angiography"
            },
            {
                "label": "C.",
                "text": "Renal duplex Doppler ultrasound"
            },
            {
                "label": "D.",
                "text": "Captopril-stimulated renography"
            }
        ],
        "correct_answer": "Renal duplex Doppler ultrasound",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Renal duplex Doppler ultrasound is the next best step in evaluation for this patient with resistant hypertension and abdominal and carotid bruits.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The diagnosis of fibromuscular dysplasia (FMD) should be considered for this woman with abrupt onset hypertension in whom there is a consistent family history and abdominal and carotid bruits. Decreased kidney function after starting an ACEI or ARB may be an additional clue to the diagnosis. Patients with suspected FMD should initially undergo noninvasive studies to define anatomy, confirm the diagnosis, and help plan percutaneous intervention. The choice of initial diagnostic study is institution-dependent. Renal duplex Doppler ultrasound, for example, requires technical proficiency, with reported sensitivity and specificity of 60%–90%. Duplex ultrasonography can be used to determine the velocity of the flow in the renal arteries and document kidney size or asymmetry. CT angiography (CTA) has sufficient resolution to identify most FMD lesions in main renal arteries but has decreased sensitivity for branch arteries. Magnetic resonance angiography (MRA) may be less accurate for FMD compared with CTA. For atherosclerotic renal artery stenosis, CTA and MRA are 90% sensitive and specific.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">FMD registry data show that FMD is diagnosed much later than previously believed, at an average age of 51.9 years. Female predominance (91%) is well known, but the frequency of a strong family history (79%) was not previously appreciated. Patients with renal artery involvement often (68%) have carotid or vertebral involvement as well. The most common presenting symptoms are headache (52%), pulsatile tinnitus (27.5%), and dizziness (26%). Chest pain or shortness of breath was observed in 16% of patients. Several of these symptoms can also be seen with pheochromocytoma, but the suggestion of vascular disease elsewhere should prompt evaluation for FMD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Digital subtraction angiography is the gold standard for the diagnosis of FMD but is reserved for planning catheter-based interventions or for diagnosis when noninvasive studies are inconclusive.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has a high pretest probability of FMD, and measures to establish this diagnosis should be pursued before evaluating for other causes of resistant hypertension. If the initial investigation fails to demonstrate evidence of renovascular hypertension, further evaluation for primary aldosteronism by measuring the plasma aldosterone-to-renin ratio would be indicated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Captopril-stimulated renography is not recommended to diagnose FMD because of poor interobserver agreement, variable sensitivity and specificity, and difficulty in interpreting results when there is asymmetric kidney blood flow or function or bilateral disease.</p>\n</div>",
        "references": []
    },
    "75": {
        "question": "<div class=\"qtext\"><p>A 70-year-old man with CKD stage G3b/A1 receiving therapy with sunitinib for metastatic renal cell carcinoma is referred to evaluate new-onset hypertension. He denies dyspnea, peripheral edema, or headache.</p>\n<p>BP is 158/90 mm Hg, increased from 132/76 mm Hg last month. Fundoscopic examination shows no papilledema. There is trace edema bilaterally. Neurologic examination is normal.</p>\n<div style=\"margin-bottom: 15px;\">\n<table style=\"border: 1px solid black; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><strong>Value</strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><strong>Reference Range</strong><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><strong><b>Blood</b></strong><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  WBC count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">10,400/µL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">4000–11,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Hemoglobin<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">11.4 g/dL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">14–18<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Platelet count<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">310,000/µL<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">150,000–450,000<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Creatinine<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">1.6 mg/dL (stable)<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">0.7–1.3<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\"><b>Urine</b><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 38.6412%;\">  Protein-to-creatinine\n                    ratio<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 29.087%;\">0.3\n                    mg/mg<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; width: 32.2718%;\">&lt;0.2<br/></td>\n</tr>\n</tbody>\n</table>\n</div>\n<p>Urinalysis shows 1+ albumin and no blood, with negative microscopy. Peripheral blood smear shows no schistocytes.</p>\n<p><strong>Which ONE of the following is the best NEXT STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Perform magnetic resonance venogram of the abdomen"
            },
            {
                "label": "B.",
                "text": "Prescribe lisinopril"
            },
            {
                "label": "C.",
                "text": "Perform renal artery duplex Doppler ultrasound"
            },
            {
                "label": "D.",
                "text": "Prescribe diltiazem"
            },
            {
                "label": "E.",
                "text": "Discontinue sunitinib"
            }
        ],
        "correct_answer": "Prescribe lisinopril",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Linsinopril should be prescribed in this patient with new-onset hypertension and no evidence of end-organ damage.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypertension is a frequent complication of antiangiogenic therapy, but hypertension in the absence of end-organ damage does not mandate stopping therapy. The National Cancer Institute Angiogenesis Task Force recommends treatment to a target BP of &lt;140/90 mm Hg or treatment to maintain the diastolic BP &lt;20 mm Hg above baseline for patients with low-normal baseline BP. Some evidence suggests that hypertension is a biomarker for improved tumor response. The preferred classes of medications for treating hypertension in this scenario has yet to be established, but ACEIs or ARBs, especially in patients with proteinuria, or dihydropyridine calcium channel blockers are reasonable choices. A review of bevacizumab-induced hypertension in patients with ovarian cancer suggested amlodipine as first line followed by the addition of an ACEI or ARB if needed. Non-dihydropyridine calcium channel blockers, such as verapamil and diltiazem, are generally avoided because they inhibit cytochrome P450 3A4 and decrease sunitinib metabolism. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Reasons to discontinue antiangiogenic therapy include posterior reversible encephalopathy syndrome, thrombotic microangiopathy, or nephrotic syndrome, none of which is present in this case.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Arterial and venous thromboembolism have been reported with antiangiogenic therapy, most commonly with bevacizumab and aflibercept. Renal arterial or venous thrombosis could cause hypertension, but the absence of flank pain and hematuria make these diagnoses less likely. Thus, abdominal magnetic resonance venogram of the abdomen or renal artery duplex Doppler ultrasound would not be indicated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Proteinuria associated with antiangiogenic therapy may result from endothelial injury to glomerular capillaries and thrombotic microangiopathy. Collapsing focal segmental glomerulosclerosis has also been reported.</p>\n</div>",
        "references": []
    }
}